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 Abstract 
 
Amyloid fibres are characteristic of over 25 degenerative human diseases including 
Alzheimer’s and Parkinson’s disease.  Amyloid fibres are insoluble, highly stable, 
ordered cross-β sheet structures, which form as a result of conformational change and 
aggregation in a range of unrelated soluble proteins and peptides.  High molecular 
weight oligomers, potentially on-pathway to amyloid formation, have been posited as 
the toxicity agent in amyloid-associated disease.  Heterogeneity of amyloid fibres and 
oligomers precludes the use of standard structural biology techniques. 
 
The work presented utilised recombinant human cystatin B as a model system for 
structural analysis of amyloid fibres and oligomers, particularly for the structurally 
homologous human cystatin C which directly causes a form of amyloid angiopathy.  
Limited proteolysis of cystatin B amyloid fibre shows that the core structure consists 
maximally of residues 27-80 out of a total 98.  Electron microscopy techniques, 
including mass per unit length measurements, reveal an average fibre width of 8.6 nm 
and formation of four fibre classes, composed of 4, 8 and 16 molecules per 4 -strand 
rise.  These data are incompatible with the previous native-like model, therefore a new 
working fibre model is proposed where native β-strands 2 and 3 are extended into a 
single strand with adjacent β-strands 4 and 5 forming the other half of a β-sheet arc, 
which is stacked in parallel, perpendicular to the fibre axis.   
 
Stable proteinase-K resistant G4R mutant cystatin B oligomers were generated and 
preliminary characterisation presented, with identification of five structural classes 
ranging in diameter from 8-88 nm.  Furthermore, investigation of a potential amyloid 
therapeutic in Salvia plant extracts was carried out with dye binding kinetic assays and 
electron microscopy.  The work herein primarily constrains a new non-native β-sheet 
cystatin B amyloid fibre model and has initiated new avenues of research into cystatin 
oligomer structure and novel therapeutic agents.   
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Chapter 1: Introduction 
 
1.1 Background in Brief 
 
Amyloid-related diseases, or amyloidoses, include over 25 familial, sporadic or 
transmissible pathological conditions, some with high prevalence in the human 
population (Stefani, 2010), and include Alzheimer’s disease (AD) (Selkoe and Schenk, 
2003), Parkinson’s disease (PD) (Lang and Lozano, 1998) and Huntington’s disease 
(Perutz, 1999) (see table 1.1.1).  Many of these diseases are late-onset chronic diseases 
which have become increasingly important as the populations in developed nations age.  
For example, Alzheimer’s disease (AD) is the fourth most widespread illness in the 
economically developed world, with an estimated 24 million sufferers (Ballard et al., 
2011) and therefore understanding the cause and developing a treatment for 
amyloidoses is essential.   
 
Amyloidoses are characterised by amyloid fibre deposits in samples of affected tissue.  
Amyloid fibres are insoluble, highly ordered and typically highly stable protein 
deposits, formed as a result of conformational change and aggregation of normally 
soluble protein.  Amyloid fibres are highly stable due to extensive hydrogen bonding, 
and thus may accumulate and persist within cells for long periods of time (Dobson, 
2003).  However to complicate the issue, long mature amyloid fibres appear to be 
relatively inert and the quantities of aggregate in disease can range from nearly 
undetectable to kilograms of protein in affected organs (Ye and Godzik, 2003).   
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Instead of amyloid fibres directly causing disease, prefibrillar protein complex 
intermediates either on or off  pathway to amyloid formation, broadly termed 
‘oligomers’, have been identified by electron microscopy (EM) (Lashuel et al., 2002) 
and with conformation specific antibodies as the possible toxicity agent in amyloid-
associated disease (Glabe, 2004).  Although conclusive proof of direct cytotoxicity of 
these structures remains elusive, overexpression, duplication and sequence mutations of 
amyloid forming proteins such as Aβ in Alzheimer’s disease or huntingtin in 
Huntington’s disease can lead to early-onset and/or increased risk of disease, thus 
proving these proteins are involved in disease aetiology (Benilova et al., 2012) .  
 
Table 1.1.1 Selected Amyloid Fibre Forming Proteins and Associated Diseases 
Based upon a table from (Hard and Lendel, 2012). 
 
Protein/Peptide Disease(s) Notes 
Aβ Alzheimer’s disease Accumulation of Aβ plaques 
α-synuclein 
Parkinson’s disease, 
dementia with Lewy 
bodies and others 
 
β2-Microglobulin 
Haemodialysis-related 
amyloidosis 
Systemic amyloidosis 
Huntingtin Huntington’s disease 
Accretion of polyglutamine-containing 
aggregates (Perutz, 1999). 
Insulin 
Injection-localised 
amyloidosis 
 
IAPP (amylin) Type II diabetes 
Accumulation of islet amyloid 
polypeptide (IAPP). 
Lysozyme Systemic amyloidosis  
PrP (prion) 
Spongiform 
encephalopathies 
Includes Creutzfeldt-Jakob disease 
(CJD) – amplification of misfolded 
prion protein (PrP
sc
). 
Tau 
Alzheimer’s disease, 
frontotemporal dementia 
and others 
Forms tau neurofibrillary tangles. 
TTR 
(Transthyretin) 
Familial amyloidotic 
polyneuropathy (FAP), 
senile systemic 
amyloidosis 
FAP is caused by amyloid fibre 
composed largely or entirely of TTR 
(Costa et al., 1978). 
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Despite limited evidence supporting toxicity of amyloid fibre itself, these structures 
must still be studied because they are robust with extensive hydrogen bonding, thus may 
accumulate and persist within cells for a long period of time and are proposed to act as a 
reservoir species for toxic protofibrils and oligomers (Benilova et al., 2012, Harper et 
al., 1997, Walsh et al., 1997).  The potential of amyloid fibres as a reservoir species is 
highlighted by the dynamic nature of amyloid fibres which exhibit extensive, but slow 
molecular recycling whereby the protein components of a fibre dissociate and reattach 
over a period of days (Sanchez et al., 2011, Carulla et al., 2005).  Understanding the 
structure of amyloid fibres is therefore essential for the research field as it is one of the 
potential therapeutic targets whereby stabilisation or ablation of fibre could remove 
damaging concentrations of toxic species.   
 
The protein chemist also asks; how does a broad range of soluble proteins lacking 
sequence or structural homology form amyloid fibre with a common morphology shown 
in electron microscopy and a suggested universal, cross-β core structure from X-ray 
fibre diffraction (Blake and Serpell, 1996).  For example, amyloid found in Alzheimer’s 
disease is composed of a 40-43 residue peptide (Selkoe and Schenk, 2003), whilst 
amyloid associated with Creutzfeldt-Jacob disease (CJD) is generated from a 30 kDa 
glycoprotein (Zahn et al., 2000).  This notion therefore produces the suggestion that 
amyloid fibre structures are generic and formed from short regions of relatively 
homologous protein sequence producing an extensive β-sheet structure (Chiti et al., 
2003).  Therefore, even without the medical importance, amyloid formation is a 
fascinating aspect of protein folding.  Furthermore, the high prevalence and growing 
requirement for developing therapeutics is driving the importance of research into 
amyloidoses.  This includes research on the protein structures formed, the mechanism of 
formation, toxicity and the search for effective treatments 
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1.2 Definitions 
 
To be designated an amyloid fibre forming protein by the Nomenclature Committee of 
the International Society of Amyloidosis, the protein must occur in tissue deposits and 
exhibit affinity for Congo red and green birefringence when viewed by polarisation 
microscopy. Furthermore, the protein must have been unambiguously characterised by 
protein sequence analysis (DNA sequencing in the case of familial diseases). Current 
nomenclature lists include 27 human and nine animal amyloid fibre forming proteins 
together with a list of eight inclusion bodies that exhibit some of the properties of 
amyloid fibres (Sipe et al., 2010). 
 
Nomenclature in the literature is diverse and controversial which provides poor clarity 
in descriptions as no consensus has been reached, particularly in the study of 
‘oligomers’.  Described below is my personally suggested nomenclature consensus 
which is developed from a variety of sources from different fields of amyloid protein 
study and is similar to that described in (Kodali and Wetzel, 2007, Fandrich, 2012).  
The terminology defined here will be used throughout this work. 
 
Amyloid Fibre  
Primarily straight, morphologically regular, unbranched protein fibres with diameters 
typically in the 2-20 nm range and several micrometers long (Fandrich, 2012, Kodali 
and Wetzel, 2007) (see figure 1.2.1).  Amyloid fibres are typically composed of 2-6 
protofilaments and can be flat or twisted, with the latter leading to apparent fibre 
constrictions at regular distances, termed crossovers.  Helicity of fibres is usually left-
handed, with some rare exceptions to this rule (Fandrich, 2012).  Most amyloid fibres 
exhibit; (i) cross-β x-ray fibre diffraction patterns (ii) β-sheet rich circular dichroism 
(CD) and Fourier Transform Infrared spectroscopy (FTIR) spectra (iii) high affinity for 
dyes such as thioflavin T (ThT) and Congo red (CR) (iv) core structures highly resistant 
to hydrogen/deuterium exchange and proteolysis. Amyloid fibres often consist of 
multiple protofilaments twisted around a fibril axis (Kodali and Wetzel, 2007).  Section 
1.5 presents a review of current structural data on amyloid fibre. 
 
Protofilament 
Individual strand of which a mature amyloid fibre is composed. 
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Protofibrils 
Non-spherical, filamentous structures absent of periodic substructure which are thought 
to represent late-stage intermediate species in amyloid fibre formation.  Compared to 
mature amyloid fibre, protofibrils are characteristically smaller in diameter (< 10 nm), 
shorter (< 400 nm in length) and more curvilinear.  Protofibrils typically have a weaker 
affinity for ThT and CR dyes than mature fibres but still contain high levels of β-sheet 
structure identified by CD, FTIR, and X-ray fibre diffraction (Fandrich, 2012).   
 
Oligomer 
In amyloid research, it is a blanket term used for structurally distinct species larger than 
monomer, typically metastable, and should only be used for structures without a fibrous 
morphology to define the difference between oligomers and protofibrils (figure 1.2.1).   
The nomenclature is perhaps unclear due to little structural information, diverse sizes in 
single preparations and a variety of morphologies exhibited.  The noun oligomer is 
derived from the Greek word oligos, meaning “a few”, which arguably in usage can 
depend upon the total sum of entities. It has been suggested that aggregate is a better 
descriptive term (Fandrich, 2012), however I feel that an aggregate, as used in geology, 
is a collection of entities with different sizes, shapes, no ordered structure and formed 
from various materials.  The latter two features poorly describe these oligomers which 
individually have an ordered structure, are made of the same material and neither are the 
single entities bound together, therefore I do not feel it is not a suitable description.   
 
Oligomers have distinct morphologies in which the structures and composition of 
individual monomers are probably homologous.  In the literature oligomers of varied 
morphology have been described as amorphous aggregates, micelles, prefibrillar 
aggregates, soluble oligomers, globular oligomers, Aβ-derived diffusible ligands 
(ADDLs) (Giasson et al., 2003) and protofibrils (Nelson et al., 2005).  However, due to 
common use in current literature, this body of work uses nomenclature based on 
oligomer size classification described herein as low molecular weight oligomers (LOs) 
and high molecular weight oligomers (HOs) which for convenience are  described 
respectively as less than and greater than 10 protein molecules.  Additional detailed 
morphology classifications such as annular and spherical oligomers will be discussed 
when necessary.  Some reviews on the subject include (Lashuel and Lansbury, 2006, 
Benilova et al., 2012, Fandrich, 2012).   
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Intermediate oligomer 
Transitional oligomeric species on-pathway to forming amyloid fibre 
 
Amorphous aggregate   
Accumulation of protein molecules absent of clearly defined structural characteristics. 
 
Amyloid Fibre Seed 
Entity that when added may induce kinetically stable molecules to aggregate, often 
through growth of the seed itself (Kodali and Wetzel, 2007). 
 
 
Figure 1.2.1 Amyloid Fibres, Protofibrils and Oligomeric Structures 
AFM and EM images of structures formed by amyloid forming proteins.  (A) AFM of globular Aβ 
oligomers.  (B) EM of annular Aβ oligomer. (C) AFM of small curly α-synuclein protofibrils and thicker 
mature fibres.  (D) AFM of mature Aβ amyloid fibre.  Figure adapted and reprint permission obtained  
(Bartolini et al., 2011) (A, D), Macmillan Publishers Ltd: [Nature] (Lashuel et al., 2002) (B) and (Koo et 
al., 1999) (C).  
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1.3 Amyloid Associated Disease 
 
Amyloidoses, include over 25 familial, sporadic or transmissible pathological 
conditions, some with high prevalence in the human population (Stefani, 2010).  Table 
1.1.1 contains some of the most common and well-studied examples.  Many age-related 
degenerative disorders are recognised to be amyloid-associated diseases with the 
accumulation of misfolded proteins and are often termed ‘protein misfolding diseases.  
Aggregate clearance is often slowed down by disease and ageing, leading to the 
accumulation of misfolded and misassembled proteins which then leads to amyloid 
associated diseases (Smith, 2003).   
 
A further link to amyloid forming proteins being causally related to the aetiology of 
amyloidoses is the finding that familial mutations which increase protein concentration 
or aggregation potential often cause early disease onset and premature death.  Amyloid 
diseases predominantly involve the aggregation of a specific protein; however a range 
of other components including additional proteins and carbohydrates may become 
incorporated into deposits when formed in vivo (Dobson, 1999).   
 
The effects of amyloidosis in vivo vary widely depending on the nature of the misfolded 
protein and the location of the aggregation.  Systemic amyloidosis, the deposition of 
protein throughout the body  can cause medical problems due to the volume of material 
in tissues (Falk et al., 1997).  Two important examples of this are human cystatin C 
amyloid angiopathy, in which deposition of amyloid around blood vessels can lead to 
circulation problems and stroke (Palsdottir et al., 1988) and haemodialysis-related 
amyloidosis in which β2-microglobulin forms plaques in the skeletal joints of 
individuals on dialysis.  In most neurodegenerative diseases however, the primary 
symptoms appear to be the result of ‘toxic gain of function’, which is poorly understood 
(Dobson, 2003).   
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1.4  Amyloid Assembly 
 
1.4.1  Protein Conformation Change 
Virtually any peptide sequence can form amyloid fibre in appropriate conditions 
(Fandrich et al., 2001).  However, peptides and proteins which aggregate readily in 
neurodegenerative disease predominantly adopt unstructured conformations in their 
normal biological state (Chiti et al., 2003), and are thus more likely to sample 
conformational states suitable for amyloidosis. It is suggested that amyloid forming 
proteins, if not natively unstructured become structurally destabilised before forming 
amyloid.  Natively folded proteins therefore form amyloid through an unfolded, or at 
least transient locally misfolded state.  Local misfolding can be self-catalysed so that a 
misfolded conformer induces similar misfolding in the protein population in a manner 
identical to prion propagation (Dhulesia et al., 2010, Eichner et al., 2011, Jahn et al., 
2006).  Amyloid fibres then elongate from seeds by self-templated growth.  
 
Within a protein or peptide, short sequences may form ‘Aggregation prone regions’ 
which share similar physical characteristics responsible for amyloidogenesis.  These 
‘amyloid hotspots’ are often regions of instability frequently containing a high 
percentage of aromatic and hydrophobic side chains (Maurer-Stroh et al., 2010), 
negatively charged amino acids and a high propensity to convert from α-helices to β-
sheets (Chiti et al., 2003). 
 
It has also been suggested that there are ‘aggregation gatekeepers’, which reduce 
aggregation by opposing nucleation of aggregates.  These ‘gatekeeper’ peptides disrupt 
with the repulsive charge effect (arginine, lysine, aspartate, and glutamate residues), the 
entropic penalty of arginine and lysine or incompatibility with β-sheet structure in the 
case of proline (Reumers et al., 2009).  Proline is highly effective as a β-sheet ‘breaker’ 
and proline isomerisation, a typically slow process, is suggested be required for 
amyloidogenesis in several proteins, including β2-microglobulin (Eichner et al., 2011) 
and cystatin B (Kokalj et al., 2007).  Additionally, chaperone specificity for certain 
‘aggregation gatekeepers’ has been shown whereby chaperone proteins recognise 
patterns of charged residues followed by hydrophobic regions (Reumers et al., 2009).  
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Despite the potential that amyloid fibre is a structure that can be assumed by any 
polypeptide, amyloidogenesis is extremely specific with only very similar proteins 
forming fibres with one another.  In some cases, a single residue change is enough to 
prevent the co-fibrilisation of two proteins (Hill et al., 1997), although in larger proteins 
only a small amyloidogenic region needs to be conserved (Sambashivan et al., 2005).  It 
has been determined that six residues peptides represent the minimum length required 
for amyloid formation (Fernandez-Escamilla et al., 2004).   
 
1.4.2  Amyloid Formation Events 
 
Typical ‘Visible’ Microscopic Pathway Determined by EM and AFM 
1. Formation of spherical particles (HOs) which can range in diameter from 3 nm 
to 25 nm or the production of amorphous aggregates (Glabe, 2004).  This 
structural rearrangement may in some cases utilise specific structural 
transitions such as domain swapping. 
2. Small ‘bead-like’ structures are sometimes observed and lead to formation of 
protofibrils.  These structures are commonly short, thin, and sometimes curly 
(Dobson, 2003). 
3. Mature amyloid fibres formation  
 
1.4.3  Kinetics and Thermodynamics of Amyloid Formation 
In protein misfolding diseases linked with amyloid fibre and oligomer formation, it is 
important to consider the kinetic and thermodynamic underpinnings (see figure 1.4.1).  
Most proteins in physiological conditions fold into their native state because the free 
energy of activation (ΔG‡ which dictates the folding rate) separates the unfolded and 
transition state and is surmountable.  Therefore the folded state is substantially more 
stable than the unfolded state.  The difference in free energy, ΔG, dictates the relative 
populations of folded and unfolded proteins.  For aggregation-prone proteins, the 
misfolded oligomeric state can however be more stable than the native folded/unfolded 
conformation in certain conditions and thus the oligomeric state becomes populated.  
ΔG‡* determines the rate of conversion to oligomeric forms, whilst ΔG* dictates the 
relative populations in competition with the intrinsic clearance mechanisms which 
remove the misfolded protein (Cohen and Kelly, 2003). 
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Figure 1.4.1  Thermodynamics of Protein Folding and Misfolding 
In physiological conditions the native state is favoured, however in ‘misfolding conditions’, 
aggregation/multimeric/fibrous states may be energetically favoured over the natively folded state.  ΔG‡ 
dictates the folding rate whilst the difference in free energy, ΔG, dictates the relative populations of 
folded and unfolded proteins.  ΔG‡ * determines the rate of conversion to aggregation competent forms, 
whilst ΔG* dictates the relative populations of folded and unfolded states.  ΔG‡# dictates the rate of high 
molecular weight oligomeric structure formation, whilst the ΔG# dictates the relative population.  ΔG‡ 
◊
 
determines the rate of conversion to amyloid fibre structures, whilst ΔG* 
◊
 dictates the quantity of amyloid 
fibre (Cohen and Kelly, 2003). 
 
Amyloidogenesis typically exhibits a lag phase, whereby little fibre formation occurs, 
which is subsequently followed by an exponential growth phase until a thermodynamic 
equilibrium is reached (see figure 1.4.2).  The amyloidogenesis lag phase can be 
reduced or ablated by the addition of ‘seeds’ which when observed by EM, are mostly 
small fragments of amyloid fibre usually generated by sonication of mature fibres.  In 
addition, the fibre seed conformation controls product conformation in a cross-seeding 
reaction.  If a fibre seed contains a small percentage of a second conformation, and if 
that conformation has a favourable elongation rate, then the minor fibre conformation 
can dominate the population after a few cycles of seeded growth (Antzutkin et al., 2002) 
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The seeding phenomena strongly suggests a nucleated growth mechanism whereby the 
rate limiting step depends upon the existence of a rare perhaps stochastically generated 
nucleus (Hortschansky et al., 2005).  The rarity of the nucleus could be explained if 
nucleus formation is thermodynamically unfavourable where the resultant 
intermolecular interactions do not outweigh the entropic cost of association.  However, 
the exponential growth phase, in the simplest case, could be due to further addition of 
monomer to the nucleus becoming thermodynamically favourable by increased 
intermolecular interactions and therefore overcoming the entropic barrier  (Jarrett and 
Lansbury Jr., 1993). 
 
 
Figure 1.4.2 Typical Fibrilisation Kinetics 
Amyloid fibre formation typically follows a kinetic profile of a nucleation-dependent process which 
exhibits a lag phase followed by an exponential growth period and subsequent thermodynamic 
equilibrium (solid line).  At a high concentration or very favourable environmental conditions, nucleation 
is so rapid no lag phase is observed (dashed line).  The addition of a nucleus or seed eliminates the 
nucleation step and therefore also ablates the lag phase (Jarrett and Lansbury Jr., 1993).   
 
Amyloidogenesis is complex with several posited steps, figure 1.4.3 shows a suggested 
basic scheme of the Aβ1-42 amyloidosis assembly process as an example.  The protein 
species inhabiting the lag and elongation phase are not clearly defined and may vary for 
different proteins.    High-resolution atomic force microscopy (AFM), low-energy 
electron-spray ionisation ion mobility tandem mass spectroscopy (ESI-IMS-MS) and 
analytical ultracentrifugation (AUC) identifies a continuum of aggregated protein states 
starting as low as dimers for both Aβ and β2-Microglobulin (β2M), although equally 
other studies have found oligomers to be relatively homogeneous  (Kodali and Wetzel, 
2007, Ostner et al., 2013).   
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Figure 1.4.3   Schematic of the Amyloidosis Assembly Process 
This suggested basic scheme describes the classes of structure possibly on pathway to amyloid fibre 
formation.  Suitable technique ranges for morphological and/or quantitative evaluation of the prevailing 
species are shown in the grey box.  X-ray crystallography (X-ray) and nuclear magnetic resonance 
spectroscopy (NMR) can be used to determine the native folded conformation, with the latter reporting on 
structural dynamics.  Circular dichroism (CD) and fourier transform infra-red spectroscopy (FTIR) is 
used to determine the secondary structure content, whilst mass spectroscopy (MS) can determine the 
stoichiometry and overall morphology of monomers to soluble oligomers. Atomic force microscopy 
(AFM) and electron microscopy (EM) can be used to observe small oligomeric and fibrous structures, 
whilst fluorescence light microscopy (FLM) can be used to observe larger oligomers and fibres in real 
time.  Analytical ultracentrifugation (AUC) can be used to observe the stoichiometry of the structures 
formed assuming specific structural states.  Conformation specific antibodies can be used to report on the 
type of structures present when compared with other techniques.  Figure based on one presented in 
(Bartolini et al., 2011) with permission. 
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1.4.4  Models of Amyloid Formation 
There are at least four prevalent mechanisms proposed for amyloid formation which are 
shown in figure 1.4.4 and discussed in (Kelly, 2000, Serio et al., 2000, Murphy, 2007), 
with no mechanism being conclusively proven, although all follow the requirement for a 
nucleus and/or conformational conversion process.  These mechanisms include the 
template assembly model (TA) (Griffith, 1967), Monomer Directed Conversion (MDC) 
(Prusiner, 1982), the nucleated polymerisation model (NP) (Jarrett and Lansbury Jr., 
1993) and nucleated conformational conversion (NCC) (Serio et al., 2000).  
   
Figure 1.4.4 Prevalent Models of Amyloidogenesis 
Smooth circles represent the A-state protein, which is analogous to the conformation adopted in amyloid 
fibre; jagged circles identify the soluble S-state protein; and open circles denote possible conformational 
heterogeneity.  (A) Templated assembly.  (B) Monomer-directed conversion.  (C) Nucleated 
polymerisation (D) Nucleated conformational conversion.  Figure modified and reprint permission 
obtained from Macmillan Publishers Ltd: [Nature Structural Biology] (Kelly, 2000). 
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The templated assembly model involves the soluble S-state binding to a pre-assembled 
nucleus followed by a rate-determining structural conversion and addition to the end of 
the fibre (Griffith, 1967).  This model predicts that the lag phase should decrease 
proportionally to an increase in soluble protein concentration whilst the rate of fibre 
elongation should remain unaffected. The lag phase should also be reduced upon the 
addition of a seed. 
 
The monomer-directed conversion model proposes that a monomeric peptide adopts a 
conformation analogous to that of the fibre state, termed the A-state.  In the rate-
determining step, the A and S-state bind and the S-state monomer is converted to the A-
state.  The resultant dimer then dissociates and the A-state dimers then rapidly combine 
with the end of the growing fibre.  This model predicts that the presence of a seed 
should not affect the rate or reduce the lag phase of the reaction since the rate limited 
step occurs in the soluble protein (Prusiner, 1982).   
 
In the nucleated polymerisation model, an equilibrium between the A and S-states 
occurs and with the assembly competent A-state forming the rate-limiting A-state 
nucleus.  This A-state nucleus then rapidly forms a fibre by the addition of A-state 
monomers being stabilised and incorporated into the growing end of the fibre.  In this 
model an increase in soluble protein concentration should accelerate the rate of fibre 
assembly and decrease the lag phase. The addition of a seed should abolish the time 
required for seed formation and so remove the lag phase (Jarrett and Lansbury Jr., 
1993).  Amyloid fibre assembly in vitro commonly displays a lag phase prior to rapid 
assembly.  In many cases the addition of preformed aggregates eliminates the lag phase 
in a process known as ‘seeding’.  In addition, this mechanism is common in nature with 
examples including actin polymerisation as well as microtubule and flagellum assembly 
and is therefore one of the current preferred assembly models (Jarrett and Lansbury Jr., 
1993).   
 
The nucleated conformation conversion model posits that conformational 
rearrangements within structurally dynamic oligomers induces the formation of a 
nucleus, which once formed interacts with other structurally flexible oligomers 
composed of a distribution of subunits and forms a group of subunits which can 
associate with similar structures or fibre to form extended fibrous structures. This model 
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rationalises low level concentration dependence, because at higher protein 
concentrations, oligomers form higher molecular weight complexes which are assembly 
incompetent.  This mechanism can furthermore describe why an increase in seed 
concentration may produce minimal rate enhancements, because the limitation is 
oligomer concentration, not fibre ends (Serio et al., 2000).  At the time of writing no 
consensus has been achieved with amyloid formation models, in part because the 
intermediate and oligomeric structures remain elusive and poorly understood kinetically 
and structurally. 
 
 
1.5  Amyloid Fibre Structure 
 
1.5.1  Introduction 
Most amyloid fibres by EM and AFM exhibit similar morphologies; long, unbranched 
and often twisted structures with diameters typically between 4-20 nm and several 
micrometers long (Fandrich, 2012, Kodali and Wetzel, 2007).  Amyloid fibres also 
exhibit a characteristic ‘cross-β’ x-ray fibre diffraction pattern revealing that the 
organised core structure is composed of β-sheets whose strands run perpendicular to the 
fibre axis (see figure 1.5.8) (Blake and Serpell, 1996).  It has been proposed that the 
fibre core is primarily stabilised with a large number of hydrogen bonds between the 
polypeptide backbones (Dobson, 1999).  However, the side chains must also contribute 
significantly to the specificity of aggregation and stability of the fibre (Huff et al., 
2003).  This latter idea forms the basis of prediction programmes that can estimate a 
sequence-based propensity to form amyloid.  This in turn feeds into the design of 
biomolecules with improved solubilities. 
 
Twisted right handed β-sheets are in a lower energy conformation than left handed and 
flat β-sheets (Chothia, 1973), thus are likely to be a preferred morphology.  
Furthermore, evidence from Fourier transform infrared spectroscopy (FTIR) of 
numerous amyloid fibres (including cystatins) along with EM reconstructions and AFM 
measurements suggest that amyloid fibre β-sheets are flattened (Zandomeneghi et al., 
2004).  
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Parallel in-register β-sheets have been observed by solid state NMR (SSNMR) in Aβ1−40 
(Petkova et al., 2002) and Aβ1−42 fibres (Antzutkin et al., 2002),  amylin fibres (Luca et 
al., 2007), various yeast prion fibres (Baxa et al., 2007, Shewmaker et al., 2006), HET-s 
(218-289) fibres (Wasmer et al., 2008), and PrP peptide fibres (Walsh et al., 2009).  
Parallel in-register β-sheet aligns hydrophobic residues plus glutamine and asparagine 
residues with themselves, potentially maximising favourable hydrophobic interactions 
and polar-zipper interactions, respectively, for any amino acid sequence (Perutz et al., 
1994).  Anti-parallel β-sheets have also been found in amyloid fibres but, until recently, 
only in fibres formed by short peptides that contain a single hydrophobic segment in a 
single β-strand (Tycko, 2011, Kammerer et al., 2004). 
 
A further complication is observed structural polymorphism of amyloid fibres, in which 
the same fibre preparation or subtle changes in growth condition produces distinct 
structural variation, observable in EM and SSNMR (Petkova et al., 2005).  As an 
example, Aβ1-40 quiescently generated striated-ribbon and agitated twisted pair fibre 
structures are reviewed in section 1.5.3 and figure 1.5.1.  Amyloid fibre polymorphism 
may exhibit itself in varying quaternary structure, protofilament self-association and 
substructure (e.g. side-chain packing within the protofilament).  The kinetic origins of 
this polymorphism remain unknown (Kodali and Wetzel, 2007, Eichner et al., 2011). 
 
A basic common structure is however, likely adopted because universal amyloid 
specific antibodies react with generic epitopes on all types of amyloid fibre and soluble 
oligomer.  These antibodies specifically bind amyloid but not native protein, thus 
providing further proof of non-native structure.  It therefore seems likely that this class 
of antibody recognises a specific conformational epitope; a turn or hydrogen bonding 
motif on the polypeptide backbone (Glabe, 2004).  This antibody conformation-
specificity is further supported by consistent amyloid binding of accessory molecules, 
including serum amyloid P component, proteoglycans/glycosaminoglycans and 
apolipoprotein E (Huff et al., 2003). 
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1.5.2  Methods of Amyloid Fibre Structure Determination  
Standard high resolution experimental techniques such as X-ray crystallography and 
traditional solution NMR fails to yield structural information on the large heterogeneous 
fibre structures.  Therefore a combination of biophysical and biochemical techniques is 
required to develop structural constraints which lead to refinement of the structural 
models.  These techniques include X-ray fibre diffraction, solid-state NMR (SSNMR), 
with complementary information provided by hydrogen-deuterium (H/D) exchange, 
electron paramagnetic resonance spectroscopy (EPR), limited proteolysis (LP), site-
directed mutagenesis, transmission electron microscopy (TEM) and atomic force 
microscopy (AFM).  The high degree of secondary structure found in amyloid fibres 
also permits study by fourier transform infra-red spectroscopy (FTIR) and circular 
dichroism spectroscopy (CD). As of writing however, no atomic resolution fibre model 
has been reliably constrained for a natively folded globular protein such as the all-β-
sheet proteins β2-microglobulin and transthyretin.   
 
Dye Binding Assays 
When stained with Congo-red, amyloid fibres exhibit green birefringence when viewed 
under cross-polarised light (Sipe and Cohen, 2000).  Amyloid fibre also binds thioflavin 
T (ThT) and thioflavin S, which when bound exhibit a shift in fluorescence emission 
maxima.  Congo-red birefringence and ThT fluorescence shift most likely results from 
alignment of the dye molecules when bound to the fibre. The fibre must display a 
common epitope and the dye binding most likely occurs through specific associative 
binding through the extended β-sheet or intercalation (Glenner et al., 1972, Wolfe et al., 
2010). 
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Microscopy Techniques 
TEM and AFM are often used singly and in conjunction to provide complementary 
information on morphology and dimensions of amyloid fibre and their intermediates.  
TEM and AFM have also been used to follow the formation of oligomeric and fibrous 
structures and fibrilisation by discontinuous and continuous methods (Goldsbury et al., 
1999).  A specialised scanning transmission electron microscopy (STEM) can be used 
to make mass per unit length (MPL) measurements, e.g. χ kDa/nm and is used to 
determine the spacing of repeating units in amyloid fibre (Wall et al., 2008).  Therefore 
this measurement has been performed on several amyloid fibre forming proteins and 
forms a major part in amyloid fibre structural modelling (Petkova et al., 2002).  Cryo-
electron microscopy has been used to produce 3D reconstructions of amyloid fibres by 
particle averaging and although it doesn’t provide atomic resolution it strongly aids 
structural modelling (White et al., 2009, Serpell et al., 2000, Jimenez et al., 1999).   
 
The crystal structure of a designed peptide incorporating motifs found in a large number 
of known amyloidogenic peptides has been solved from small needle-like crystals by 
electron diffraction.  In this instance X-ray diffraction was poor and the subsidiary 
technique was then used (Makin et al., 2005).  This KFFEAAAKKFFE peptide was 
shown to be stabilised in an anti-parallel configuration by π-π stacking interactions 
between phenylalanine side chains, charge balancing and inter-chain hydrogen bonding.  
The crystallisation was presumably made possible due to the compact, homogeneous 
nature of the fibres which have no large mobile regions which would impede crystal 
packing.  However, the interpretation of crystal structures relies on a careful evaluation 
of how closely the crystals reflect the structural organisation within the fibre states 
(Marshall et al., 2010).   
 
X-Ray Fibre Diffraction 
Most of the initial detailed amyloid fibre structural information was determined by X-
ray fibre diffraction (Blake and Serpell, 1996).  Amyloid fibre produces diagnostic 
reflections in two positions: meridional reflections of 4.7Å from repeating β-sheet along 
the fibre axis and 10 Å equatorial bands generated from electron density perpendicular 
to the fibre axis, which is indicative of cross-β structure (Geddes et al., 1968, Blake and 
Serpell, 1996).  The meridional reflections are produced by the repeated interstrand 
hydrogen bond spacing between the β-sheets whilst the orthogonal equatorial reflections 
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are generated by intersheet interactions.  Well aligned fibre preparations can also be 
used to determine further structural information, such as helical pitch/helical repeating 
unit, accurate overall shapes, dimensions and even the presence of a hydrated fibre core 
(Blake and Serpell, 1996, McDonald et al., 2012).  Fibre diffraction can however, only 
image these molecular details in exceptionally favourable cases (Chandrasekaran and 
Stubbs, 2006, Stubbs, 1999). 
 
X-Ray Crystallography  
A range of X-ray microcrystal structures have been determined from short known 
amyloidogenic peptide sequences.  Sequences such as GNNQQNY form both fibres in 
the traditional sense and microcrystals which form in identical conditions, exhibit small 
fibrous appendages and in some cases appear composed of several aligned, nanometer-
sized blocks which may be the result of individual mature fibre aggregation into the 
crystalline form.  Furthermore, these crystals are primarily composed of β-strands 
stacked perpendicular to a single axis and produce similar inter-sheet/inter-strand 
spacings to that of X-ray fibre diffraction patterns (Nelson and Eisenberg, 2006, 
Marshall et al., 2011). 
 
The resultant structures are cross-β spines of two β-sheet amide stacks tightly packed 
complementary to one another in a dry interface with wet interfaces between adjacent 
cross-β spines.  A study with 30 peptides derived from Aβ, tau, PrP prion, insulin, islet 
amyloid polypeptide, lysozyme, myoglobin, α-synuclein and β2-microglobulin all 
showed this similar overall topology.  5 out of 8 structural arrangements were observed 
distinguished by (i) strand orientation in parallel or anti-parallel, (ii) β-sheet packing 
with the same surface adjacent to one another (‘face-face’) or opposing (‘face-back’) 
and (iii) β-sheet orientation parallel (‘up-up’) or anti-parallel (‘up-down’) (Serpell, 
2000).  In my view these structures are unlikely in many cases to directly match the 
structures formed by the full length polypeptide due to the array of feasible interactions 
available to a larger molecule.  However, these structures highlight the possible 
variations in orientation and provide a clear indication of potential polymorphism.   
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Spectroscopic Techniques  
Circular dichroism (CD) and fourier transform infra-red (FTIR) spectroscopy 
techniques have been used to estimate the secondary structure content of amyloid fibres 
and using these techniques it has been shown that a wide variety of proteins adopt a 
high β-sheet content in amyloid fibres.  FTIR spectra in particular show a strong peak 
characteristic of large-scale β-structures, which appears as fibres are formed 
(Zandomeneghi et al., 2004).  
 
Limited Proteolysis 
To date, limited proteolysis has been exploited to analyse amyloid fibre formation in Aβ 
peptide (Kheterpal et al., 2001), α-synuclein (Miake et al., 2002), HET-s (Balguerie et 
al., 2003a), Ure2p (Baxa et al., 2003), PI3-SH3 (de Laureto et al., 2003), bovine α-
lactalbumin (de Laureto et al., 2005), β2-microglobulin (Myers et al., 2006) and 
lysozyme (Frare et al., 2006).  Limited proteolysis occurs primarily at sites with high 
chain mobility and rarely within regular secondary structure.  Therefore, conformational 
parameters such as accessibility, mobility and protrusion correlate with limited 
proteolysis data (Hubbard, 1998).   
 
Hydrogen/Deuterium Exchange 
Quenched hydrogen/deuterium (H/D) exchange (Hoshino et al., 2002, Alexandrescu, 
2001) experiments on amyloid fibres have been used to map the solvent-accessible 
regions, thus inferring some structural information.  This method observes the rate at 
which amide protons exchange with deuterons of the peptide backbone (or vice versa).  
This rate is dependent on solvent accessibility of the amide protons; amides that are 
solvent exposed exchange rapidly, whilst those that are incorporated within structured 
regions of the protein or involved in stable hydrogen bonding networks exchange at a 
slower rate and are thus determined to be ‘protected’ from exchange.  The exchange 
process is quenched by freezing and drying the samples followed by rapidly 
dissociating the fibres in organic solvent such as dimethyl-sulphoxide (DMSO) and 
analysis by NMR or MS.  NMR is the typically preferred method of observation 
because it provides residue specific information from an assigned 2D transverse 
relaxation optimised spectroscopy or heteronuclear single quantum coherence (TROSY 
or HSQC) NMR spectrum (Pervushin et al., 1997).   
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MS can be a complementary approach as this method provides information on the 
populations of partially and fully exchanged species, however cannot provide residue 
specific information.  MS therefore provides information on the homogeneity of the 
sample.  H/D exchange has also been used to demonstrate the dynamic nature of 
amyloid fibre, whereby molecules were shown to dissociate and re-associate with the 
fibres (Carulla et al., 2005, Sanchez et al., 2011).  H/D exchange could also be used to 
ascertain a change in amyloid fibre dissociation rate or binding event and monitor how 
the structure is perturbed by the binding of novel therapeutic agents.   
 
Solid-State Nuclear Magnetic Resonance 
SSNMR is the only technique which can obtain atomic resolution in non-crystalline 
solids and has therefore been used to measure specific inter-residue distance, torsion 
angles and dynamics of peptide and protein molecules within amyloid fibres.  To 
generate structural models of the amyloid fibres the SSNMR constraints must be 
combined with data from other techniques such as X-ray fibre diffraction, MPL 
measurements and EM (Petkova et al., 2002, Antzutkin et al., 2002, Shewmaker et al., 
2006, Baxa et al., 2007, Luca et al., 2007, Paravastu et al., 2008, Fawzi et al., 2011, 
McDonald et al., 2012, Wasmer et al., 2008).  The contribution of this technique to 
current understanding of amyloid fibre structure is discussed further in the following 
sections. 
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1.5.3 Amyloid β Peptide  
Amyloid β 1-40 
SSNMR combined with other techniques such as mass-per-unit-length (MPL) 
measurements has produced structural constraints for Aβ1-40, sufficient to produce 
molecular level modelling, with only small unresolved variations in packing interface 
alignment (Petkova et al., 2002, Petkova et al., 2005, Petkova et al., 2006, Paravastu et 
al., 2008).  In both the quiescently generated striated-ribbon and agitated twisted pair 
Aβ1-40 fibre models the first 9 residues are structurally disordered, whilst residues 10-22 
and 30-40 form in-register parallel β-sheets only through intermolecular hydrogen 
bonding.  Residues 23-29 form a tight loop, linking the two β-sheets into a β-arc, often 
described as a ‘hairpin’.  The twisted pair Aβ1-40 fibre is composed of three Aβ1-40 
monomer arcs constructed around a central hydrated hydrophobic channel in a 
triangular cross section with three-fold symmetry (see figure 1.5.1)  (Paravastu et al., 
2008, McDonald et al., 2012).  The striated-ribbon Aβ1-40 fibre instead has a two-fold 
symmetry and is composed of two Aβ1-40 monomer arcs per protofibril (Petkova et al., 
2002).  Limited proteolysis with trypsin and chymotrypsin proved relatively 
inconclusive with hydrolysis sites throughout the peptide.  This is perhaps a result of an 
observed equilibrium state between monomer/soluble peptide and amyloid fibre, thus 
the results are possibly skewed by soluble unfolded peptide hydrolysis (Kheterpal et al., 
2001).  
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Figure 1.5.1  Aβ1-40 Amyloid Fibre Structural Models 
Experimentally based structural models of striated-ribbon and agitated twisted pair Aβ1-40 fibre.  
Unstructured N-terminal residues 1–8 are omitted.  (A) Ribbon representation of the lowest-energy model 
for ﬁbres with the twisted morphology.  Modelling calculations assume three-fold symmetry, consistent 
with MPL data and SSNMR spectra, and are constrained by secondary, tertiary, and quaternary structural 
data from solid state NMR.  (B)  Atomic representation, viewed down the ﬁbre axis. Hydrophobic, polar, 
negatively-charged, and positively charged amino acid sidechains are green, magenta, red, and blue, 
respectively. Backbone nitrogen and carbonyl oxygen atoms are cyan and pink.  (C) Comparison of 
twisted (Upper) and striated ribbon (Lower) ﬁbre morphologies from negatively stained TEM. (D)  
Atomic representation of a striated ribbon fibre (Paravastu et al., 2008).  (E and F)  Mass-per-unit-length 
(MPL) histograms of twisted fibre (E) and striated fibre (F).  The red dashed lines indicated predicted 
MPL values from the models.  The solid blue lines are from multiple-Gaussian fits.  Figure modified and 
reprinted from (Paravastu et al., 2008, Tycko, 2011) with permission from Elsevier. 
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Amyloid β 1-42 
Modelling of Aβ1-42 amyloid fibre has been conducted using the (Petkova et al., 2002) 
Aβ1-40 SSNMR study β-sheet arrangement and combining structural constraints of Aβ1-
42 side-chain packing pairwise mutagenesis studies and H/D exchange NMR data (Luhrs 
et al., 2005).  The parallel in-register β-arc (hairpin) structure remains analogous to Aβ1-
40, although individual residue involvement is not identical.  Aβ1-42 residues 1-17 are 
disordered whilst residues 18-26 and 31-41 form parallel β-sheets linked with a loop 
formed from the intervening amino acids (see figure 1.5.2).  This structure is stabilised 
by a proposed salt-bridge between K28 and D23 and hydrophobic interactions mediated 
by residues L17, F19 and A21 in β-sheet 1 and even-numbered residues of β-sheet 2.  
The model closely fits other experimental data such as H/D exchange NMR in which 
residues 12-25 and 28-42 are protected for 120 minutes.  AFM of Aβ1-42 fibres suggests 
an average height between nodules (generated by fibre twist) to be 3.5 nm, a width of 
~4 nm and twist nodules 110 nm apart (Olofsson et al., 2006).   
 
 
Figure 1.5.2 Aβ1-42 Amyloid Fibre Structural Model 
Ribbon and space filling model showing the amyloid fibre core β-arc structure of Aβ1-42 residues 17-42.  
(A) Side view of individual hairpin ribbons with illustrated inter-β-strand salt bridge between residues 
D23 and K28, indicated by dotted lines and framed by rectangles.  (B)  Top view of β-sheet arc (hairpin) 
motif.  Hydrophobic, polar, negatively charged, and positively charged amino acid side chains are shown 
in yellow, green, red and blue, respectively and all others are shown in white (Luhrs et al., 2005).   
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1.5.4  β2-Microglobulin 
The cryo-EM reconstruction of β2-microglobulin (β2m) revealed a high degree of 
complexity and two structural polymorphs shown in figure 1.5.3 (White et al., 2009).  
Type A exhibits polarity, whereby both ‘crescent half-fibres’ (protofilaments) are 
orientated in the same direction along the fibre axis and type B is bipolar, with opposing 
protofilaments orientations.  Scanning transmission EM (STEM) based mass-per-unit-
length measurements (MPL) were used to deduce the molecular packing of β2m fibres 
with type A and B structures consistent with 53±3 kDa/nm fibres and fibres with half 
the width (type C) matching a smaller population of fibres with an MPL of 27±3 
kDa/nm.  An interpretation of these values could be that type C are protofilaments, 
whilst type A and B are more populous mature fibres as this twisted morphology is 
more intimate than simple random lateral association.   
 
An atomic level model which fits the EM density and biochemical and biophysics data 
has yet to be conclusively constrained, despite attempts at fitting domain swapped 
dimers, staggered native monomers and other models, all of which neither entirely fit 
the density nor match previously determined structural constraints.  A model with pairs 
of protein subunits threaded through each ‘crescent’ with flexible hinge regions between 
the protofilaments is possible.  However, a proffered model for the type A and B forms 
of ß2m amyloid fibre is based on a dimer-of-dimers subunit packing, with each elliptical 
cylinder corresponding to two ß2m monomers (White et al., 2009).  This model is 
perhaps favoured due to H/D exchange kinetics which suggests multiple environments 
for individual residues within the fibre structure (Yamaguchi et al., 2004).   
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H/D exchange data from β2m suggests that the N terminal β-strands (A and G) are less 
protected in mature amyloid fibres than the natively folded protein, thus extraneous 
from the fibre core.  β-strands B-E on the other hand show a high degree of H/D 
exchange protection and are thus incorporated into the fibre core.  The H/D exchange 
protection of β-strand F fibre was not reported for experimental reasons (Hoshino et al., 
2002).  Subsequent experimental work identified that the C-terminal β-strand was 
protected by an amplitude of ~50%, and thus incorporated within the amyloid fibre core 
in at least half of the fibre composing molecules.  This varied protection is also 
indicative of residue protection throughout the fibre.  When H/D exchange was probed 
from hours up to 13 days, a biphasic exchange mechanism was observed with rapid and 
subsequent exceptionally slow exchange.  This biphasic nature suggests multiple amino 
acid environments, perhaps due to inherent structural differences.  These differences 
could be due to the helical twist observed in many fibres leading to a mixture of 
exposed and buried residues or lateral association/assembly of fibres/protofilaments 
which could also reduce solvent exposure (Yamaguchi et al., 2004), or indeed varied 
structural motifs within structural ‘sub-units’. 
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Figure 1.5.3  β2-Microglobulin EM Structural Reconstruction and Model 
(A-D)  Three-dimensional reconstructions of type A (left) and type B (right) forms of ß2m amyloid fibres.  
A and B are side views down the fibre axis and C and D are equatorial views.  One dimeric density unit is 
indicated by a red box in B. The directions of the half-fibril crescents are indicated by the arrows below A 
and B.  (E)  Superposed contour plots of the A type (lilac) and B type (green) fibre repeat units, showing 
that the two fibril types have the same underlying organisation that differs only in the orientation of the 
two stacks, either parallel or anti-parallel.  (F and G) Schematic representation of the dimer-of-dimers 
subunit packing for the type B form of ß2m amyloid fibre; each elliptical cylinder corresponds to two ß2m 
monomers. The outermost (orange) protofilaments in the model are disordered in the map, so their full 
density is not reconstructed.  Reprinted from (White et al., 2009) with permission from Elsevier. 
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1.5.5  Cystatin B 
The current cystatin B amyloid fibre model is based on EM fibre width measurements 
(Jensson et al., 1987), H/D exchange data (Morgan et al., 2008) and application of the 
simplest model based on the assumption of near-native β-sheet conformation, which is 
supported but not implicitly constrained by the current data available (see figure 1.5.4).  
From H/D exchange data, the cystatin B amyloid fibre core is likely to be comprised of 
β-strands 2, 3, 4 and 5, the C-terminal region and includes the loop between strands 2 
and 3.  Protection in this loop is indicative of the retention of the 3D domain-swap 
interface and hence the topology of the dimeric form is used in figure 1.5.4.  The α-helix 
and the first ß-strand of the native structure are excluded from the fibre core.   
 
The current cystatin B model, shown in figure 1.5.5, also requires the removal of β-
bulges in β-strand 2 and 5 which then allows amide four NH and carbonyl groups to 
form intermolecular hydrogen bonds in the direction of the fibre axis.  From H/D 
exchange protection it is suggested that β-strand 2 residues K39, V41, F43, S45 and 
partnered β-strand 5 residues T81, S83, Y85 and T87 contribute to hydrogen bonding in 
this interface.  In this model the β-sheet face from which the central native α-helix has 
been removed is hydrophobic and the alternate face has a net positive charge at neutral 
pH due to lysine or arginine residues at position 40, 44, 68 and 89 (Morgan et al., 
2008).  The current proposed model from the H/D exchange data is based upon the 
model posited in (Staniforth et al., 2001), whereby the fibre composes a dimer of 
domain-swapped dimers stacked in the fibre.  The model in figure 1.5.5, panel E and F 
is historical with the H/D exchange data not completely satisfied by this model and the 
AFM and EM measurements of cystatin B amyloid fibre (Zerovnik et al., 2002a) 
suggest a ‘flat tape’ morphology which the model in panel F does not entirely fulfil. 
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Figure 1.5.4 Hydrogen/Deuterium Exchange Topology of Cystatin B 
Hydrogen/deuterium exchange protection mapped onto the native state topology diagrams of cystatin B 
(left) and protection values plot (right).  Protected residues are coloured red, those in orange show partial 
protection, blue are unprotected and white residues are undetermined.  The protection value plots includes 
above them rectangles denoting α-helices, β-sheets by arrows and lines for loops whilst the dotted line 
shows the arbitrary threshold required for protection to be assigned .  Adapted from (Morgan et al., 2008) 
with permission from Elsevier. 
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Figure 1.5.5 Cystatin B Amyloid Fibre Model 
(A-D) Cartoon representation of the simplest model consistent with H/D exchange data.  The α-helix 
represented is actually unfolded within the fibre and is only shown for clarity.  (A) Secondary structure 
representation of the repeating structural moiety within the fibre core.  (B) Stacking of the dimer-like 
amyloid core units to create a ribbon, consistent with the observed protection of strand 5 of the globular 
fold.  (C) Simplified view of (B), showing the shape of the building blocks. (D) Two ribbons, represented 
as in (C), packed through the hydrophobic faces generated by the displacement of the α-helix to create a 
fibre model consistent with the overall EM cross-section dimensions of cystatin fibres from (Jensson et 
al., 1987).  (E) Schematic representation of cystatin B fibre produced from native-like 3D domain 
swapped dimers.  (F) Space filling model of two domain-swapped dimers fitted into the EM cross-section 
of a ‘generic amyloid fibre’.  Images A-D are from (Morgan et al., 2008) and reprinted with permission 
from Elsevier and panels E and F are reprinted by permission from Macmillan Publishers Ltd: [EMBO] 
(Staniforth et al., 2001). 
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1.5.6  HET-s (218-289) Prion   
The full amyloid fibre structural model formed by residues 218–289 of the Podospora 
anserina HET-s prion protein has been determined by SSNMR structural restraints and 
is shown in figure 1.5.6 (Wasmer et al., 2008).  HET-s (218-289) forms a parallel in-
register left-handed β-solenoid with each molecule forming two β-strand helical 
windings from four β-strands, three of which contribute to form a triangular 
hydrophobic core.  The triangular hydrophobic core is tightly packed, dry interface 
containing almost exclusively hydrophobic residues (Ala, Leu, Ile and Val).  The only 
polar residues in the core are T233 and S273, which are suggested to form hydrogen 
bonds and stabilise the formation of a turn between β-strands 1 and 2.  In contrast, all 
the charged residues face outwards and are located in highly solvent accessible β-arc 
regions.  Three of the charged residues are stacked in the direction of the fibre axis, 
which compensates for the charge and allows salt-bridge formation.  In this structure at 
least 23 hydrogen bonds, three salt bridges and two asparagines ladders have been 
determined.  The cross-section of the structure is approximately circular, thus 
potentially explaining why no helical twist has been observed in electron micrographs 
(Wasmer et al., 2008).  The SSNMR model matches data from H/D exchange, water 
accessibility and mutant studies (Ritter et al., 2005).  This C-terminal proteinase K 
resistant core of prion fibres is unstructured in solution and forms infectious fibres in 
vitro (Balguerie et al., 2003b).     
 
The HET-s fibres have a triangular cross-section that is superficially similar to the 
threefold-symmetric Aβ1-40 model, the details of the two models are however quite 
different. Specifically, (i) β-sheets in HET-s fibres contain both intramolecular and 
intermolecular backbone hydrogen bonds, whereas β-sheets in Aβ1-40 fibres contain only 
intermolecular hydrogen bonds; (ii) each side of the triangular cross-section in HET-s 
fibres is formed by a single β-sheet layer, whereas each side of the triangular cross-
section in threefold-symmetric Aβ1-40 fibres is formed by two β-sheet layers; (iii) the 
MPL of HET-s fibres (40) is 0.5 monomer per 0.47 nm, compared with the 3 monomers 
per 0.47 nm of threefold-symmetric Aβ1-40 fibres; (iv) HET-s fibres also have no long 
axis symmetry (Tycko, 2011). 
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Fig. 1.5.6 Structure of the HET-s (218–289) Fibre 
(A) Side view of the five central molecules of the lowest energy structure of HET-s (218–289) calculated 
from the NMR restraints. The fibre axis is indicated by an arrow. (B) Top view of the central molecule 
from (A).  β-sheet β3 and β4 lie on top of β1 and β2, respectively.  (C) NMR bundle: superposition on 
residues N226 to G242, N262 to G278 of the 20 lowest-energy structures of a total of 200 calculated 
HET-s structures. Only the solenoid core residues are shown.  (D) Representation of the well-defined 
central core of the fibre (N226 to G242, N262 to G278).  Hydrophobic residues are coloured white, acidic 
residues red, basic residues blue, and others green (lowest-energy structure). (E and F) Schematic 
representations of the two windings in (D): the first winding [N226 to G242, displayed in (E)] of the β-
solenoid is located beneath the second one [N262 to G278, displayed in (F)]. Abbreviations for the amino 
acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, 
Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.  Figure from 
(Wasmer et al., 2008).  Reprinted with permission from AAAS. 
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1.5.7  Human Prion Protein PrP  
One of the suggested human prion protein (hPrP) models, which is similar to the 
SSNMR model of HET-s (218-289), suggests the formation of a parallel left handed β-
helix with α-helical regions located in extended loop regions which are excluded from 
the fibre core (see the figure below) (Govaerts et al., 2004). 
   
  
Figure 1.5.7  Modelling of Human Prion Protein Amyloid Fibre  
(A) β-helical model of the N-terminal hPrP.  (B) Model of the hPrP monomer.  (C) Crystal structure of 
trimeric carbonic anhydrase from Methanosarcina thermophila (PDB ID code 1THJ) which shows a 
similar structure thus proving the feasibility of such a model. (D) Trimeric complete model of hPrP.  
Models from (Govaerts et al., 2004). 
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1.5.8  Transthyretin 
A Transthyretin (TTR) fibre model from X-ray fibre diffraction and EM dimensions 
suggest a fibre composed of four parallel protofilaments of 50-60 Å which combine to 
produce a uniform fibre width of ~130Å.  The protofibril structure shown in figure 1.5.8 
is composed of four β-sheets, arranged perpendicular to the fibre axis, with a helical 
pitch of 115.5Å which relates to 24 β-strands per helical turn (Blake and Serpell, 1996).  
  
 
Figure 1.5.8 Transthyretin Protofilament X-Ray Diffraction Structural Model  
(a) Model of the transthyretin protofilaments core structure viewed (top) normal to the filament axis and 
(below) along the filament axis. The arrows represent the paths, but not necessarily the directions, of the 
β-strands. The β-sheets are arranged in parallel to the filament axis. (b) An isolated β-sheet shown for 
clarity.  Figure reprinted from (Blake and Serpell, 1996) with permission from Elsevier. 
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1.6 High Molecular Weight Oligomeric Species 
 
Soluble oligomers can form on or off pathway to amyloid formation and range in size 
from dimers to large spherical or fibre-like aggregates (protofibrils) and large annular 
aggregates (figure 1.6.1)  (Lashuel et al., 2002).  Aβ peptide oligomers for example, 
range in size from dimer (4.5 kDa) to dodecamer (56 kDa), and to species measured in 
nanometre diameters (Haass and Selkoe, 2007).   
 
 
Figure 1.6.1 Annular Oligomer Images  
Representative images of the many amyloid forming proteins which produce these variable diameter, 
channel- or pore-like properties in vitro.  Images (A and C) are from EM, whilst the AFM images in B 
and D are from pore structures reconstituted in lipid bilayers.  Figure adapted from (Lashuel and 
Lansbury, 2006) and reprinted with permission.   
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Oligomers generated from several proteins such as Aβ and lysozyme interacts and alters 
the fluorescence spectra of the dye 1-anilino-8-naphalene sulfonate (ANS).  This dye 
has been used in protein folding studies as a marker for surface-exposed hydrophobic 
patches and molten-globule-like characteristics.  Thus strong ANS interactions indicate 
incomplete burial of hydrophobic groups within these oligomeric assemblies (Fandrich, 
2012).  Oligomers bind specific antibodies such as A11, and some bind the OC antibody 
which was raised against protofibrils and also recognises amyloid fibre structures, thus 
suggesting a similar structure (Glabe, 2008).  
 
Oligomer-specific antibodies typically display a common epitope distinct from those 
present on mature fibres.  This epitope is therefore likely to be a common peptide 
backbone motif, such as an array of hydrogen bond donors and acceptors at the edge of 
a β-sheet or a turn motif.  Due to antibody specificity for oligomers, the epitope must be 
either conformationally distinct or be greatly reduced in the mature fibre structure.  The 
latter may explain binding affinity of oligomer-specific antibodies; during fibre 
elongation the length increases but the amount of β-sheet backbone exposed at the 
terminal end is reduced (Glabe, 2004). 
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1.7 Amyloid and Oligomer Toxicity 
 
Early prefibrillar protein aggregates or intermediate oligomers appear highly damaging, 
whereas the mature fibres appear relatively inert and correlate poorly with disease 
progression (Dobson, 2003).  Short amyloid fibres may in fact be responsible for 
toxicity (see figure 1.7.1) (Xue et al., 2009), or these fibres could be less stable and 
allow rapid exchange between toxic oligomer species.  Annular oligomers, have little 
known about the detailed molecular structure although bare coarse similarity to pore-
forming toxins (see figure 1.6.1), thus suggesting an ability to perturb the integrity of 
cellular membranes (Fandrich, 2012). 
 
A large body of evidence suggests that certain oligomeric structures are the principal 
pathogenic species and form unregulated membrane pores or disrupt homeostasis 
(Glabe, 2004).  For instance, nerve biopsies of individuals exhibiting early signs of 
peripheral neuropathy in familial amyloid polyneuropathy have shown the presence of a 
non-fibrous transthyretin aggregate (Huff et al., 2003).  Oligomer specific antibody 
binding has been found to block toxicity of a wide range of oligomeric amyloid 
precursors.  This ‘universal’ blocking of toxicity suggests soluble amyloid oligomers 
share a primary mechanism of pathogenesis, likely based on a common structure 
(Glabe, 2004).  A further example of this is observed with soluble oligomers of amyloid 
forming non-pathogenic proteins such as HypF and the SH3 domain inducing 
significant toxicity in cell culture.  A disulphide bonded Aβ β-sheet arc determined to 
spontaneously form only soluble oligomeric species and protofibrils has been shown to 
yield a higher degree of toxicity than WT Aβ1-42  preparations (Sandberg et al., 2010).  
A number of studies have also indicated that the presence of amyloid oligomers 
increases the permeability of membranes, possibly by forming pores or channels 
(Lashuel et al., 2002, Lashuel and Lansbury, 2006, Milanesi et al., 2012). 
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Figure 1.7.1 Amyloid Fibre Assembly and Fragmentation Landscape and 
Toxicity Mechanism  
Amyloid fibre assembly and fragmentation landscape with fibre load plotted against fibre length.  The 
intensity of the red background represents the toxicity potential.  The thick red arrow in (A) illustrates a 
representative fibre assembly pathway that would occur in the presence of repeated fibre fragmentation or 
where nucleation is fast, relative to elongation, and results in rapid amyloidogenesis with short fibre 
length distributions.  (B1 and B2) The short fibre may lead to enhanced toxicity through decreased fibre-
fibre interaction or increased fibre-membrane interaction.  (B2-5) Increased interaction between short 
fibres and membranes could result in membrane damage and/or a cytotoxic response by fibres puncturing 
through the membrane, extending on the membrane surface or producing cytotoxic species such as a pore.  
The thin blue arrow in (A) illustrates a fibre assembly pathway whereby little fibre fragmentation 
occurs, nucleation is slow relative to fibre elongation and results in a slow increase of fibre load and the 
formation of long fibres.  (B6-8) These longer fibres are less likely to be biologically available due to 
increases in fibre-fibre interaction, a suggested decrease in membrane interaction and reduced frequency 
of fibre passing through the membrane, when compared to the short fibres.  Fragmentation after 
assembly (either mechanical or chaperone mediated) shortens the average fibre length and thereby 
enhances the cytotoxic potential without apparent morphology changes.  Figure from (Xue et al., 2009).  
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1.8  Amyloid Disease Therapeutics 
 
1.8.1  Introduction 
The mechanism by which amyloid forming proteins and peptides cause disease is 
currently controversial, leading to substantial difficulties in drug development.  
However, significant efforts have been made in the search for novel therapeutics, with 
many in late stage clinical trials such as those for Alzheimer’s disease described in table 
1.8.1 (Palmer, 2011).  Current treatment methods only alleviate symptoms and do not 
slow disease progression, therefore it is vital to develop effective treatment (Hard and 
Lendel, 2012). 
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COMPOUND MOLECULE TYPE MECHANISM OF ACTION STATUS 
Ginko biloba Herbal Extract Unknown No efficacy 
Bapineuzumab 
Humanised 
Monoclonal Antibody 
against Aβ 
Removal of Aβ peptide 
No efficacy, 
dangerous to 
human health 
Solanezumab 
Humanised 
Monoclonal Antibody 
against Aβ 
Removal of Aβ peptide 
Questionable 
efficacy 
Docosahexanoic 
acid 
Long chain fatty acid Membrane precursor No efficacy 
Alpha-tocopherol Small molecule Antioxidant No efficacy 
Arovastin Small molecule 
HMG CoA-reductase inhibitor 
(cholesterol production 
pathway) 
No efficacy 
Dimebon Small molecule 
H1-histamine receptor with 
neuroprotective activity 
No efficacy 
(AZD-103) 
(scyllo-inositol) 
Small molecule 
Prevents and reverses Aβ 
amyloid fibre formation 
No efficacy 
Non-steroidal 
anti-inflammatory 
drugs (NSAIDS) 
Small molecule Anti-inflammatory No efficacy 
Rosiglitazone Small molecule 
Peroxisome proliferator-
activated receptor γ agonist 
No efficacy 
Semagacestat Small molecule γ-secretase inhibitor No efficacy 
Simvastatin Small molecule 
HMG CoA-reductase inhibitor 
(cholesterol production 
pathway) 
No efficacy 
Tarenflurbil Small molecule 
γ-secretase modulator (reduces 
Aβ concentration) 
No efficacy 
Tramiprosate Small molecule Reduces Aβ concentration No efficacy 
Valproate Small molecule 
GABAA receptor agonist and 
Na channel blocker 
No efficacy 
Vyndaqel Small molecule 
Stabilises transthyretin 
tetramer 
Approved in 
Europe 
Xaliproden Small molecule 
5HT1A serotonin receptor 
agonist 
No efficacy 
Table 1.8.1 Completed Phase III Clinical Trials of Alzheimer’s Disease 
Neuroprotective Therapeutics  
Table based on one in (Palmer, 2011) and recent reports on Solanezumab and Bapineuzumab (Panza et 
al., 2012). 
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1.8.2 Therapeutic Modes of Activity 
Therapeutic interventions for amyloid related disease must do one of three things: (i) 
manipulate the intrinsic stability of and/or the height of kinetic barriers to the disease 
causing protein state (see figure 1.8.1) (Cohen and Kelly, 2003), (ii) diminish the 
amyloid disease protein concentration, e.g. β-secretase inhibition to reduce Aβ 
concentration (iii) block the downstream pathological mechanism which currently, is 
poorly understood and controversial.   
 
Direct Interventions could be considered to target five protein states: native, amorphous 
aggregate, oligomer and protofibril/short amyloid fibre and mature amyloid fibre (see 
figure 1.8.2).  Determination of the toxic species is however, unclear and complicates 
therapeutic discovery with oligomer and protofibril/short amyloid fibre being primarily 
instigated (Hard and Lendel, 2012).  With this in mind, an ideal therapeutic method 
would be to stabilise the native state, amorphous aggregate or amyloid fibre, in this 
order.   
 
 
Figure 1.8.1 Misfolding and Aggregation Factors in Amyloid Disease 
Analysis of the interplay between protein/peptide sequence, monomer concentration, and the presence of 
therapeutic in altering the free energy of activation (ΔG‡ = ΔH‡ - TΔS‡), for amyloidogenesis.  Situations 
above the diagonal resist protein misassembly.  Figure based on one present in  (Cohen and Kelly, 2003).   
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Fig. 1.8.2 Strategies to Inhibit the Formation of Amyloid Fibres 
(a)–(e) depict biochemical mechanisms of action that could be employed by small or large ligands (red) 
binding to different states of amyloid-forming peptides (blue). (a) Stabilisation of the native state. (b) 
Sequestering of monomeric (partially) unfolded peptide. (c) Stabilisation or promotion of off-pathway 
oligomers. (d) ß-Sheet breakers that terminate fibre elongation. (e) Disassembly of amyloid fibres. In 
addition, refolding (f) and clearance (g) mechanisms (purple) mediated by chaperones or antibodies. The 
mechanism of aggregate/amyloid fibre clearance if intracellular, is mediated by lysosomes or the 
proteasome, or alternatively extracellular secretion and subsequent uptake by phagocytes.  Figure 
reproduced from (Hard and Lendel, 2012) with permission from Elsevier. 
 
Stabilising the native state is the simplest in terms of reducing protein toxicity, however, 
obtaining a sufficient degree of specificity in vivo can be difficult and may introduce 
side-effects or suffer delivery issues.  An alternative strategy would be to stabilise and 
enhance non-fibrillar amorphous aggregation, thus allowing intra/extracellular clearance 
mechanisms to remove the misfolded protein.  In a similar manner, stabilising non-toxic 
oligomer species may be a suitable approach, although ensuring safety by avoiding 
conversion to toxic forms and accurate in vivo toxicity determination may prove more 
challenging and risky.   
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Finally stabilising amyloid fibre could also be a suitable treatment for non-systemic 
amyloid diseases, with the primary aim of reducing the time toxic intermediates such as 
oligomer and protofibril/short amyloid fibre exist, thus reducing damage (Hard and 
Lendel, 2012).  The limitations to these latter approaches include the increase of 
intermediate populations, which depending on the mode of toxicity may increase 
cytotoxicity.  For example, once formed evidence suggests that amyloid fibres are 
dynamic and may act as a reservoir for toxic misfolded protein species, due to the 
dynamic nature of amyloid fibre (Carulla et al., 2005, Sanchez et al., 2011).  In 
conclusion, no methodology is ideal with many novel therapeutics targeting different 
states, with varying success in vitro and in vivo.  However, there is hope with several 
novel therapeutics in late stage clinical trials and the recent licensing in Europe of 
Vyndaqel, the first anti-aggregate/amyloid pharmaceutical.   
 
1.8.3 Therapeutic Discovery Strategies 
Screening for reduced amyloid fibre formation is typically performed by monitoring 
amyloid binding compound fluorescence, e.g. thioflavin T and S.  Relying on external 
fluorescent probes is potentially troublesome due to potential binding competition and 
interference between the reporter and novel therapeutic molecules (Lendel et al., 2009, 
Buell et al., 2010, Hudson et al., 2009).  However, the technique remains a starting 
point for compound screening, and the best molecules can then be followed up by an 
array of biophysical, biochemical and in vivo assays.  Large screening projects such as 
the one performed by the Mandelkow group have identified some general structural 
features such as hydrophobic patches and hydrogen bonding groups (Bulic et al., 2009).  
Other screening methods include surface plasmon resonance binding assays, cellular 
toxicity assays, filter retardation assays of insoluble amyloid fibre (Wanker et al., 1999) 
as well as traditional affibody and antibody binding screens.   
 
Developing atomic level structural models has also been a major research goal to aid 
therapeutic development and is now coming to fruition with the development of 
SSNMR and complementary biophysics/biochemistry methods (Petkova et al., 2002, 
Luhrs et al., 2005).  These methods include multi-dimensional solution-state nuclear 
magnetic resonance spectroscopy (NMR) to map intermolecular interactions, electron 
and atomic-force microscopy to visualise changes in oligomeric and fibrous 
morphology.  Furthermore, fluorescence spectroscopy, circular dichroism spectroscopy 
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and size-exclusion chromatography quantify changes in protein/peptide structure and 
the underlying kinetics and thermodynamics, while mass spectrometry identifies 
effector molecules and the binding stoichiometries.  The use of these techniques to 
determine the underlying modal activity of novel therapeutics will be essential to 
persuade reluctant pharmaceutical companies to perform clinical trials and develop 
pharmaceuticals for the spectrum of amyloid-related diseases.  
 
Therapeutic molecule binding must be strong (µM, or ideally sub-µM) to allow for low 
physiological concentrations and have favourable pharmacokinetics.  Good 
pharmacokinetics is essential and remains the largest stumbling block for 
pharmaceutical development.  The acronym ADMET, describes the five essential 
pharmacokinetics criteria; absorption, distribution, metabolism, excretion and toxicity.   
 
Amyloid-related disease research has been concentrated on widespread diseases such as 
Alzheimer’s and Parkinson’s disease, with the aim of treating as many people as 
possible with the least time and work required.  For these diseases it is easier to acquire 
funding and a breakthrough treatment may lead to development of treatment for other 
related diseases.  Corollary to this, therapeutic development of rare ‘orphan’ diseases 
e.g. familial amyloidotic polyneuropathy (FAP) is stringent but often requires a lower 
degree of clinical testing due to lower numbers of affected individuals, thus is favoured 
by some pharmaceutical companies, partly due to additional government support and 
extended exclusivity rights.  This simpler mode of development could be an ideal route 
for treatments using unconventional mechanisms, with success leading to novel 
therapeutics for more prevalent diseases.  The ideal strategy would be to stabilise the 
native state of a protein, thus enabling the proteins normal function and avoid any 
possible toxic state.  This may not be possible in some cases, thus using a variety of 
approaches is essential.    
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1.8.4 Therapeutic Molecule Classes 
 
Small Molecules 
Small molecule inhibitors of protein aggregation are very different from traditional drug 
design, which has typically targeted enzyme function, cell signalling and membrane 
transport proteins.  Many of the currently investigated small molecule inhibitors act as 
general anti-amyloid agents, with effects on a range of amyloidogenic proteins 
(Ehrnhoefer et al., 2008, Bulic et al., 2009, McKoy et al., 2012).  This non-specific 
behaviour is typically an undesirable property for drug candidates but does offer the 
potential for broad-spectrum therapeutics, so long as the side-effects are manageable 
and do not adversely affect functional human amyloid fibres such as those in the 
endocrine system (Maji et al., 2009).   
 
Natural products are an excellent source of novel small molecule therapeutics as they 
provide a greater diversity of chemical space than combinatorial chemistry.  Natural 
products and existing drug treatments also contain a higher number of chiral centers, 
elevated structure rigidity and a smaller number of aromatic moieties than molecules in 
combinatorial chemistry libraries (Feher and Schmidt, 2003).  The increased variety and 
structural specificity of natural products therefore leads to increased chance of 
discovering a pharmacophore, with combinatorial chemistry utilised in later 
development stages for optimisation.  
 
Small molecule classes identified include N-phylamines, anthraquinones, 
thioxothiazolidinones, inositol derivatives, porphyrins and polyphenols have been 
studied.  Removal or substitutions of hydroxyl groups has been shown to reduce 
efficacy, thus indicating hydrogen bonding is essential in the interaction (Bulic et al., 
2009).   
 
The polyphenols are a broad class of small molecules which have received significant 
research interest and show inhibitory activity on a variety of amyloids such as α-
synuclein, IAPP, Aβ, PrPsc and tau (Porat et al., 2006).  Polyphenols are often observed 
in plants such as ginko biloba, tea bush, grape or turmeric and thus are regarded as 
natural products (Bulic et al., 2009).  The polyphenols include flavonoids such as 
baicalein (Zhu et al., 2004) and epigallocatechin-gallate (EGCG) (Ehrnhoefer et al., 
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2006), tannic acids (Bulic et al., 2009) and lignins such as curcumin, resveratrol and 
rosmarinic acid (Ono et al., 2004).  Some of these small molecule therapeutics require a 
relatively low inhibitor concentration for a marked effect, which mirrors the polymer 
chemist’s use of small-molecule nucleating agents in plastics polymerisation (Kodali 
and Wetzel, 2007).  However, polyphenols commonly display very high metabolic 
turnover, which frequently manifests itself in reduced oral bioavailability and reduced 
blood-brain barrier penetration, thus minimising potential as lead therapeutic structure, 
without modification (Bulic et al., 2009)  
The exemplary plant derived polyphenol (-)-epigallocatechin gallate (EPCG) is found in 
large amounts in green tea, efficiently inhibits amyloid fibre formation of both Aβ, α-
synuclein, huntingtin and produces oligomeric structures (Ehrnhoefer et al., 2008, 
Ehrnhoefer et al., 2006).  EPCG also destabilises Aβ and α-synuclein amyloid fibre to 
produce protein aggregates that are non-toxic to mammalian cells (Bieschke et al., 
2010).  The mechanism by which it performs this action is poorly understood and 
controversial.   
 
Affibodies 
Affibodies are small protein domains, capable of specific binding to target proteins in a 
similar manner to antibodies.  Most affibodies are based on the α-helical bacterial 
receptor domain Z, derived from staphylococcal protein A and using combinatorial 
approaches to rationally design or randomise 13 solvent-accessible surfaces, specific 
interaction can be achieved and screened for with phage display (Nord et al., 1997).  
Affibodies therefore can potentially be used for binding amyloid-forming native protein 
state, oligomer or fibre-like structures with lower immunogenicity, see section 1.8.5 and 
figure 1.8.4 for the ZAβ3 example. 
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Antibodies 
Antibody mediated therapy has been cited as one of the most promising with two in late 
stage clinical trials (Palmer, 2011, Pul et al., 2011).  The mechanism of action of 
immunotherapy is controversial, with some antibodies showing reduced protein 
concentrations in neuronal cells, cerebral spinal fluid and blood plasma.  Antibodies 
have been suggested to cross the blood-brain barrier and clear amyloid by Fc-mediated 
phagocytosis by microglia (Bard et al., 2000) or act as a ‘peripheral sink’ in blood 
plasma and cerebral spinal fluid, thus shifting the equilibrium concentrations of amyloid 
in the central nervous system and thereby reducing concentrations of toxic amyloid 
species (DeMattos et al., 2001).  
 
Bapineuzumab, a lead monoclonal antibody which binds the Aβ peptide N-terminal, has 
in 2012 failed clinical testing with 6% of the mild-moderate Alzheimer’s disease 
subjects developing aseptic meningoencephalitis and rare brain microhemorrhages, 
which indicates undesirable immunogenicity.  Solanezumab, a second lead monoclonal 
antibody which binds the middle region of Aβ peptide has been proven safe but the 
efficacy is under question with only 30% of the phase III trial subjects showing 
improvements in symptoms, when  compared with the control group (Panza et al., 
2012).  Although the first trials with these antibodies are discouraging, the methodology 
remains feasible and a range of antibodies which target specific protein states (Kayed et 
al., 2003) such as amyloid fibre and specific oligomers remains of interest for research 
and treatment purposes. 
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1.8.5 Therapeutic Discovery Examples 
 
Native-State Stabilisation 
Therapeutic molecule binding to the native state thermodynamically increases the 
population relative to non-native state (Miroy et al., 1996).  An ideal example of this is 
the transthyretin (TTR) stabilising therapeutic tafamidis meglumine (Vyndaqel, Pfizer), 
which has been approved for use by the European Medicine Agency in November 2011 
to treat familial amyloidotic polyneuropathy (FAP).  This small molecule works by 
binding the native state thyroxine binding sites (see figure 1.8.3), thus bridging the 
dimeric interface via hydrophobic and ionic interactions which stabilise the tetrameric 
native-state thus avoiding the aggregation-prone monomeric state (Connelly et al., 
2010).   
 
In a similar manner to FAP treatment, novel therapeutics for amyloid lateral sclerosis 
(ALS) caused by superoxide dismutase-1 (SOD-1) amyloidosis, have been designed.  In 
silico screening has been performed (Ray et al., 2005) followed by experimentally 
testing small molecule activity to bind and stabilise the dimer, thus avoiding the 
amyloidogenic monomer state (Nowak et al., 2010).  In much the same way, a single-
domain fragment of a camelid antibody raised against WT lysozyme stabilises the 
native-state D67H lysozyme mutant and inhibits amyloid formation, which otherwise 
causes hereditary systemic amyloidosis  (Dumoulin et al., 2003).   
 
Native-state stabilisation of proteins and peptides which are thought to be natively 
unfolded is also possible, although less straightforward due to challenging specificity.  
The therapeutics described above use relatively well understood techniques to design 
and develop the pharmaceutical in a manner analogous to enzyme binding and 
inhibition, whereas natively unfolded protein binding is much less explored and 
understood by the pharmaceutical industry.  Some solace may be had by the finding that 
α-synuclein, which was previously thought to be natively unfolded, forms a folded 
tetrameric α-helical structure (Bartels et al., 2011) when expressed in mammalian cells.  
This discovery yields hope for a TTR-like treatment method for Parkinson’s disease and 
points to possibly incorrect findings and assumptions of other proteins and peptides 
commonly described as natively unfolded, an example being the Aβ peptide. 
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Figure 1.8.3 Structure of the Transthyretin: Thyroxine (T4) Complex and the 
Basis for Kinetic Stabilisation.  
(a) Crystal structure of TTR with T4 bound to each T4 binding site (PDB code: 2ROX). (b) Close-up 
view of one T4 binding site with T4 bound.  (c) Kinetic stabilization of TTR by small molecule binding to 
the natively folded tetramer, which stabilises the ground state and increases the tetramer dissociation free-
energy barrier, thus preventing amyloidogenesis and pathology. (d) Schematic of one of the two T4 
binding pockets within TTR occupied by a small molecule TTR kinetic stabilizer.  Y represents a linker 
of variable chemical structure (e.g. NH, O, CH CH, C(O)NH, etc.) joining the two aryl rings, which 
typically bear a combination of alkyl, carboxyl, halide, trifluoromethyl, or hydroxyl substituents (X and 
Z).  Figure reproduced from (Connelly et al., 2010) with permission from Elsevier. 
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Aggregation Inhibition 
Strong binding of therapeutic agents to aggregation prone regions of amyloidogenic 
peptides will prohibit self-assembly and avoid aggregation.  An example of this is the 
affibody ZAβ3 which forms a non-polar, large tunnel-like binding site in which Aβ 
binds as a β-strand arc (β-hairpin) (see figure 1.8.4).  The affibody was generated by 
biotinylation of Aβ1-40 and immobilisation on streptavidin coated beads followed by 
selection of affibody binders from a phage display library.  ZAβ3 monomer is 
comprised of a three helix bundle which forms a disulfide bonded dimer and generates 
the central binding site.  Aβ residues 17-36 interact with two affibody β-strands to form 
a four stranded intermolecular β-sheet (Hoyer et al., 2008).  The equilibrium 
dissociation constant (Kd) of ZAβ3 for Aβ1-40 and Aβ1-42 is 17 nM indicating ideal tight 
binding, however the affibody:Aβ complex involves a high activation free-energy 
barrier, thus may require optimisation (Hoyer and Hard, 2008).   
 
ZAβ3 inhibits amyloid fibre formation in a 1:1 stoichiometric ratio and acts to dissolve 
pre-formed aggregates over several hours.  ZAβ3 also acts to dissolve mature amyloid 
fibre by sequestering monomeric Aβ, thus shifting the equilibrium, however, the fibre 
dissolution kinetics remained very slow in physiological buffers, thus indicating high 
kinetic barriers.  In addition, the ZAβ3 affibody when expressed in WT or E22G Aβ1-42 
expressing transgenic Drosophila melanogaster, restores the life-span to that of WT 
flies with WT Aβ1-42 and to ¾ of the lifespan in E22G flies.  In these affibody flies, 
aggregation is inhibited and Aβ is cleared from the fly by an unknown mechanism 
(Luheshi et al., 2010).  
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Figure 1.8.4 Structure and Amino Acid Sequences of the ZAβ3:Aβ1-40 Complex 
(a) Amino acid sequences of Aβ1–40 and ZAβ3. Helical and β-sheet secondary structure in the ZAβ3: Aβ1–
40 complex is indicated by cylinders or arrows respectively. ZAβ3 helices are labelled according to their 
position in the Z domain affibody scaffold. (b and c) Cartoon topology of the ZAβ3: Aβ1–40 complex 
from equatorial (b) and meridian (c) perspectives. Aβ1–40 is depicted in orange, ZAβ3 subunits in blue.  
The subunit-linking disulfide bond is shown in yellow and the essential I31 side chains of both ZAβ3 
subunits are shown in grey (c).  Disordered N-termini are not displayed in (b) and (c).  NMR structure 
reproduced from (Hoyer and Hard, 2008) with permission from Elsevier. 
 
Inhibition of Amyloid Elongation 
β-sheet breakers work by binding to the terminal exposed central hydrophobic regions 
of amyloid fibres and inhibit elongation (Tjernberg et al., 1996).  Protease-resistant D-
amino acid peptides, proline residues and charged terminal amino acids have been 
inserted into these therapeutic peptides to avoid rapid proteolysis and disrupt intrinsic 
peptide β-sheet propensity.  N-methylation is used in many β-sheet breaker peptides to 
inhibit formation of amyloid fibres from the blocking peptide themselves, improving 
ADMET properties and is also reported to improve membrane penetration though rapid 
phospholipid bilayer diffusion (Gordon et al., 2002).  Alternating N-methylated peptide 
presents a hydrogen-bonding ‘complementary’ face to the amyloid target, whilst the 
other ‘blocking’ face has N-methyl groups in place of backbone NH groups, thus 
preventing further aggregation (Hughes et al., 2000).  Much of this work has been 
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directed at binding the Aβ peptide, often targeting residues 16-20 (KLVFF) peptide 
region (Tjernberg et al., 1996, Soto et al., 1998, Kokkoni et al., 2006) and other β-sheet 
forming regions such as residues 25-35 (Hughes et al., 2000).  These studies yielded 
positive results in biochemical/biophysics/in vitro assays often showing inhibition of 
amyloid formation, disaggregation of mature fibres and reduced toxicity. 
 
A Novel Therapeutic with Unknown Activity: 
The phage particle, NPT001, developed by NeuroPhage Pharmaceuticals has been 
shown to potently clear pathologic protein plaques.  This M13 based filamentous 
bacteriophage was serendipitously discovered to mediate disruption of amyloid 
assemblies (Dimant et al., 2009, Dimant and Solomon, 2010).  NPT001 has been shown 
to reduce Aβ and tau protein plaques in Alzheimer’s disease (AD) preclinical studies, 
whilst also disrupting alpha-synuclein amyloid fibres, which play a critical role in 
Parkinson’s disease (PD).  A study by Neurophage Pharmaceuticals demonstrated that a 
single intracranial NPT001 treatment produced significant reductions in neuropathology 
along with improved motor performance in a PD mouse model. Specifically, NPT001 
significantly reduced alpha-synuclein protein plaques in studied mouse brains. In 
addition, NPT001 was well-tolerated and produced no observable adverse effects.  The 
effect of this therapeutic agent is non-specific and therefore provides additional scope 
for treatment of rare medical conditions such as frontal temporal dementia, progressive 
supranuclear palsy, and prion diseases.  Further experimentation is being performed on 
this therapeutic including NMR binding studies and H/D exchange NMR (Peter Davis, 
Andrea Hounslow and Jon Waltho, unpublished). 
 
1.8.5 Conclusions 
A range of potential therapeutics are being developed using a wide range of approaches 
including small molecules based on natural products and larger, more sophisticated 
biomolecules.  Small molecules have potential advantages in increasing the delivery 
through the blood-brain barrier and longer in vivo lifetimes while careful development 
of larger biomolecules are yielding increased specificity on novel targets. 
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1.9  Cystatins as a Model Amyloid 
 
1.9.1  Cystatin Superfamily 
The cystatin superfamily are reversible, high affinity, broad specificity cysteine protease 
inhibitors (Hou et al., 2004) and have roles implicated in protein turnover (Turk and 
Bode, 1991, Turk et al., 2001), neurogenesis (Taupin et al., 2000), the innate immune 
response (Kopitar-Jerala, 2006) and sperm maturation and fertilisation (Cornwall et al., 
2011).  Cystatins bind protease active sites through hydrophobic interactions of the N-
terminal residues and the loops between β-strand 2-3, containing the highy conserved 
QVVAG motif and the loop between β-strands 3-4 (see figure 1.9.1)  (Gottlieb et al., 
1997).  The highly constrained loop between β-strand 2-3 provides the required 
resistance to protease hydrolysis (Abrahamson, 1993). The structurally homologous 
cystatin superfamily is divided into three families; type I cystatins (also known as 
stefins) which are typically intracellular, type II cystatins which are distinguished from 
Type I by intramolecular disulphide bonding and are typically extracellular and  
kininogens (type III) which are extracellular and composed of three cystatin domains 
(Barrett et al., 1986, Abrahamson, 1993).   
 
1.9.2  Human Cystatin B 
Human cystatin B (alternative nomenclature, stefin B) is a 98 amino acid, 11 124 Da, 
mixed α-helix/β-sheet globular cysteine protease inhibitor containing no disulphide 
bonds.  The native topology of cystatin B is that of a five-stranded β-sheet surrounding 
a central perpendicular α-helix (β1α1β2β3β4β5, “hot dog fold” [PDB:1STF]) as shown in 
figure 1.9.1 and 1.9.2 (Stubbs et al., 1990). Cystatin B is ubiquitously expressed and 
located in the cytoplasm, nucleus and associates with a specific subset of lysosomes, 
possibly counteracting inappropriate proteolysis caused by cathepsins leaking from 
lysosomes (Alakurtti et al., 2005).  In vitro, Cystatin B binds tightly to cathepsins B, H, 
L and S.  The main function of cathepsins is non-selective degradation of intracellular 
proteins and antigen processing in apoptosis.  It has therefore been suggested that 
Cystatin B is part of a multi-protein complex involved in apoptosis (Joensuu et al., 
2008).  Cystatin B also appears to have an endogenous neuroprotective role as deficient 
mice exhibit cerebral granular cell apoptosis which results in loss of motor control, 
ataxia (loss of voluntary coordination of muscle movements) and myoclonus (twitching 
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of muscle) (Pennacchio et al., 1998).  Additional functions are suggested by double 
knockout mice deficient in cystatin B and cathepsin B which display ataxia and 
monoclonus (uncontrolled twitching) but show markedly reduced apoptosis 
(Houseweart et al., 2003). 
 
 
Figure 1.9.1 Cystatin B Inhibition Binding Site 
(Green) Cystatin B, (gray) papain, (red) primary binding site loop QVVAG which is highly conserved in 
the cystatin family (blue) secondary binding loop residues LPH and (orange) N-terminal glycine and 
serine which are weakly involved in binding.  X-ray crystal structure of cystatin B complexed with papain 
[PDB:1STF] graphically rendered in Pymol (DeLano Scientific, CA. 
 
The neuroprotective role of cystatin B is further highlighted with mutations resulting in 
myoclonus epilepsy of type I (EPM1), a rare frequency (1 in 20 000, in Finland), 
monogenic autosomal recessive progressive and degenerative epilepsy also known as 
Unverricht-Lundborg disease.  EPM1 has an onset between 6 and 13 years with variable 
progression to cerebellar ataxia and mental deterioration (Norio and Koskiniemi, 1979).  
Four protein coding region mutations in EPM1 have been reported and are proven to be 
responsible for disease onset; nonsense (g.2388C>T, p.Arg68X), frame-shift 
(g.2400_2402delTC, pLys73fsX2) and two missense (g.426G>C, p.Gly4Arg and 
g.2398A>C, p.Glu71Pro) (Rabzelj et al., 2005).  The G4R mutant cystatin B displays 
similar folding stability and structure to the WT, however in fibrillisation conditions 
remains in the prefibrillar aggregate state for four times longer than the WT.  The R68X 
mutant on the other hand is reported to be unstructured in standard conditions (pH 7.0, 
25°C) and very rapidly forms amyloid fibres (Rabzelj et al., 2005). 
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However, protein coding region mutations only account for 14% of 58 EPM1 alleles 
studied.  Instead, the main incidence of EPM1 is caused by >3 dodecamer (12-mer, 
CCCCGCCCCGCG) nucleotide repeats located ~70 nucleotides upstream of the 
transcription start site nearest the 5’ end of the cystatin B gene.  The pathophysiology of 
these gene instabilities is unclear, although is most likely responsible for absence or 
reduction of cystatin B in specific tissues of affected individuals thereby reducing the 
inhibition of proteases involved in apoptosis and leading to uncontrolled cell death 
(Lalioti et al., 1997). 
  
1.9.3  Human Cystatin B Amyloid Fibre 
Cystatin B fibre preparations with 30 µM protein produced at 37 °C, pH 4.7 and 10 % 
2,2,2, trifluoroethanol (TFE) consistently produce long unbranched smooth fibres, over 
a period >5 days.  The addition of TFE is essential for fibre formation in vitro for 
experimentally useful timescales and has been shown to induce NMR chemical shift 
changes on the dimeric domain swapped β-strands 2 and 3 (Paramore et al., 2012).  
These fibres extensively laterally associate and share identical morphology in EM 
micrographs, see figure 1.9.2.  The fibres produced are 3.4 (±0.3) nm in height 
exhibiting a twist with a periodicity of 27 nm as determined by AFM, (Zerovnik et al., 
2002a) with most mature fibres tens of micrometers long.  These fibres are 1% sodium 
dodecyl sulphate (SDS) and 6 M guanidine hydrochloride (GuHCl) soluble.   
 
Cystatin B Amyloid Formation Pathway 
The cystatin B amyloidogenesis pathway described in figure 1.9.2 is complicated by the 
in vitro dynamic equilibrium of the dominating dimer species (~90%), followed 
respectively by monomer (~10%) and tetramer (~1%).  However, it is suggested that the 
human cystatins A, B, C and chicken cystatin simply form amyloid fibres via a 3D 
domain swapped dimer intermediate (Staniforth et al., 2001, Janowski et al., 2001).  A 
range of oligomeric states is not uncommon, with several low molecular weight 
oligomers (dimer-dodecamer) observed in soluble Aβ preparations (Stine et al., 2011).  
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Figure 1.9.2 Cystatin B Amyloid and Oligomer Formation Pathway  
Cystatin B in vitro equilibrates to form predominantly domain swapped dimer along with some monomer 
and tetramer.  In specific destabilising conditions WT cystatin B forms amyloid fibre and rare instances of 
high molecular weight oligomer.  PDB: monomer 1STF, tetramer/dimer 2OCT, graphically rendered in 
Pymol (DeLano Scientific, CA).  The tetramer structure is from (Kokalj et al., 2007) reprinted with 
permission from Elsevier.  
 
1.9.4  Human Cystatin C 
Human cystatin C (HCC) is structurally homologous to cystatin B and in 120 amino 
acids shares 26% sequence homology and 38% sequence similarity to the shorter human 
cystatin B (Y31 polymorph) protein (see figures 1.9.3 and 1.9.4).  Therefore human 
cystatin B is an amenable and suitable homologue for HCC amyloid fibre formation.   
HCC is an extracellular type II cysteine protease inhibitor and is cellularly the most 
widely distributed human cystatin.  HCC contains two disulphide bonds, one in the 
extended loop between β-strands 3 and 4, whilst the other stabilises the C-terminal by 
linking β-strands 4 and 5.  Similar fold stability is achieved in the intracellular cystatin 
B by a reduced three residue loop linking β-strands 3 and 4, as well as an extended c-
terminal which forms a hydrogen bond back to β-strand 4 (Japelj et al., 2004, Martin et 
al., 1995, Waltho et al., 1995).   
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HCC is directly associated with human cystatin C amyloid angiopathy (HCCAA), a 
systemic progressive amyloidosis, with symptoms including recurrent stroke, paralysis 
and dementia followed by pathological cerebral haemorrhage typically from the age of 
17 to 40 years of age.  The L68Q polymorphism is the only mutation responsible for 
HCCAA pathology (Jensson et al., 1987, Ghiso et al., 1986, Palsdottir et al., 1988).  The 
replacement of a hydrophobic leucine for a hydrophilic glutamate in the largely 
hydrophobic interface between the β-sheet and α-helix, reduces the folding stability of 
HCC which when partially unfolded can form amyloid fibres.   
 
HCCAA exhibits amyloid deposition in the tunica intima and/or outer wall of the small 
arteries and arterioles of the leptomeningea, cerebral cortex, basal ganglia, brainstem 
and cerebellum in all autopsied cases (Levy et al., 1989, Revesz et al., 2003, 
Gudmundsson et al., 1972).  Further to this HCC has been found to co-localise with Aβ 
fibre deposits in the brains of patients with AD, hereditary cerebral haemorrhage with 
amyloidosis - Dutch type (HCHWA-D) and sporadic cerebral amyloid angiopathy 
(CAA) (Levy et al., 2001, Deng et al., 2001, Vinters et al., 1990, Haan and Roos, 1992).   
 
Query:      Human cystatin B, 2OCT chain: A, Length: 98 
Subject:    Human cystatin C, 1G96 chain: A, Length: 120 
 
2OCT.A   1 MMSGAPS--ATQPATAETQHIADQVRSQLE---EKYNK------KFPVFKAVSFKSQVVA  49 
              | |      |  |  .   . ||  |.    .|||           . |  . |.|| 
1G96.A   1 SSPGKPPRLVGGPMDASVEE--EGVRRALDFAVGEYNKASNDMYHSRALQVVRARKQIVA  58 
 
2OCT.A  50 GTNYFIKVHVG-----------D----EDFVHLR-----VFQ--SLPHENKSLTLSNYQT  87 
           | |||. | .|           |     |  ||.      ||  ..| .  ..|||     
1G96.A  59 GVNYFLDVELGRTTCTKTQPNLDNCPFHDQPHLKRKAFCSFQIYAVPWQG-TMTLSKSTC 117 
 
2OCT.A  88 NKAKHDELTYF  98 
             |         
1G96.A 118 QDA-------- 120 
Figure 1.9.3 Human Cystatin B and C Global Sequence Alignment 
(Green)  identical residues, (pink) similar residues, (blue) sequence mismatch, (brown) 
insertion/deletion.  Needleman-Wunsch global sequence alignment (Needleman and Wunsch, 1970) was 
performed on PDB sequences of human cystatin B polymorphism Y31 (2OCT) and human cystatin C 
(1G96).  Alignment tool available at http://www.rcsb.org/pdb/ (Prlic et al., 2010). 
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Cystatin B: ------MMSGAPSATQPATAE-TQHIADQVRSQLEEKYNK-- 
Cystatin C:  SSPGKPPRLVGGPMDASVEEEGVRRALDFAVGEYNKASNDMY 
  
Cystatin B: KFPVFKAVSFKSQVVAGTNYFIKVHVG----------------  
Cystatin C: HSRALQVVRARKQIVAGVNYFLDVELGRTTCTKTQPNLTTCTK 
  
Cystatin B: --------------------------------------DEDFV  
Cystatin C:  TQPNLTTCTKTQPNLTTCTKTQPNLDNCPFHDQPHLKRKAFCS  
 
Cystatin B: HLRVFQSLPHENKSLTLSNYQTNKAKHDELTYF 
Cystatin C:  FQIYAVPW-----QGTMTLSKSTCQDA  
 
Figure 1.9.4 Human Cystatin B and C Structural Alignment 
Structural alignment performed with with X-ray crystallography PDB coordinates of human cystatin B 
(Blue) and human cystatin C domain swapped dimer(Green), (1OCT) and (1G96) respectively.  The 
secondary structure elements of both proteins align very closely with only two cystatin B loop regions 
(β2β3 and C-terminal) being distinct and larger than those in cystatin C (Dark grey), whilst one large loop 
in cystatin C (β3β4) is much larger than that of cystatin B (Light grey).  Dimers were compared due to the 
availability of comparable coordinates and clear indication of shared secondary structure elements.  The 
sequence segments determined to reliably align are labelled in yellow.  The comparison was performed 
with the jFATCAT-flexible algorithm (Ye and Godzik, 2003) available at http://www.rcsb.org/pdb/ (Prlic 
et al., 2010) and rendered in Pymol (DeLano Scientific, CA).  
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 1.10  Introduction to Thesis 
 
The initial aim of this project was to develop faster, more generally applicable methods 
for defining the structure of cystatin amyloids. H/D exchange methods and lengthy site-
directed disulphide bridge mapping of the structure had yielded a model where fibres 
were composed of stacked dimer-like structures where the topology of the native β-
sheet remained relatively intact despite the exclusion of a large part of the N-terminal 
region of the molecule. A main task was to establish whether this architecture had 
implications for cystatin B amyloids formed in different solution conditions and 
whether oligomeric non-fibrillar forms contained structure reminiscent of the fibre.  The 
amyloid fibre structural work presented in chapter 3 of this thesis uses four strategies to 
investigate the structure of cystatin B amyloid fibre.  The first method is limited 
proteolysis of mature cystatin B amyloid fibre to probe for the fibre core amino acid 
residues and indicate structural features.  Scanning transmission electron microscopy 
(STEM) mass-per-unit-length (MPL) and transmission electron microscope (TEM) 
width measurements were performed on cystatin B fibres to determine the protein 
molecule frequency and maximum spatial dimensions, which restrains the possible 
structures.   
 
In order to apply this methodology to other forms of cystatin B, the formation of 
oligomeric structures, described in chapter 4, was performed with preliminary EM and 
biochemical characterisation with the intention of future structural study.  Compared 
with its extracellular analogue, cystatin C, these cystatin B oligomeric structures are 
poorly populated and a challenge to isolate (Paramore, 2011), however this was 
partially overcome.  Further work is also described in the appendices. 
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Chapter 2: Materials and Methods 
 
2.1  Introduction 
 
This chapter details common experimental procedures used throughout the work 
presented.  Further details of material and methods particular to specific experiments are 
presented in the results chapters.  
 
2.2  Buffers and Reagents 
 
Unless stated otherwise, all reagents were purchased from, BDH Laboratory Supplies, 
Fisher, Melford or Sigma-Aldrich.  Deionised water (18.2 Ω) from an Elga Purelab 611 
Classic UVF was used throughout all experiments.  Buffers were prepared according to 
the protocol described in (Sambrook et al., 1989) and filtered through a 0.2μm filter.    
1 mM sodium azide (NaN3) was added as standard to all buffers, except those used for 
bacterial growth and unless otherwise stated. 
 
2.3  Growth Media and Solutions 
 
2.3.1  Luria-Bertani Media 
Taken from (Sambrook et al., 1989).  For each litre, the following was added to 
deionised water: 
 10 g bacto-tryptone (Oxoid ltd, UK) 
 5 g yeast extract (Oxoid) 
 10 g NaCl (Melford) 
 
Media was sterilised by autoclaving, and antibiotics added after the media had cooled.  
LB-agar was produced by the addition of 15 g/l bacto-agar (Oxoid) to the media prior to 
autoclaving. 
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2.3.2  Antibiotic Stock Solutions 
Ampicillin (Melford): 1000x stock solution was prepared by dissolving ampicillin 
sodium salt in water at a concentration of 100 mg/ml and subsequently 0.2 μm filter 
sterilised.  1 ml and 5 ml aliquots were stored at -20°C until needed, when they were 
gently thawed and added to growth media to a final concentration of 100 μg/ml. 
 
Chloramphenicol (Melford): Stock solution was prepared by dissolving 
chloramphenicol in 20% ethanol/water at a concentration of 100 mg/ml, and 0.2 μm 
filter-sterilised (Sambrook et al., 1989).  A 10 ml stock was stored at 20°C until needed 
and added to growth media to a final concentration of 50 μg/ml or 25 μg/ml for recently 
weakened transformed cells.  This antibiotic was only required for pLysS containing 
cells to maintain the T7 repressor encoding plasmid with an incorporated 
chloramphenicol resistant gene. 
 
2.3.3  Isopropyl-β-D-galactosidase (IPTG) 
1 M stock solution was prepared by dissolving 120 mg/ml in water and subsequent 0.2 
μm filter sterilisation.  Fresh solution (or aliquots stored at -20°C) was added to growth 
media to a final concentration of 0.5 mM to induce protein overexpression.  
 
2.4  DNA Manipulation 
 
2.4.1  Gene Origin and Expression Vector  
To date, the Y31 variant of cystatin B, the first to be isolated and cloned  (Jerala et al., 
1988) is the most characterised form.  However, the E31 variant is the most widely-
occurring form in the human population, and is the sequence present in Genbank 
(www.ncbi.nlm.nih.gov, accession number 20357564).  Therefore work in this study 
has been performed on the E31 variant with a C3S mutation remaining from 
crystallographic studies (Rabzelj et al., 2005).  The WT-E31 cystatin B used is encoded 
on a pET-11a vector which was a kind gift from Eva Zerovnik of the Josef Stefan 
Institute, Ljubljana, Slovenia.  The pET-11a vector places expression of cystatin B 
under control of the T7 promoter, and additionally carries the β-lactamase gene, which 
provides ampicillin resistance to transformed cells. 
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2.4.2         Competent Cells 
Escherichia coli strain XL10-Gold was used for stock plasmid production and E. coli 
XL1-Blue was used in mutagenesis.  BL21 (DE3)-Gold and BL21 (DE3)-Gold pLysS 
E. coli cells were used for protein expression.  Glycerol stocks of untransformed strains 
in 15% glycerol 25% LB were stored at -80°C.  
 
E.coli cells of the desired strain were streaked from glycerol stocks onto non-selective 
LB-agar plates and incubated at 37°C overnight (pLysS cells were grown on 25 μg/ml 
chloramphenicol plates to avoid plasmid loss).  A single colony was picked and used to 
inoculate 5 ml of LB media, subsequently incubated at 37°C overnight with shaking at 
230-250 rpm.  200 μl of the overnight culture was used to inoculate an identical 10 ml 
of LB, incubated at 37°C, 230-250 rpm until the optical density at 600 nm (OD600) 
reached 0.6.   
 
Cells were pelleted by centrifugation, supernatant discarded and the cells gently 
resuspended in 3.3 ml ice-cold RF1 buffer, pH 5.8: 
 30 mM KCH3CO2 
 100 mM RbCl 
 10 mM CaCl2 
 50 mM MnCl4 
 15 % glycerol 
 
After 30 minutes of incubation on ice, the cells were again pelleted by centrifugation, 
the supernatant discarded and the cells gently resuspended in 1 ml ice-cold RF2 buffer, 
pH 6.5: 
 10 mM MOPS 
 10 mM RbCl 
 75 mM CaCl2 
 15% glycerol 
 
After a further 30 minute incubation on ice, the cells were divided into 200 μl aliquots 
and either immediately transformed or stored at -80 °C. 
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2.4.3  Transformation 
1 μl of plasmid DNA was added to ~200 μl competent cells and incubated on ice for 30 
minutes.  Cells were transferred into a cold 14 ml Falcon tube, heat-shocked at 42 °C 
for 90 seconds and returned to ice for a further 2 minutes.  800 μl of non-selective LB 
media was added, and the cells incubated at 37 °C with shaking at 230-250 rpm for 90 
minutes.  100 μl of undiluted, ten-fold and one hundred-fold diluted cells were plated on 
selective LB-agar and incubated overnight at 37 °C. 
 
2.4.4       Plasmid Extraction 
Plasmid DNA was extracted and purified from 5 ml overnight cultures of E. Coli XL1-
Blue or XL10-Gold using QIAprep Spin Miniprep kits (Qiagen) according to the 
manufacturer protocol.  The plasmid was eluted in 50 μl of autoclave sterilised 
deionised water, quantified and stored at -20°C.   
 
2.4.5   Quantification of DNA Concentration 
The concentrations of plasmid and oligonucleotide solutions were calculated using the 
optical density at 260 nm, where an absorbance reading of 1.0 is equivalent to a 
nucleotide concentration of 33 μg/ml.  Plasmid preparations were considered free of 
protein contamination if the ratio A260 nm/A280 nm was greater than 1.7.  All absorbance 
readings were taken with a Varian Cary 50-Bio UV-Vis spectrophotometer. 
 
2.4.6  Site-Directed Mutagenesis 
Site-directed mutagenesis (SDM) was used for single amino acid substitution mutants or 
stop codon addition for truncate mutants of cystatin B.  The QuikChange
®
 II 
mutagenesis kit (Stratagene) was used in all the mutants produced in this study and the 
manual can be referred to for more details. 
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125 ng of each forward and reverse primer containing the desired mutation were added 
to a PCR reaction mix containing: 
 30 ng plasmid template, 
 1 µl dNTP mix, 
5 µl 10x reaction buffer (100 mM KCl, 100 mM (NH4)2SO4, 200 mM Tris-HCl 
pH 8.8, 20 mM MgSO4, 1 % Triton® X-100, 1 mg/ml nuclease-free BSA). 
The reaction mixes were then made up to a final volume of 50 µl with sterilised 
deionised water. 
  
1µl Pfu Turbo DNA polymerase was added to the reaction.  PCR was then performed in 
a Techne Progene thermocycler, using 18 cycles of: 
 1 minute at 95°C (melting) 
 1 minute at 55°C (annealing) 
7 minutes at 68°C (extension). 
 
Reactions were subsequently digested for 1 hour with Dpn1 restriction endonuclease to 
selectively digest methylated template DNA.  Plasmid DNA was transformed into 
competent XL1-Blue E.coli cells and plated onto selective LB-agar, containing the 
relevant antibiotic.  Colonies which grew on the selective agar were grown overnight 
and the plasmid extracted as described in section 2.4.4.  
 
The primers were synthesised, a-la-carte by MWG and were optimised for site-directed 
mutagenesis using the Stratagene QuikChange
®
 Primer Design Program.   
 
2.4.7    DNA Sequencing 
Plasmids produced by site-directed mutagenesis were sequenced to confirm the 
mutation by the Core Genomic Facility, University of Sheffield.  Sequences were 
aligned and analysed using Finch TV Version 1.4.0 (Geospiza, Inc). 
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2.5  Protein Expression and Purification 
 
2.5.1  Predicted Protein Physical-Chemical Characteristics 
Predicted extinction coefficients, molecular weights and pKa were calculated from 
proteins sequences using the “ProtParam” tool on the ExPASy Proteomics Server at 
http://www.expasy.ch/tools/protparam.html (see table 2.5.1).  This data was utilised in 
buffer choice to maximise protein solubility and ion-exchange suitability.  The 
predictions additionally aided the choice of correct ultrafiltration and dialysis 
membranes, identification in SDS-PAGE and calculation of protein concentration.   
 
Protein pI Predicted ε280nm Predicted Molecular Weight (Da) 
WT-E31 6.97 4470 11 124 
G4R-E31 8.04 4470 11 222 
α-3C-β-E31 6.97 4470 11 927 
D61X-E31 9.22 1490 6 565 
R68X-E31 6.25 1490 7 421 
Table 2.5.1 Predicted Protein Physical-Chemical Characteristics 
Characteristics determined from the amino acid sequence using the ProtParam program. 
 
2.5.2  Protein Overexpression  
A single colony of freshly transformed E. coli BL21 (DE3) Gold cells was used to 
inoculate a 50 ml overnight starter culture of LB media containing 100 μg/ml ampicillin 
(additional 50 μg/ml chloramphenicol was added for pLysS cells).  The cells were 
subsequently incubated overnight at 37°C, 230-250 rpm.  The starter culture was diluted 
1:100 commonly into 1 litre of selective LB media and incubated at 37 °C with shaking 
at 230 rpm until OD600 reached ≈ 0.6.  Cultures were then induced with IPTG to a final 
concentration of 0.5 mM and mostly incubated for a further 4 hours at 37 °C, 230 rpm. 
 
2.5.3    Cell Harvesting 
Induced cells were harvested by centrifugation at 10 000 rpm, 4 °C for 10 minutes.  The 
growth media discarded, and cell pellets resuspended in ~50 ml 10 mM sodium 
phosphate buffer, pH 6.0.  Cell resuspensions were either sonicated immediately or 
stored at -80 °C.   
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2.5.4  Cell Lysis and Protein Solubilisation 
Immediately before sonication ~0.1 mg/ml DNAse 1 (Sigma), one Complete protease 
inhibitor tablet (Roche Diagnostics) and MgCl2 to a final concentration of 20 mM was 
added accordingly to 50 ml cell resuspensions.  Cells were kept in an ice/water bath and 
sonicated at 15 μm intensity for 4 x 1 minute bursts with one minute cooling intervals 
between each sonication cycle.  Cell debris was removed by centrifugation at 15 000 
rpm, 4°C for 15 minutes.   For WT-E31 cystatin B the soluble protein supernatant was 
directly used in further purification steps.   
 
2.5.5   Purification 
Protein cell extract was loaded onto a 100 ml SP-Sepharose (GE Healthcare) cation-
exchange column at 2 ml/min, equilibrated in the case of WT with 10 mM sodium 
phosphate buffer, pH 6.0 (Kenig et al., 2004).  The column was washed until the OD280 
of the eluent stabilised.  Bound protein was then eluted with a 160 ml total volume 
buffer with a 0-500 mM NaCl gradient.  Eluent was collected in 4 ml fractions and 
presence of cystatin B verified by SDS-PAGE (see figure 2.1).  Cystatin B typically 
elutes at ~ 200 mM NaCl.   
 
Fractions containing cystatin B were pooled and concentrated to ~10 ml volume (13 ml 
maximum) using an Amicon ultra-filtration stirred-cell device in conjunction with a 
Millipore regenerated cellulose membrane with a molecular weight cut-off (MWCO) of 
10 000 or 3 000 Da.  The concentrated protein was 0.2 μm filtered and loaded onto a 
400 ml preparative Superdex 75 (GE Healthcare) size-exclusion column, equilibrated 
with filtered and degassed 10 mM appropriate buffer/100 mM NaCl (Kokalj et al., 
2007).  Buffer was run through the column at a rate of 3 ml/min and 6 ml fractions were 
collected.  The OD280 of the eluent was monitored and fractions identified by SDS-
PAGE as containing pure cystatin B were pooled, 0.2 μm filtered and stored at 4 °C.  A 
typical purification scheme for WT-E31 cystatin B is illustrated in figure 2.1.  
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Figure 2.5.1  Purification of WT-E31 Cystatin B 
A: Elution profile of WT-E31 from SP-sepharose ion exchange chromatography   
B: SDS-PAGE of ion exchange fractions.  Lanes are as follows: M: broad range pre-stained markers 
(BioRad), lane 1: wash, lane 2: cell extract, lanes 3-8: eluent with increasing salt concentration.   
C: Elution profile of WT-E31 cystatin B from SEC.  D: SDS-PAGE of SEC fractions.  Lanes are as 
follows: M: broad range pre-stained markers, lane 1: load, lane 2: tetramer peak, lane 3-5: dimer peak, 
lane 6: monomer peak.  E: SEC-HPLC trace showing purity and oligomeric state of purified cystatin B.  
Peaks are as follows: monomer is observed at 11.6 ml, dimer at 11.2 ml and tetramer at 10.6 ml.  
Diagram from Sharma (2009). 
M 1 2 8 3 4 5 6 7 
M 1 2 3 4 5 6 
Cystatin B fractions Load 
NaCl gradient 
0 
mM 
500 
mM 
Wash 
Wash Cell 
extract 
Cystatin B fractions 
200, 116 
kDa 
7 
19.7 
29 
37 
51 
86 
A B 
200, 116 
kDa 
7 
19.7 
29 
37 
51 
86 
Load Dimer 
peak 
Tetramer 
peak 
Monomer 
peak 
Monomer 
Dimer 
Tetramer 
C D 
Tetramer 
Dimer 
Monomer 
Elution volume (ml) 
E 
O
D
2
8
0
n
m
 
A
b
so
rb
an
ce
 (
A
.U
.)
 
68 
 
2.6  Protein Procedures 
 
2.6.1 Electrophoresis 
All SDS-PAGE was carried out using a Bio-Rad Mini Protean II apparatus.  The 
standard method described below was used for all experiments except where described 
otherwise.   
 
SDS-PAGE Buffers 
4 x upper buffer 0.5 M Tris/HCl, 0.4 % (w/v) SDS, pH 6.8 
4 x lower buffer 1.5 M Tris/HCl, 0.4 % (w/v) SDS, pH 8.8 
Running buffer 25 mM Tris/HCl, 190 mM glycine, 0.1 % (w/v) SDS, pH 8.3 
2 x loading buffer 100 mM Tris/HCl pH 6.8, 200 mM DTT, 4 % (w/v) SDS,  
 0.2 % (w/v) bromophenol blue, 30 % (v/v) glycerol.  200 μl  
aliquots were frozen at -20 °C and defrosted when required.  
 
Gel Preparation 
4 % stacking gels were cast above 16 % resolving gels as described below: 
16 % resolving gel 
 2.5 ml 4 x lower buffer 
 4 ml 40 % Bis-acrylamide (acrylamide: bis-acrylamide ratio 37.5:1; Bio-Rad) 
 3.5 ml deionised water 
 100 μl 10 % (w/v) ammonium persulphate (APS) 
 10 μl N, N, N', N'-tetramethylethylenediamine (TEMED) (Bio-Rad) 
4 % stacking gel 
 2.5 ml 4 x upper buffer 
 1.1 ml 40 % Bis acrylamide 
 6.4 ml deionised water 
 100 μl 10 % (w/v) ammonium persulphate (APS) 
 10 μl N, N, N', N'-tetramethylethylenediamine (TEMED) (Bio-Rad) 
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Samples were typically prepared with a 1:1 ratio of 2x loading buffer to protein 
solution, and 5 – 20 μl were loaded depending on the expected sample concentration.  
Samples were not heated prior to loading, as this has been observed to promote 
oligomerisation of cystatins (Rosie Staniforth, personal communication); instead 
samples were incubated at room temperature for approximately 10 minutes before 
loading.   
 
Molecular Weight Markers 
Bio-Rad pre-stained broad range molecular weight markers were used with the typical 
mass values stated below: 
 Myosin   200 000 Da 
 Β-galactosidase  116 250 Da 
 Bovine serum albumin 86 000 Da 
 Ovalbumin   51 000 Da 
 Carbonic anhydrase  37 000 Da 
 Soybean trypsin inhibitor 29 000 Da 
 Lysozyme   19 700 Da 
 Aprotinin   7 000 Da 
 
Electrophoresis 
SDS-PAGE gels were electrophoresed for ~60 minutes at constant voltage of 180V.  
Cystatin B WT E31 runs at an apparent molecular weight of 15 kDa.  Gels were stained 
with (0.25 % (w/v) Coomassie Brilliant Blue, 10 % (v/v) acetic acid, 45 % (v/v) 
methanol) for a minimum of 1 hour with gentle agitation at room temperature, then 
destained at room temperature with agitation (10 % (v/v) acetic acid, 45 % (v/v) 
methanol) until bands were clearly visible.  Destained gels were scanned between two 
transparencies with an Epson Stylus DX3800 combination printer. 
 
2.6.2 Protein Solution Concentration and Buffer Exchange 
For large volumes (greater than 15 ml), an Amicon ultra-filtration stirred-cell was used 
in conjunction with an appropriate Millipore 3 or 10 kDa molecular weight cut-off 
(MWCO) filter.  For volumes less than 15 ml, solutions were concentrated using 
Vivaspin centrifugal concentrators (Vivascience) with a MWCO of 3 or 10 kDa.  For 
volumes less than 0.5 ml, a Microcon centrifugal concentrator (Millipore) with a 3 or 10 
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kDa MWCO was used.  Buffer exchange was achieved either by repeated rounds of 
concentration and dilution with the required buffer, or by dialysis using Spectra/Por 
dialysis tubing with an appropriate 6 – 8  or 3 kDa MWCO. 
 
2.6.3  Determination of Protein Concentration 
UV absorption spectra were recorded on a Varian Cary 50-Bio UV-Vis 
spectrophotometer using a 500 μl Hellma quartz black-walled cuvette with a pathlength 
of 1 cm. The concentration of protein solutions were calculated using the Beer-Lambert 
Law: 
A = ε x c x t  
 
A is absorbance, ε is molar extinction coefficient (M-1 cm-1), c is concentration (M), and 
t is pathlength (cm).   
 
2.6.4  Analytical Size Exclusion Chromatography 
The purity and oligomeric states of protein solutions was typically analysed by size 
exclusion high pressure liquid chromatography (SEC-HPLC) using a Shodex KW803 
column and KW-G guard column (Shodex, Japan) with a Perkin Elmer Series 200 
HPLC system equipped with a UV-visible absorbance detector.  Usually, a 20 μl sample 
was injected, and the optical density (OD) of the eluent monitored at OD280 nm. 
 
2.6.5  Dot Blot Immunoassay 
 
Reagents 
Primary antibody: Human cystatin B Polyclonal goat IgG, raised against     
2-98 (full length) E. coli derived recombinant cystatin B  
(R&D Systems, cat. no. AF1408). 
Secondary antibody: Rabbit anti-goat IgG (H and L chain) horse radish 
peroxidase conjugate (Calbiochem, cat. no. 401515-2ml). 
Chemiluminescence Reagent: Super Signal West Pico Stable Peroxidase solution and 
Luminol Enhancer (horse radish peroxidase) 
(ThermoFisher cat. no. 2124 and 1862123) 
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Buffers 
Tricine Buffer Saline (TBS): 20 mM Tris-HCl, pH 7.5, 150 mM NaCl 
TBS-Tween (TBS-T):  As above with 0.05% v/v Tween 20 
TBS-T-milk (TBS-TM): As above with 3% v/v low fat (1%) milk powder 
 
Blotting  
Serially-diluted samples (2µl) were spotted onto a marked grid of nitrocellulose blotting 
membrane (Amersham Hybond ECL, RPN3030) and dried at RT.  Blocking of non-
specific sites was carried out at RT for 30-60 minutes with TBS-TM.  The membrane 
was then washed 3 times in d.H2O and incubated with the primary antibody (2-0.2 
µg/ml) for 30-90 minutes at RT.  The membrane was then washed a further 3 times in 
d.H2O and three times with TBS-T, the latter for 5 minutes each.  Incubation of the 
secondary antibody (0.1 µg/ml) was performed for 30 minutes at RT, followed by a 
wash 3 times in d.H2O and three times with TBS-T, the latter for 15 minutes (x1) and 5 
minutes (x2) and once with TBS for 5 minutes.  The samples on the membrane were 
then incubated for 2 minutes with the chemiluminescence reagents mixed in a 1:1 ratio 
followed by exposure of X-ray film in a dark room for 30 seconds, 5 minutes and 18 
hours for reliable luminescence detection. 
 
2.6.6  Circular Dichroism 
Circular dichroism was performed with a Jasco J-810 spectropolarimeter using 0.1 cm 
pathlength cells over a 190-300 nm range.  Spectra were acquired at RT or 25°C with a 
data pitch of 1 nm at a rate of 20-50 nm/min a suitable response time such as 8 or 2 
seconds respectively and typically averaged over 5 accumulations.  Mean residue 
elipticity, [Θ]MRW (deg∙cm
2
 dmol
-1
) was calculated to allow reliable comparison of 
different proteins using the equation: 
 
       
          
        
  
 
Θ is the measured elipticity in degrees, Mr is the protein molecular weight in kDa, c is 
the protein concentration in mg/ml, d is the pathlength in centimetres, NA is the number 
of amino acids per protein.  The factor of 100 in the equation originates from the 
conversion of the molar concentration to dmol/cm
3
 (Creighton, 1989).   
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2.7 Amyloid Fibre 
 
2.7.1 Cystatin B Amyloid Formation 
Cystatin B amyloid fibres were typically generated by quiescent incubation of 30 µM 
soluble protein at 37 °C in fibrilisation buffer (15 mM sodium acetate buffer, pH 4.7, 
150 mM NaCl and 10 % 2,2,2, trifluorethanol (TFE)) (Zerovnik et al., 2002b).  The 
protein was first buffer exchanged by ultrafiltration in TFE-free fibrilisation buffer, for 
a maximum of a few days before triggering fibrilisation.  Addition of TFE initiates the 
polymerisation process, and was thus added immediately before kinetics were 
measured.  For work with mature amyloid fibres, the morphology was examined by 
transmission electron microscopy (TEM) following a minimum three week incubation.  
This incubation period ensured 100% soluble to insoluble protein conversion and almost 
exclusive fibre formation as determined by TEM and subsequent UV spectroscopy of 
soluble fractions following centrifugation. 
 
2.7.2 Amyloid Fibre Formation Kinetics 
Amyloid fibre formation was monitored by thioflavin-T (ThT) binding.  When bound to 
amyloid fibres, the dye fluoresces maximally at ~480 nm (Naiki et al., 1989, Naiki and 
Gejyo, 1999).  To monitor fibrilisation kinetics, an aliquot of freshly prepared 10 mM 
ThT stock solution was added, where possible, to the batch of protein to be used in the 
fibrilisation, prior to triggering with the addition of 2,2,2, trifluoroethanol (TFE).  In 
these conditions ThT has no observable effects on reaction kinetics (Giannini, 2004).   
 
A ThT dye control was monitored for degradation and photobleaching during the 
incubation period alongside the protein preparations which were incubated in the dark.  
Spectra were recorded on Shimadzu RF-5301PC or Cary Eclipse spectrofluorimeters, 
using 1.4 ml fluorimetry quartz cuvettes (Hellma), with an excitation and emission 
pathlength respectively of 10 and 4 nm.  Samples were excited at 442 nm and emission 
spectra were recorded from 450 – 600 nm.  Emission at 482 nm was plotted as a 
function of time to follow kinetics of the fibrilisation reaction.  Data analysis and fitting 
was performed typically in a manner described in (Hortschansky et al., 2005) using 
Microsoft Excel and Graphpad Prism 6.0 for Windows (GraphPad Software, La Jolla 
California USA).  A single or double exponential function was used with the premise 
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that in the absence of a reliably determined multi-state kinetic model the basic 
assumption of concentration dependence is the simplest means of kinetic determination 
and line fitting for means of clarity.  
 
2.7.3 Transmission Electron Microscopy 
TEM negatively stained sample grids were prepared by addition of 2 µl sample 
solutions, for 1 minute, onto the glow-discharged surface of a carbon-coated 
copper/palladium grid (400-square mesh, Agar scientific).  Samples were then blotted 
and washed twice in deionised water, then washed and blotted in 1% (w/v) uranyl 
formate stain and finally a 20 second soak in stain before blotting and drying.  200-
250Å carbon-coated grids were prepared in-house to avoid contamination of polymer 
which is sometimes observed in commercially prepared grids, which increases the 
background noise.  Uranyl formate stain is used to enhance contrast compared to the 
standard uranyl acetate.  TEM was carried out on a Phillips CM100 instrument 
operating at 100 kV and magnification of 5 200 x, 11 500 x, 21 000 x typically and 
when warranted up to 52 000 x.  Images were recorded on a 1024 x 1024 pixel Gatan 
CCD camera using Gatan Digital Micrograph 3 software.   
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Chapter 3: Structural Determination of 
Cystatin B Amyloid Fibre 
 
3.1 Introduction 
 
3.1.1 Background 
The current cystatin B fibre structure model is primarily based on hydrogen/deuterium 
(H/D) exchange NMR data (Morgan, 2006) and is presented in the introduction (section 
1.5.5).  A major challenge facing structural biologists in the amyloid field is the 
observation of a variety of amyloid structures produced from the same protein or 
peptide (Petkova et al., 2006), in different conditions and even within the same 
preparation.  The relevance of the currently posited model to different experimental 
conditions and indeed to other members of the cystatin superfamily, including the 
amyloidosis-linked cystatin C needed to be tested further. H/D exchange studies involve 
lengthy analyses and may not be applicable to all fibre preparations so different, more 
rapid methods were investigated for the characterisation of the cystatin B model system. 
 
3.1.2 Limited Proteolysis 
Limited proteolysis has been exploited successfully to analyse amyloid fibre structure in 
many systems including Aβ peptide (Kheterpal et al., 2001), α-synuclein (Miake et al., 
2002), HET-s (Balguerie et al., 2003a), Ure2p (Baxa et al., 2003), PI3-SH3 (de Laureto 
et al., 2003), bovine α-lactalbumin (de Laureto et al., 2005), β2-microglobulin (Myers et 
al., 2006) and lysozyme (Frare et al., 2006).  Limited proteolysis occurs primarily at 
sites with high chain mobility and rarely within regular secondary structure.  Therefore, 
conformational parameters such as accessibility, mobility and protrusion correlate with 
limited proteolysis data (Hubbard, 1998).   
 
The use of serine proteases, which monomeric cystatin B inhibits (see figure 1.9.1) 
(Barrett et al., 1986), allows for clear determination of fibre structure without the 
complication of soluble protein digestion products.  The cystatin B protease binding 
motif is composed primarily of a constrained loop linking β-strand 2 and 3 
(Abrahamson, 1993), which is inactivated by the straightening and extension of the β-
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strands in the 3D domain swapped dimer and tetramer (Staniforth et al., 2001, Kokalj et 
al., 2007) and is also observed within the fibre (Morgan et al., 2008).  Although the 
cystatin B monomer in vitro typically constitutes 10% of the protein population it 
remains in excess in the 1:1000 and 1:50 ratio protease: cystatin digests,thus leading to 
effective protease inhibition in soluble protein preparations.  The inhibitory action upon 
elastase and proteinase K makes them highly useful proteases because any soluble 
cystatin B available through dynamic fibre exchange processes (‘molecular recycling’) 
is unlikely to be cleaved and thereby clarifying the results obtained in this ideal system. 
 
3.1.3 Mass Mapping 
Mass mapping of cystain B amyloid fibre produces a measurement of the mass per unit 
length (MPL), e.g. χ kDa/nm which can be used to determine the spacing of repeating 
units (Wall et al., 2008).  This measurement has been performed on several amyloid 
fibre forming proteins and forms a major part in amyloid fibre structural modelling (see 
section 1.2) (Petkova et al., 2002).  Knowledge of the mass of the fibre as well as its 
dimensions provides even greater restrictions on the models proposed, in the absence of 
a fuller 3-dimensional reconstruction of the structure from cryoEM data. STEM MPL 
can be used on particle masses from 30 kDa to 1 000 MDa with increasing accuracy the 
larger the particle, e.g. ±10% for 100 kDa particles to ±4% with 1 MDa particles.  
 
These measurements were performed with a scanning transmission electron microscope 
(STEM) equipped with a digital dark annular field detector on unstained samples bound 
to a carbon coated copper grid.  The electron elastic scattering from the sample atoms is 
directly related to the particle mass and was detected by the dark annular field detector.  
The intensity of the elastically scattered electrons was compared to the reference sample 
(tobacco mosaic virus) and the MPL of the sample then determined (Wall et al., 2008).  
To measure the elastic scattering intensity each measurement requires the designation of 
a rectangular axial area around a specific fibre section and a suitable amount of 
surrounding background.  The background intensity is then subtracted and the 
remaining intensity from the fibre integrated to provide intensity values.  These 
intensity values were then calibrated against the tobacco mosaic virus (TMV) standard 
(131 kDa/nm) and the final intensities corrected for electron-irradiation mass loss.  The 
intensity over a given span (1 nm) produces the final mass per unit length measurement 
(x kDa/nm).  
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3.1.4 Sequence Specific Amyloid Fibre Prediction  
A prevalent theory posits that short regions of protein sequence modulate protein 
aggregation and amyloid fibre formation (Chiti et al., 2003), which have been termed 
‘amyloid hotspots’ (Conchillo-Sole et al., 2007).  These sequence based prediction 
programs are primarily based on a set of values in (Chiti et al., 2003) whereby the rates 
of aggregation of unfolded polypeptide chain were correlated with physicochemical 
properties such as hydrophobicity, secondary structure propensity and charge.  
Therefore an appraisal of the currently available amyloidosis sequence prediction 
programmes was performed and matched to the experimental data available. 
 
3.1.5 Combining Structural Data 
In this chapter, data is presented on the limited proteolysis of cystatin B to produce a 
map of protease accessible regions external to the fibre core. Electron Microscopy and 
AFM has been previously used by the Zerovnik group to determine cystatin B fibre 
dimensions.  However, it was felt that in-house determination was essential due to 
potential variation in condition and thus morphological differences.  Mass per unit 
length measurements were then carried out at the University of Manchester in 
collaboration with Dr David Holmes. By combining the results with existing data from 
hydrogen-deuterium exchange NMR spectroscopy (Morgan et al., 2008), EM and 
atomic force microscopy (AFM) (Zerovnik et al., 2002a), the results significantly 
challenge the current model. 
 
77 
 
3.2 Materials and Methods 
 
3.2.1. Amyloid Fibre Formation 
The human cystatin B used in this study is the 98 amino acid E31 polymorph, C3S 
mutant (Rabzelj et al., 2005) expressed and purified by the method described in section 
2.5.  Amyloid fibres were formed by 37°C incubation of 30 µM cystatin B in pH 4.7, 15 
mM sodium acetate buffer with100 mM NaCl, 1 mM sodium azide and 10% (v/v)  
2,2,2, trifluoroethanol (Zerovnik et al., 2002b).  All pH dependent fibrilisations were 
carried out using the method described in section 2.7.  The pH dependent fibrilisations 
were performed at 37°C, in pH 3.3 (no TFE), pH 4.0, 4.7, 6.0 and 7.4 (see table 3.2.1) 
with 10% TFE with WT cystatin B and were trialled along with WT G4R 
monomer/dimer mixtures and G4R high molecular weight oligomer (HO) at pH 4.7, 
10% TFE.   
 
pH Component 1 Component 2 Component 3 Component 4 
3.3 
15 mM 
glycine/HCl 
260 mM sodium 
sulfate 
1 mM sodium 
azide 
N/A 
4.0 15 mM sodium 
acetate/acetic acid 
150 mM NaCl 
10% v/v 2,2,2 
trifluoroethanol 
4.7 
6.0 10 mM 
Na2HPO4/NaH2PO4 7.4 
Table 3.2.1  pH Dependant Fibrilisation Buffer Table 
 
Soluble cystatin B preparations and amyloid fibres are entirely composed of full length 
1-98 residue protein, determined by MS.  Fibre morphology was examined by TEM 
following a minimum three week incubation which leads to 100% soluble to insoluble 
protein conversion and almost exclusive fibre formation as determined by TEM and 
subsequent UV spectroscopy of soluble fractions following centrifugation.  For limited 
proteolysis the fibre preparation was concentrated to 90 µM monomer equivalent and 
exchanged into buffers suitable for each protease (table 3.2.2) by centrifugation at        
13 000 g RCF(max) for 15 minutes, the supernatant removed, replaced with the 
proteolysis buffer and centrifuged for a further 15 minutes before repeating the process.   
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Protease 
Protease: 
Cystatin B 
Mass Ratio 
Protease 
Final 
Conc. 
Cystatin
Conc. 
Digest Buffer Inhibitor 
Inhibitor 
Final 
Conc. 
First WT Digest 
Endoproteinase 
Lys-C 
1:1000 
36 nM,  
1 µg/ml 
90 µM, 
1.0 
mg/ml 
25 mM Tris-
HCl, pH 8.0 
TLCK 10 µM 
Elastase 1:1000 
38 nM,  
1 µg/ml 
10 mM Tris-
HCl, pH 8.0 
PMSF 100 µM 
Pepsin 1:500 
57 nM,  
1 µg/ml 
15 mM Na 
Acetate, pH 4.0 
Pepstatin 
A 
7 µg/ml 
Proteinase K 1:1000 
35 nM,  
1 µg/ml 
10 mM Tris-
HCl, pH 8.0,  
1 mM CaCl 
PMSF 5 mM 
Second WT Digest 
Elastase 1:50 
380 nM, 
20µg/ml 
90 µM, 
1.0 
mg/ml 
25 mM Tris-
HCl, pH 8.0 
PMSF 5 mM 
Pepsin 1:50 
570 nM, 
20µg/ml 
15 mM Na 
Acetate, pH 4.7 
Pepstatin 
A 
100 µg/ml 
Proteinase K 1:50 
350 nM, 
20µg/ml 
10 mM Tris-
HCl, pH 8.0,  
1 mM CaCl 
PMSF 5 mM 
Table 3.2.2 WT Cystatin B Limited Proteolysis Experimental Parameters 
 
3.2.2 Limited Proteolysis Reaction 
Proteinase K from Tritirachium album limber, elastase from porcine gut mucosa and 
pepsin were used in this study due to their wide coverage of predicted cut sites within 
the soluble cystatin B protein whilst endoproteinase Lys-C was used for greater 
specificity.  Proteolysis reactions were carried out initially at 1:1000 protease: cystatin 
B ratio (by mass) at 25 °C with and then in a 1:50 ratio at 37 °C except for pepsin which 
was initially carried out at a 1:500 ratio.   
 
Proteinase K digestion was carried out in 10 mM Tris-HCl pH 8.0 buffer with 1 mM 
CaCl2  and quenched with a final concentration of 5 mM phenylmethanesulfonyl 
fluoride (PMSF).  Elastase digestion was carried out in 10 mM Tris-HCl pH 8.0 buffer 
and quenched with a final concentration of 100 µM and 5 mM phenylmethanesulfonyl 
fluoride (PMSF) respectively in the 1:1000 and 1:50 protease: protein digests.  Pepsin 
digestion was carried out initially in 15 mM sodium acetate buffer, pH 4.0 and then in 
the same buffer at pH 4.7 and inhibited with 0.7µg/ml and 0.1 mg/ml of pepstatin A 
respectively in the 1:500 and 1:50 protease: protein digests.  Endoproteinase Lys-C 
digestion was performed in 25 mM Tris-HCl, pH 8.0, 1 mM ethylenediaminetetraacetic 
acid (EDTA) buffer and the reaction was inhibited by a final concentration of 10 µM 
Nα-Tosyl-L-lysine chloromethyl ketone hydrochloride (TLCK).  All proteases and 
inhibitors were purchased from Sigma Aldrich, with the same supply used in all 
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experiments, and stored frozen at -20°C.  Fresh aliquots were used for each digestion 
and stored according to the manufacturer instructions to maintain activity.   
 
The proteolysis method was devised to determine the hydrolysis of cystatin B fibre with 
separation of the still intact fibre and fragments in solution and is described in figure 
3.2.1 and in detail below.  The reaction solution containing fibre in proteolysis buffer 
was equilibrated at the desired reaction temperature for ≥ 5 minutes prior to proteolysis.  
Protease was added to the reaction solution and a T = 0 hour sample was immediately 
removed and the reaction quenched with an inhibitor.  An SDS-PAGE aliquot was taken 
and an equal volume of loading buffer added.  The remaining aliquot was centrifuged at 
13 000 g RCF(max) for 15 minutes.  The supernatant was retained for analysis, the pellet 
washed by repeating centrifugation in fresh reaction buffer and the final pellet 
resuspended in an equal volume of 6 M GuHCl.  The aliquots were initially stored on 
ice and frozen at – 20 °C shortly after processing.  Each time point was treated in an 
identical manner.  Controls included; a soluble protein digest for each protease and 
condition, fibre in proteolysis buffer to monitor molecular recycling and dissociation in 
the buffers used, protease alone and protease with inhibitor.  Controls were all treated in 
an identical manner to the digests to allow observation of autolysis and subsequent 
erroneous fragment detection.  
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Figure 3.2.1  Limited Proteolysis Sample Preparation Method  
The method described can be used for amyloid fibres from most proteins with some specific alterations.  
The SDS-PAGE sample is suggested to be optional as its use was limited in fragment analysis, although 
is useful in inferring that hydrolysis has been effective before use of MS equipment. 
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3.2.3 Protease Selection and Experimental Design Implications 
This study used proteinase K, elastase and pepsin due to their wide coverage of 
predicted cut sites within the soluble cystatin B protein, whilst endoproteinase Lys-C 
was used for greater specificity in specific regions.  Proteinase K (from Tritirachium 
album limber) is one of the most active serine endopeptidases known (three times more 
active than bovine trypsin) with little cleavage specificity and can readily degrade 
natively folded protein to individual amino acids.  Carboxyl groups of aliphatic, 
aromatic and hydrophobic amino acids show some preferential cleavage (Ebeling et al., 
1974).  Proteinase K is predicted to cleave cystatin B at 41 sites spread across the entire 
protein sequence (cleavage typically at residues F,Y,W,G,A,V,L,I and T).  Predicted cut 
sites were determined from amino acid sequence with PeptideCutter software, which is 
available online via the Expasy server.  See figure 3.2.2 for the predicted cut sites map, 
produced with the assumption of complete accessibility.   
 
Elastase (from porcine pancreas) is a serine protease which typically hydrolyses amino 
acids with straight side chains; alanine >> valine > leucine > glycine and serine (Atlas 
et al., 1970, Thompson and Blout, 1973, Gold and Shalitin, 1975), unless proceeded 
immediately by proline or preceded by proline-X-Y- (e.g. P,A,A,A) (Thompson and 
Blout, 1973), thus 31 specific cleavage sites are predicted (see figure 3.2.2).  
Endoproteinase Lys-C (from Lysobacter enzymogenes) is a serine protease and 
hydrolyses lysine residues with nine cleavage sites predicted in cystatin B using 
PeptideCutter.  Some minor non-specific cleavage with this protease has also been 
reported. 
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Figure 3.2.2 WT Cystatin B Topology Map of Predicted Hydrolysis Positions 
Based on Sequence Alone  
The predicted cleavage positions shown are structural model free and based purely on the sequence.  
(Black triangles) proteinase K proteolysis, (green triangles) elastase and (orange triangles) 
endoproteinase Lys-C digestion.  The topology map is modified from (Morgan et al., 2008), where 
hydrogen bonding present in the dimer is shown using dashed arrows. The regions of the molecule 
involved in the formation of secondary structure in the fibre are shown as H/D exchange protected 
residues (red) whereas unstructured regions of the amyloid fibre which readily exchange hydrogen for 
deuterium are highlighted in blue. Residues for which no H/D exchange data is available are coloured 
white.  
 
3.2.4 SDS-PAGE 
Tricine-SDS-PAGE (Schagger, 2006) was used to resolve the low molecular weight 
fragments generated and stained with coomassie R250 blue in 45:45:10 v/v water: 
methanol: acetic acid staining solution. 
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3.2.5 Reverse Phase HPLC 
A Waters C4 reverse-phase (RP) column (300Å pore, 5.0 µm beads, 4.6 mm x 250 mm 
column) was used on a Perkin Elmer Series 200 HPLC machine over a linear gradient 
of 5-20% aqueous-organic solvent over 20 minutes and 20-80% over the 20 mins at 0.8 
ml/min.  Aqueous phase: milli-Q H2O (0.1% trifluoroacetic acid, TFA), organic phase 
acetonitrile (0.1% TFA).  Effluent was monitored by recording absorbance at 224 nm.  
This methodology is described as C4-RP-LC. 
 
3.2.6 Reverse Phase HPLC-ESI-MS and Mass Fragment 
Identification 
A Grace Vydac Everest C18 reverse-phase column (300Å pore, 5.0 µm beads, 2.1 mm x 
250 mm column) was run on a Waters Alliance 2695 HPLC machine over a linear 
gradient of 5-50% aqueous-organic solvent over 40 minutes and 50-95% over 5 mins at 
0.2 ml/min.  Aqueous phase: milli-Q H2O (0.1% formic acid), organic phase acetonitrile 
(0.1% formic acid).  Masses were detected by a Micromass LCT electrospray-ionisation 
time-of-flight instrument (Waters Corporation, Manchester) in positive ion mode.  This 
method is described as C18 RP-HPLC-ESI-TOF-MS.  Masslynx 3.5 software (Waters 
Corporation, Manchester) was used to determine masses present and FindPept 
(ExPASy) (Artimo et al., 2012) was used to elucidate protein fragment identities by 
matching predicted and actual masses.  See figure 3.2.3 for a flow diagram of the 
analysis methodology. 
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Figure 3.2.3 Limited Proteolysis Mass Spectroscopy and Fragment Mass 
Identification Method 
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3.2.7 Cystatin B Fibre Diameter 
To measure the fibre width, 16 electron microscopy preparations produced at pH 4.7, 37 
°C with 30µM cystatin B (15 mM sodium acetate/acetic acid buffer, 150 mM NaCl and 
10 % TFE) and collected over a period of 7 years by 3 PhD students, were each 
analysed independently, and contributed a maximum 30 values each to ensure no single 
preparation produced errant results skewing the average.  Most of the images used were 
collected by the author, due to the requirement of high resolution images and selection 
of regions with clearly defined single fibres, parameters not particularly required in 
previous studies where only fibre identification was needed.  Digital Micrograph 3 
software (Gatan, UK) was used to generate electron intensity histogram profiling 
perpendicular to the fibre axis to accurately determine and measure the fibre width.  
Images were collected on a Phillips CM100 (Philips/FEI Corporation, Holland) electron 
microscope with a 1024 x 1024 pixel Gatan CCD (Gatan, UK) camera using 21 000 x 
magnification negatively stained electron micrographs, thus each pixel is equivalent to 1 
nm and defines the maximum level of accuracy  as ± 1 nm.   
 
3.2.8 Mass Mapping 
MPL measurements were made from a standard preparation of cystatin B amyloid fibre 
(see section 2.7) exchanged into ultrapure water by centrifugation at 14 000 g, 
supernatant removal, water addition and the process repeated twice.  These fibres were 
adsorbed for two minutes onto a 600 mesh copper grid with 3 nm thick carbon film, 
washed with ultrapure water and left to air dry for 15 minutes and then dried further in 
the EM vacuum.  50 STEM annular dark field (ADF) 48 000 x electron micrographs of 
unstained cystatin B amyloid fibres were obtained on a Tecnai 12 TEM/STEM 
instrument (Electron Optics, Eindhoven, The Netherlands), equipped with a high angle, 
dark-field detector and digital scan generator.  This instrument is capable of a spacial 
resolution of ~2 nm (Holmes et al., 2001).  Image analysis was performed using 
SEMPER (Synoptics, Cambridge, UK), whereby for each measurement a rectangular 
axial area of fibre and surrounding background was selected, the background intensity 
subtracted and the remaining intensity from the fibre integrated to provide intensity 
values.  These intensity values were then calibrated against tobacco mosaic virus 
(TMV) standard (131 kDa/nm) and the final intensities corrected for electron-irradiation 
mass loss.   
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3.2.9 Sequence Specific Amyloid Prediction 
 
TANGO 
TANGO, available at http://tango.crg.es/ is designed to predict β-sheet aggregation and 
not amyloid formation, however the two show a good correlation.  TANGO is a 
statistical thermodynamics algorithm, which predicts the percentage occupancy of the β-
aggregation conformation, hydrophobicity and estimates desolvation penalties.  
Peptides are considered to have some aggregation tendency when they possess segments 
of at least 5 consecutive residues populating the β-aggregated conformation.  TANGO is 
unable to accurately predict low levels of aggregation propensity (<5% total sequence) 
(Fernandez-Escamilla et al., 2004) and inherently may fail to predict all hotspots in 
larger polypeptides due to the system being constrained to a maximum detection of 2 
hotspots (Pande, 2004). TANGO does not account for position specific differences 
(Maurer-Stroh et al., 2009) and cannot in principle quantitatively compare polypeptides 
differing widely in sequence.  (Mutants can be compared in identical conditions.) 
(Fernandez-Escamilla et al., 2004).  Overall the authors of TANGO determine the 
prediction program is 87% accurate (Fernandez-Escamilla et al., 2004).   
 
WALTZ 
WALTZ is available at: http://switpc7.vub.ac.be/cgi-bin/submit.cgi, and combines a 
position-specific sequence profile with multiple physical property parameters (helical, 
β-sheet and hydophobicity propensities), complemented with structural modelling data 
from the all-atom force field FoldX to identify motifs that can nucleate amyloid fibre 
formation in proteins.  A position-specific scoring matrix for amyloid propensity was 
generated from a modified and expanded non-redundant hexapeptide database 
(AmylHex) of experimentally verified amyloid fibre forming hexamers.  A 6 residue 
polypeptide is the minimal amyloid nucleating core, which can as an insertion induce 
amyloid fibre formation of an entire protein domain, thus is the justification for using 
hexameric sequences in the prediction program (Maurer-Stroh et al., 2009).   
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AGGRESCAN 
AGGRESCAN available at: http://bioinf.uab.es/aggrescan/ is based on aggregation 
propensity values for individual amino acids derived from in vivo experiments and 
utilises an experimentally determined hotspot threshold (HST).  The program calculates 
the average aggregation potential over a sliding window of given length and assigns the 
average value to the central residue in the window.  The window size used is: 5 residues 
for < 75 amino acids, 7 for <175, 9 for <300 and 11 for >300.  The reasoning for this 
window size change is that for longer sequences, larger ‘hotspots’ are required to 
significantly increase the aggregation propensity (due to the more extensive native 
folding), whilst short-stretches suffice for smaller peptides. The hotspot threshold 
(HST) is defined as the average of the aggregation potential of the 20 amino acids 
weighted by their frequencies in the SwissProt database.  A region in the polypeptide 
sequence is then considered an aggregation hotspot if there are 5 or more sequentially 
continuous residues with an average aggregation potential larger than the HST and none 
of them are an aggregation breaking proline (Conchillo-Sole et al., 2007).   
 
ZYGGREGATOR  
ZYGGREGATOR Combines the aggregation propensity and folding propensity for 
each individual amino acid which is then averaged in a seven residue window, or 
smaller at the N and C-terminal (Tartaglia et al., 2008).  This method also accounts for 
specific patterns of alternating hydrophobic and hydrophilic residues.  Prediction of 
folding propensity is calculated with the CamP program which predicts flexibility and 
solvent accessibility (Fernandez-Escamilla et al., 2004).  Zygregator is available on 
http://www-vendruscolo.ch.cam.ac.uk/zyggregator.r.php, which considers the pH and 
http://www-vendruscolo.ch.cam.ac.uk/zyggregator.plus.php, which considers many 
environmental conditions. 
 
AmylPred 
Amylpred, available at http://biophysics.biol.uoa.gr/AMYLPRED/input.html uses a 
consensus method from five  different prediction systems: average packing density 
(Galzitskaya et al., 2006), conformational switches (ability to convert from α helix to β 
sheet) (Hamodrakas et al., 2007), sequence patterns (hexapeptide) that match amyloid 
formation (Lopez de la Paz and Serrano, 2004) TANGO (β-sheet propensity) and 
conformational energy values (Zhang et al., 2007).  The consensus method works by 
each method individually predicting amyloid propensity, any residue that is individually 
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predicted twice to be amyloid forming is deemed as likely to be amyloidogenic.  The 
arbitrary consensus methodology has an inherent conservatism, thus this system is 
likely to produce a larger number of false-negatives, although minimise false positives 
produced from any one prediction programme.   
 
Conformational Energy 
Conformational energy (3D profiling) is based on the threading of six-residue peptides 
through the known crystal structure of the cross-β spine formed by the hexapeptide 
NNQQNY from yeast Sup35 PrP and also an ensemble of ‘near-native’ templates (n=2 
511).  The conformational energy fit is then evaluated using ROSETTADESIGN.  A 
permissive and conservative energy threshold is then used to determine the 
amyloidogenicity of the hexapeptide.  Conformational energy is claimed to reach an 
accuracy of ≈80% when a conservative energy threshold is used to separate between 
amyloid peptides and amorphous β peptides.  Cysteine or proline residues have to be 
removed as they cause errors in the energy calculations thus producing ambiguous 
results (Thompson et al., 2006).  The conformational energy program by (Zhang et al., 
2007) is based on this method and is available through the AmylPred server.  
 
Other Programs 
Average Packing Density, is based upon the observation that regions with strong 
packing density are likely to form amyloid.  This prediction program measures the 
observed number of residues within the given distance from the considered residue and 
if this value is greater than the threshold it is determined to be amyloidogenic.  The 
authors determine the predictions are consistent in 8 out of the 12 tested disease-related 
amyloid-forming proteins (Galzitskaya et al., 2006).  Conformational Switches, utilises 
the observation that sequence regions with high amyloid propensity show α-helix – β-
sheet ambivalence (Hamodrakas et al., 2007).  Pattern, searches for peptide sequences 
that are known to individually form amyloid fibre from experimentally derived peptide 
databases (Lopez de la Paz and Serrano, 2004).  
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3.3 Results 
 
3.3.1 Limited Proteolysis 
The strategy was to carry out limited proteolysis of WT cystatin B fibres using four 
carefully chosen proteases with the reaction quenched at specific time points.  Fragment 
analysis was then carried out with reverse-phase HPLC coupled to an electro-spray 
ionisation time of flight mass spectrometer (RP-HPLC-ESI-MS).  Mass spectrometry 
peaks were then analysed manually and the corresponding fragment mass identified 
using the FindPept tool available on the Expasy proteomics site.   
 
Formation and Characterisation of Amyloid Fibre 
Cystatin B fibre preparations produced at 37 °C, pH 4.7 and 10 % 2,2,2, trifluoroethanol 
(TFE) consistently produce long unbranched smooth fibres which extensively laterally 
associate and share identical morphology in TEM micrographs, shown in panels A and 
B of figure 3.3.5.  These amyloid fibre preparations are free of Cystatin B soluble 
species following centrifugation and measurement by UV spectroscopy, sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) or size-exclusion 
(SEC-HPLC).  In addition, no significant quantities of non-fibrillar aggregate or high 
molecular weight oligomer was detected by TEM.   
 
Fibre Stability 
H/D exchange protected residues within the cystatin B amyloid fibre exchange at a rate 
of around 10
-4
 s
-1
, independent of pH and residue type (Morgan et al., 2008).  This 
indicates that each individual amino acid, backbone amine group becomes available for 
exchange on average every 2.8 hours.  Although this exchange may be concerted for 
individual molecules of cystatin within the fibre, this lifetime still supports the use of 
proteolysis in analysing the structure of cystatin B fibres without a significant 
contribution from soluble molecules cycling on and off the fibre assembly (“molecular 
recycling”).  
  
Given the above considerations, a significant population of soluble full length protein 
was nevertheless clearly detected by RP-HPLC in a pepsin digestion of cystatin B 
amyloid fibre at pH 4.0.  This free protein could potentially have introduced erroneous 
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amyloid fibre digestion results, thus the digest results were discarded.  We propose that 
Cystatin B amyloid fibres generated at pH 4.7 are perhaps unstable at pH 4.0 or are 
more readily perturbed by pepsin addition in these conditions.  A further pepsin fibre 
digestion was performed at pH 4.7, with a 1:50, protease: cystatin B  ratio in which the 
fibres remained intact but undigested following 24 hour incubation at 37 °C, thus 
indicating insufficient pepsin activity in these conditions.   
 
At pH 8.0, in the proteinase K digestion buffer, a peak corresponding to 5% of the total 
protein was observed in the soluble fraction of the fibre control detected by C4 RP-
HPLC.  This could be attributed to a number of factors; (i) fibre being removed from the 
pellet and subsequently dissolving in the water/acetonitrile solvent (ii) low levels of 
soluble cystatin in fibre preparations, previously undetected (iii) the fibre is mildly 
destabilised at pH 8.0 contrary to previous work indicating stability over a period of 
months at pH 9.0 (Morgan et al., 2008).  All these factors could contribute, although the 
latter two are less likely to be responsible for the observed protein, following previous 
experimental work.  This population is thus most likely the result of experimental 
limitations (i) and is very unlikely to alter the results obtained.   
 
To conclude, soluble protein cleavage can be reduced by minimising complete digestion 
time to a matter of a few hours by manipulating the protease concentration and 
temperature.  In addition, the primary data used has been collected from fibres separated 
by centrifugation and dissolution in denaturant, thus further ensuring the digestion 
fragments observed are only from protein remaining incorporated in fibrous material. 
Very small populations of soluble cystatin B were occasionally observed by MS in the 
fibre digests, approaching the limits of detection.  This is most likely the result of carry-
over from the centrifugation step, and is not entirely removed in the wash step.  Overall 
confidence in the results presented is high due to the various methods and features 
employed in the experiment to minimise soluble protein presence and digestion in the 
fibre digests.  
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Soluble Cystatin B Digestion 
Cystatin B is a strong inhibitor of serine proteases as well as cysteine proteases.  This 
property was therefore employed to ensure that only inactived oligomeric forms of the 
protein would be digested and form part of our analysis. Soluble cystatin B control 
digests were performed identically to fibre digests and analysed with SDS-PAGE and 
C4-RP-LC and C18 RP-HPLC-ESI-TOF-MS to ensure suitable protease inhibition in 
the conditions used.  In 1:1000 protease: soluble cystatin B digests, proteinase K, 
elastase and endoproteinase Lys-C showed complete inhibition with no proteolysis 
intermediates detected by all the methods used (see figure 3.3.1 for SDS-PAGE gels of 
the digest).  Only in a 1:50 proteinase K: soluble cystatin B digest were small N-
terminal cleavage events detected.  For instance at T = 0.5 hours the full size 98 residue 
protein is detected alongside , 4-98, 6-98 and 11-98 truncate species.  Following 24 
hours of proteolysis, only 4-98 residue species are detected.  No soluble digest controls 
contained extensively digested medium sized protein fragments similar to those 
observed in fibre digests.  Once cleaved the short peptide generated is readily cleaved 
further into several small species (< 15 residues).  Therefore the results of the amyloid 
fibre digests are clearly and unambiguously from hydrolysis of amyloid fibre and not 
soluble protein.  
 
Cystatin B Amyloid Fibre Digestion  
The procedure employed identifies cystatin B protein fragments that remain integrated 
into the fibre core, see tables 3.3.1 and 3.3.2.  To map the cystatin B amyloid fibre core 
components, fibre was digested for 0.5, 1, 4 and 24 hours, after which the insoluble 
fibre digest material was separated by centrifugation, the pellet washed,  centrifugation 
repeated and the pellet, dissolved in 6 M guanidine hydrochloride followed by C18 RP-
HPLC ESI-TOF-MS analysis.  Figures 3.3.2 and 3.3.3, show that the deepest N-
terminal (NT) cleavage site frequently observed in digested but intact amyloid fibre is 
up to residue 27 and produced by proteinase-K whilst both proteinase-K and elastase 
digests up to the C-terminal (CT) residue 80.  The NT ‘native α-helical region’ is highly 
susceptible to proteolysis (see figure 3.3.4), thus confirming the unstructured nature of 
this region in the cystatin B amyloid fibre, and corroborates the H/D exchange data 
(Morgan et al., 2008).  However, in simple terms, the observation of rapid proteolysis in 
the CT contradicts the high levels of H/D exchange protection observed. 
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Figure 3.3.1 1:1000 Protease: WT Cystatin B Limited Proteolysis SDS-PAGE  
In all gels Lane 1: Bio Rad Broad Range Pre-Stained Marker.  (A)  Elastase Digest.  (B)  Endoproteinase 
Lys-C Digest.  (A and B) Lane 2-6 T = 0, 0.5, 1, 4, 24 hr amyloid fibre digest insoluble products, Lane 7-
11 T = 0-24 hr soluble cystatin B digest indicating protease inhibition and lane 12 which contains the 
control fibre and shows two fragments, which are not seen in the soluble preparation of the protein and 
could be the result of an SDS-resistant compact post-fibre species.  (C)  Proteinase K Digest: Lane 2-5 T 
= 0, 0.5, 1, 4 hr amyloid fibre digest insoluble products, Lane 6-9 T = 0-4 hr soluble cystatin B digest 
indicating protease inhibition, lane 10-13 contains the T = 0-4 hr control fibre.  All digests over time 
show at least 2-3 bands from amyloid fibre proteolysis.  When compared to the multiple peaks observed 
in RP-HPLC and MS it is clear SDS-PAGE does not resolve sufficiently, although is a useful tool for 
simply detecting protease activity. 
 
The observation that compared to the NT, the CT exhibits lower susceptibility to 
proteolysis, is shown in figure 3.3.4 which shows the average percentage value of N and 
C-terminal cleavage per unit time.  The lower susceptibility of the CT to hydrolysis is 
indicated by fewer CT cleavage fragments detected in earlier digestion time points.  For 
instance, proteinase-K and elastase at T = 0.5 hours in the 1:1000 digests indicate 
extensive N-terminal cleavage whilst the C-terminal remains entirely intact, up the limit 
of detection. 
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Digest 
Time 
(hrs) 
Fragment 
Mass (Da) 
Fragment Identity 
Fragment 
Mass (kDa) 
Fragment Identity 
 
Proteinase K 1:1000 Proteinase K 1:50 
0.5 8427 27-98 (0.6)  6274 1-57(1.8),27-80(1.7),5-61(0.1),15-68(1.1) 
 9462 18-98 (0.7) 6488 25-80(0.6),27-82(1.5) 
 9995 13-98 (1.8) 8430 18-90(1.4) 
 10161 11-98 (0.4) 
  
 10860 3-98 (1.1) 
  
 10991 2-98 (1.3) 
  1 8220 19-89 (0.3), 11-82 (0.3) 8428 27-98(0.7) 
 8427 27-98 (0.6) 6273 1-57 (0.8),27-80(0.8),5-61(1.1) 
 9463 18-98 (0.3) 
  
 10161 11-98 (0.4) 
  
 10646 6-98 (0.1)  
  
 10861 3-98 (0.1) 
  4 6488 25-80(0.2), 27-82 (1.1) 6273 1-57 (0.8),27-80(0.8),5-61(1.1) 
 7523 26-90(1.5), 27-91(1.5), 18-82 (1.5) 
 
Complete Digestion 
 7609 18-83(0.4), 25-90(0.5) 
  
 8429 27-98(1.4) 
  
 9464 18-98(1.4) 
  
 10863 3-98(1.6) 
  
 10994 2-98(1.2) 
  
 11125 1-98 (0.0) 
  24 N/A N/A N/A Complete Digestion 
     
 
Elastase 1:1000 Elastase 1:50 
0.5 8798 24-98 (1.0) 6859 24-82(1.9) 
 9820 15-98 (1.0) 8801 19-94(0.1), 20-95(0.1) 
 9994 13-98 (0.8) 6645 24-80(1.4), 8-66(1.4) 
 10161 11-98 (0.4) 8054 7-77(1.0),13-82(1.9) 
 10860 3-98 (1.1) 8491 6-80(0.4) 
 10991 2-98 (1.3) 
  1 8220 19-89 (0.4), 11-82 (0.4) 6644 24-80 (0.4) 
 8798 24-98 (1.0) 8799 24-98(0.0),19-94(1.9),20-95(1.9) 
 9820 15-98 (1.0) 8488 23-95(1.4),12-85(0.4),21-93(0.4),24-96(0.6) 
 9992 6-93 (0.2), 13-98 (1.2) 
  
 10161 11-98 (0.4) 
  
 10860 3-98 (1.1) 
  
 10990 2-98 (2.3) 
  4 6857 24-82 (0.9) 6644 24-80 (0.4) 
 6945 
6-67 (1.2), 9-69 (1.2), 20-79 (1.1), 
24-83 (0.0) 8800 24-98(1.0),19-94(0.9),20-95(0.9) 
 8052 13-82 8489 12-85(1.4),21-93(1.4),24-96(0.4),6-80(1.6) 
 8139 13-83 
  
 8220 19-89 (0.4), 11-82 (0.4) 
  
 8306 20-91 (0.4), 11-83 (1.4) 
  
 8798 24-98 (1.0) 
  
 9153 18-96 (0.7) 
  
 9067 17-94 (0.8) 
  
 9992 6-93 (0.2), 13-98 (1.2) 
  
 10160 11-98 (1.4) 
  24 6858 24-82 (0.1) 6644 24-80 (0.4) 
 6945 24-83 (0.0) 
    8800 24-98 (0.5)     
Table 3.3.1  WT Cystatin B Amyloid Fibre Limited Proteolysis Digestion 
Fragments from Proteinase K and Elastase 
The bracketed figure in the fragment identity column is the number of mass unit variance from the 
experimental and predicted fragment mass.  
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Digest 
Time 
(hrs) 
Fragment 
Mass (Da) 
Fragment Identity 
 
Endoproteinase Lys-C 1:1000 
0.5 9056 10-88 (0.2), 11-89 (0.2) 
 
9755 3-89 (0.9), 12-96 (1.0) 
 
9886 2-89 (1.1) 
 
10161 11-98 (0.4) 
 
10860 3-98 (1.1) 
 
10991 2-98 (1.3) 
 
11123 1-98 (1.5) 
1 9056 10-88 (0.2), 11-89 (0.2) 
 
9414 3-86 (1.5), 6-88 (1.5) 
 
9755 3-89 (0.9), 12-96 (1.0) 
 
9886 2-89 (1.1) 
 
10161 11-98 (0.4) 
 
10860 3-98 (1.1) 
 
10991 2-98 (1.3) 
 
11124 1-98 (0.5) 
4 5172 45-89 (0.2),  44-88 (0.2) 
 
9056 10-88 (0.2), 11-89 (0.2) 
 
9414 3-86 (1.5), 6-88 (1.5) 
 
9755 3-89 (0.9), 12-96 (1.0) 
 
9886 2-89 (1.1) 
 
10161 11-98 (0.4) 
 
10860 3-98 (1.1) 
 
10991 2-98 (1.3) 
24 9052 2-82 (0.7), 15-92 (0.2), 18-95 (0.8) 
 
9252 2-84 (0.6) 
 
9417 2-85 (0.9) 
 
9756 3-89 (0.4) 
 
9888 2-89 (0.4) 
 
10018 1-89 (0.5) 
 
10862 3-98 (0.9) 
 
10992 2-98 (0.7) 
  11125 1-98 (1.0) 
Table 3.3.2  WT Cystatin B Amyloid Fibre Limited Proteolysis Digestion 
Fragments from Endoproteinase Lys-CThe bracketed figure in the fragment identity column is 
the number of mass unit variance from the experimental and predicted fragment mass.  
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Figure 3.3.2  Limited Proteolysis Digestion Map of WT Cystatin B Amyloid Fibre 
1:1000 and 1:50 ratio protease digestions are shown, with the dark blue bars showing clearly defined 
protein digest fragments or regions, whilst the light blue bars indicate ambiguous fragment regions.  The 
far left column indicates protease and ratio used, plus the digestion time.  ProK represents proteinase K, 
Elast is elastase and EndoLysC is endoproteinase Lys-C.  At the top of the diagram, the cystatin B native 
secondary structure elements of monomer and domain swapped dimer are shown along with the amino 
acid sequence.  The thick black lines indicate predicted specific protease cleavage sites.  Red dotted lines 
define the reliable cleavage maxima.   
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Figure 3.3.3 WT Cystatin B Topology Identifying Positions of Hydrolysis  
Cleavage positions are identified by ‘scissors’ and the protease responsible is labelled: (ProK), proteinase 
K; (Elast) elastase, (ELC) endoproteinase Lys-C.  Topology map modified from (Morgan et al., 2008), 
where hydrogen bonding present in the monomer is shown using dashed arrows. The regions of the 
molecule involved in the formation of secondary structure in the fibre are shown as H/D exchange 
protected residues (red) whereas unstructured regions of the amyloid fibre which readily exchange 
hydrogen for deuterium are highlighted in blue. Residues for which no H/D exchange data is available are 
coloured white.  
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Figure 3.3.4 Terminal Region Accessibility in the 1:1000 Limited Proteolysis Digest  
Average percentage of N and C-terminal cleavage per unit time.  The N and C termini is described as 
the first and last 49 residues in the 98 amino acid protein respectively.  The percentage cleaved 
value is calculated for an individual proteolysis fragment and averaged for each digest time-
point.  This graph shows that the CT is less susceptible to proteolysis than the readily cleaved 
NT region. 
 
The proteases used in this study rapidly cleave soluble protein fragments released from 
fibre digestion as indicated by the multitude of <1000 Da polypeptides detected in mass 
spectrometry of the soluble fraction of fibre digests.  The deepest NT and CT fibre 
digestion products, if produced in a single co-ordinated reaction would have a mass of 
2714 Da (NT) and 2173 Da (CT).  Fragments of this size however were not detected, 
thus the protease either digests frequently, perhaps in a step-wise exogenous manner, 
commencing at the terminal ends along the unstructured region and/or once cleaved 
from the fibre the larger soluble peptides are rapidly hydrolysed into smaller fragments.  
Identification of the soluble protein fragments by the method employed was not 
possible due to the mass differences being insufficient to determine distinct identities.  
The rapid fragment proteolysis indicates that protease inhibition is not significantly 
limiting in amyloid fibre digests.   
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The proteases used in this study rapidly cleave soluble protein fragments released from 
fibre digestion as indicated by the multitude of <1000 Da polypeptides detected in mass 
spectrometry of the soluble fraction of fibre digests.  The deepest NT and CT fibre 
digestion products, if produced in a single co-ordinated reaction would have a mass of 
2714 Da (NT) and 2173 Da (CT).  Fragments of this size however were not detected, 
thus the protease either digests frequently, perhaps in a step-wise exogenous manner, 
commencing at the terminal ends along the unstructured region and/or once cleaved 
from the fibre the larger soluble peptides are rapidly hydrolysed into smaller fragments.  
Identification of the soluble protein fragments by the method employed was not 
possible due to the mass differences being insufficient to determine distinct identities.  
The rapid fragment proteolysis indicates that protease inhibition is not significantly 
limiting in amyloid fibre digests.   
 
Proteinase-K is shown in the 1:50 digests at 24 hours to have promoted complete 
amyloid fibre destruction most likely by extensive protein-wide cleavage of fibre sub-
units leading to subsequent dissociation of the products.  The described process most 
likely occurs at the fibre termini which may exhibit less protected, partially associated 
species as suggested in molecular dynamics simulations of polyethylene-like polymers 
(Yamamoto, 2010).  An additional process to consider is the possibility that unfolded 
region cleavage reduces fibre stability.  Additional stability inferred from the unfolded 
regions may occur through a mechanism in which the unfolded regions transiently and 
loosely interact and thus protect the fibre from sub-unit melting.  Furthermore, unfolded 
regions may sterically hinder protease access to the fibre core or act as a preferred 
‘suicide’ substrate. 
 
Notably, cleavage of β-strands 2, 3 and 4 does not readily occur within the insoluble 
material of a fibre digest.  This indicates that this β-sheet segment remains integral to 
the fibre core, whilst the α-helix and β-strands 1 and 5 are readily cleaved from the fibre 
without clearly causing fibre dissociation.  The persistence of this fibre core region 
strongly suggests that the structure is maintained independently of the regions which 
have been removed, see Figure 3.3.6.  Without major structural rearrangement, which 
seems unlikely, it is difficult to reconcile the current H/D exchange based cystatin B 
fibre model with these results and thereby suggests the model is incorrect.   
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Morphology of Partially Digested Material 
Cystatin B amyloid fibre following protease digestion remains fibrous and shows no 
clear morphological change in electron micrographs (see figure 3.3.5), thus suggesting 
the β-sheet core remains intact and stable throughout the digestion of extraneous 
unfolded regions of the protein.  Fibre width remains the same following 1:50 ratio 
protease: cystatin proteolysis.  The average fibre width after a 24 hour elastase digest 
was 9.7 ±1.5 nm (SD, n=21, max 13.3, min 7.7) and a proteinase K digest for 4 hours 
produced fibres with an average width of 9.4 ±2.3 nm (SD, n=15, max 14.4, min 6.7).  
The deviation of these values from the average undigested fibre (8.6 nm) is most likely 
due to experimental error including a small sample size and the error remains within a 
single standard deviation.  The maintenance of fibre width indicates that no major 
structural event or morphology change is likely to have occurred. 
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Figure 3.3.5 Electron Microscopy of Hydrolysed WT Cystatin B Amyloid Fibres 
EM images following limited proteolysis of WT cystatin B fibres in a 1:50, protease: cystatin B ratio with 
11 500x magnification to the left and 21 000x magnification on the right.  (A and B)  Fibres prior to 
digestion.  (C and D)  Proteinase K digested fibres after 4 hours.  (E and F)  Elastase digested fibres after 
24 hours.  Shortened fibres were sometimes observed, which most likely occurs through the repeated 
pipetting required for analysis and not by hydrolysis, although the latter cannot be entirely ruled out. 
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Fibre Polymorphism 
Limited proteolysis of fibres produced at varying pH was used to explore cystatin B 
amyloid fibre polymorphism as observed in other amyloid forming proteins and 
peptides such as Aβ (Petkova et al., 2005), the null hypothesis being that fibres 
produced in different conditions have the same morphology.  pH dependent fibrilisation 
thioflavin T screening assays were initially performed  with the help of  undergraduate 
project students (Jennifer Thompson, Lauren Wareham, and Oliver Raimond) in an 
attempt to produce cystatin B amyloid fibres in conditions closer to those experienced 
physiologically.  The pH 3.3, 4.7 and 6.0 conditions formed fibres at approximately the 
same elongation rate, (see figure 3.3.6) with increasing lag times as the pH increased.  
This indicates that the formation of the amyloidogenic nucleus is pH dependent whilst 
the nucleus/fibre templating is pH independent.  pH 4.0 was an exception with increased 
polymerisation rate and no observable lag phase, however this does not correlate with 
the trend or previous results.  The pH 7.4 conditions failed to yield detectable fibres in 
the timescale measured.  EM of the fibres formed in the varied pH (figure 3.3.7) 
confirmed the presence of fibrillar species in all incubations. 
 
 
Figure 3.3.6 Thioflavin T Assay of WT Cystatin B Fibrilisation at Varying pH 
(Red diamonds) pH 3.3 conditions (15 mM glycine, 260 mM Na2SO4 buffer), (yellow triangles) pH 4.0 
(15 mM sodium acetate buffer, 150 mM NaCl, 10% v/v TFE), (black open circles) pH 4.7 (15 mM 
sodium acetate buffer, 150 mM NaCl, 10% v/v TFE) and (green squares) pH 6.0 (10 mM sodium 
phosphate buffer, 150 mM NaCl, 10% v/v TFE).   Fluorescence measurements were normalised for 
comparison because direct fluorescence yields are difficult to interpret considering the non-linear nature 
of thioflavin T pH-dependence.  Fit performed using a variable slope model for reasons of clarity and thus 
can only be used qualitatively.   
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Figure 3.3.7 EM of Cystatin B Amyloid Fibre Produced at Varying pH 
The fibres produced at varying pH all show similar morphology.  (A) pH 3.3 generated fibre, 11 500 x 
magnification.  (B) pH 4.0 formed fibre, 21 000 x magnification. (C) standard pH 4.7 fibre, 21 000 x 
magnification. (D) pH 6.0  fibre, 11 500 x magnification.   
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To probe for fibre polymorphism, limited proteolysis was performed on the fibres 
produced at varying pH.  The digestion profiles from cystatin B fibres produced at pH 
3.3 and 4.0 were similar to that of fibres generated at pH 4.7, thus indicating that the 
results are reproducible (see figure 3.3.8). These results support the hypothesis of 
polymorphism absence in these fibre preparations.  However, although the fragments 
generated from fibres grown at pH 3.3, 4.0 and 4.7 are the same, the rate of proteolysis 
appears to be faster in the pH 3.3 fibres compared to the others tested.  This could be 
due to fibre polymorphism, which has not been observed in EM.  However, subsequent 
repeats of this proteolysis (by other members of the lab) indicates that the rate of 
hydrolysis can vary significantly and is most likely due to differences in the activity of 
the protease preparations and not the morphology of fibre samples.  Reduced mass 
spectrometer sensitivity was ruled out by repeating the fragment analysis with a high 
concentration protein control being performed, nevertheless this produced similar 
results. 
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Figure 3.3.8  Digestion Map of Varied pH Generated Cystatin B Amyloid Fibre 
Proteinase K at 1:1000 ratio protease: WT cystatin B fibre digestions were used.  Dark blue bars show 
defined protein digest fragments or regions, whilst the light blue bars indicate ambiguous fragment 
regions.  The far left column indicates protease and ratio used, plus the digestion time.  The column 
second on the left has the mass value obtained from MS of the detected fragment.  The third column from 
the left is the fragment/s identified from the mass value with the bracketed values indicating the mass 
deviation between observed and predicted fragment/s.  At the top of the diagram, the cystatin B native 
secondary structure elements of monomer and domain swapped dimer are shown along with the amino 
acid sequence.  The thick black lines indicate predicted specific protease cleavage sites.  Digestion 
profiles from fibres grown at pH 3.3, 4.0 and 4.7 are the same, although the rate of proteolysis appears to 
be faster in the pH 3.3 fibres compared to the others tested. 
 
3.3.2 Cystatin B Fibre Diameter  
In order to produce models of cystatin B amyloid fibre consistent with the new 
information from the limited proteolysis analysis, clear fibre dimensions were required. 
Cystatin B fibres are extensively laterally associated in the in vitro conditions tested 
(see figure 3.3.9 (panel A)), with the majority of fibrous material present in dense, 
‘tangles’.  The fibres measured in this study were the lowest width single fibrous 
structure that could be unambiguously defined.  Fibres which appeared to be laterally 
associated were omitted for several reasons; (i) in most cases, accurate determination of 
the total number of fibres present in one area was not possible, thus producing poor 
fibre width estimates, (ii) individual fibres are randomly associated and separated along 
the fibre length and can associate with several different fibres in loose bundles/tangles, 
(iii) association is not an essential maturity step in cystatin B fibre formation, as shown 
by very mature (  3 week     1 year, 37 C preparations) producing substantial 
populations of associated and non-associated fibres.  Therefore fibre association is 
unlikely to be structurally significant in terms of protofibril/mature fibre assembly.  
 
The result was that fibre width was measured at an average of 8.6 nm (± 1.4 nm SD, n = 
237) with a minimum and maximum of 5.0 and 13.4 nm (see figure 3.3.9).  No single 
preparation clearly deviated in width or morphology.  Previously reported cystatin B 
fibre widths of fibre grown in similar conditions from ‘many different preparations’ is 7 
± 1.5 nm and 14 nm by TEM (Zerovnik et al., 2002a), whilst AFM with fibres 
generated in similar conditions (45 µM cystatin B, TFE free, produced over 3 months) 
are 13 ± 3 nm in width and 3.4 ± 0.3 nm in height (n = many fibres) with a suggested β-
helical twist periodicity of 27 ± 2 nm (Zerovnik et al., 2002a). The results generated in 
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this study have clarified the fibre width by accurate measurements in well-defined 
conditions and determination of the minimum observable fibre size, without the 
addition of laterally associated fibres described as different structural entities.  I propose 
the fibres measured at 13 and 14 nm are actually two fibres laterally associated which 
may not be apparent in lower resolution EM micrographs and AFM images.   
 
Figure 3.3.9 WT Cystatin B Fibre Width Determination 
(A) Typical cystatin B fibre image showing the edge of a ‘tangle’, laterally associated and individual 
fibres.  (B) Measurement of cystatin B fibre width using the electron intensity histogram profiling 
function of Digital Micrograph 3 software.  (C) Measurement of fibre width uses framing of the fibre 
with the heavier uranyl formate stained regions limiting the boundaries.  (D) Histogram of cystatin B fibre 
width measurements with the peak distribution around 9 nm.  
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3.3.3 Mass Mapping of Cystatin B Amyloid Fibre 
To determine the spacing of repeating units in the amyloid fibre mass mapping was 
performed to generate χ kDa/nm  mass per unit length values (MPL).  From the 590 
measurements, four major fibre classes were observed (see figure 3.3.10 and table 3.3.3) 
and Gaussians were then fitted to determine the MPL.  The MPL Gaussian peak values 
were 26.2 ±5.0 kDa/nm, 38.7 ±3.3 kDa/nm, 49.8 ±16 kDa/nm and 97.5 ±22 kDa/nm.  
Fitting Gaussians also determines peak amplitudes, which can then be used as a crude 
measure of species occupancy and suggests that the first 3 classes are approximately 
equally populated.  The third class is actually more widely distributed suggesting a 
higher population; however, it is thought that an additional fibre class could be 
incorporated and account for this variability.  The extra class however, could not be 
fitted due to the quality of the data.  The standard deviation is also calculated in the fit 
and provides a measure of data accuracy.  
 
 
Figure 3.3.10 Mass Per Unit Length Measurements of WT Cystatin B Fibre 
Histogram (3 kDa/nm bins) of the STEM MPL measurements, with the data fitted to four Gaussians, 
shown in black and the combined Gaussian fit is plotted in red.  4-Gaussian fit to:   
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When considering the MPL data, other experiments must be taken into account to 
explain the results beyond a simple measurement.  This includes EM fibre width 
measurements, (section 3.3.2) average of 8.6 ± 1.4 nm, and an average fibre thickness 
from AFM of 3.4 ± 0.3 nm (Zerovnik et al., 2002a).  These measurements define the 
two height and width dimensions whilst the physical size of the protein monomers 
making up the fibre determines the length of the ‘box’ that x number of protein 
molecules must fit into.  MPL measurements then determine the x number of molecules 
value.   
 
The H/D exchange data collected on cystatin B fibres reliably predicts the existence of 
secondary structure present with these protected regions highlighted red in figure 3.3.3. 
The fibre secondary structure includes the extended -strand present in the dimer, which 
is composed of strand 2 and 3 of the monomeric structure.  The native -strand 4, -
strand 5 and a 5 residue element at the C-terminus of the protein is also structured in the 
amyloid fibre.  Considering the double length of the extended β-strand (20 residues), it 
is useful to think of the monomer occupying the space of 4 strands (in effect, the 
original strands 2-5) with the potential of a short, fifth strand (the C-terminus). Building 
a model requires arranging these secondary structural elements, which we believe to be 
-strands (based on FTIR measurements, Morgan 2006) in a way consistent with the 
EM dimensions and available X-ray fibre diffraction data which suggests a cross- 
arrangement (meridional and equatorial reflections of 4.7Å, and 10 Å, which are 
indicative of intra-β-sheet and inter-β-sheet interactions respectively (Jenko et al., 
2004)).   
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The collected data therefore suggests either 4 or 5 β-strands per cystatin B molecule are 
incorporated into the fibre (native β-sheet 2-5 or 2-5 and the C-terminal). For simplicity, 
we start with the model proposed in Morgan et al. (2008) where 4 β-strands were 
arranged down the same -sheet such that each dimer gave a rise of 4.7 Å multiplied by 
4 which equals 18.8 Å (1.88 nm) (see figure 3.3.11). It is also useful to consider 
whether five β-strands for each molecule is accommodated, giving a rise of 23.5 Å (5 x 
0.47 = 2.35 nm).  Table 3.3.3 shows the breakdown of the fibre classes measured in the 
MPL experiment and the number of cystatin B molecules per 4 and 5 β-strand rises.  
This analysis shows that a 4-β-strand rise has approximately 4, 6, 8 and 16 cystatin B 
molecules whilst the 5-β-strand rise has approximately 6, 8, 10 and 20 cystatin B 
molecules.  Both β-strand rise values repeat approximately every 2 molecules, except 
for class IV which is most likely a doublet of class III.   
 
 Figure 3.3.11  Cystatin B Fibre ‘Sub-Unit’. 
β-sheet length based on meridional reflections of 4.7Å from X-ray fibre diffraction data (Jenko et al., 
2004).   
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Table 3.3.3 Values of WT Cystatin B Fibre Mass Per Unit Length  
MPL ; Mass per unit length expressed in KDa/nm.  The amplitude shown in percentage can be used as a 
crude measure to suggest that fibre classes I-III are approximately equally populated. The cystatin B 
number per 4 β-strand rise is calculated by determining the mass (KDa) for each 4 -stranded rise in the 
fibre, where each -strand occupies 0.47 nm and 4 strands thus give a rise of 1.88nm, e.g. 1.88 x 26.2. 
Following this, the number of cystatin B molecules in this mass are calculated by dividing the mass value 
by the mass of monomeric cystatin B (11 124 Da).  The same calculation is repeated for a 5 -stranded 
(2.35 nm) rise.  The calculations assume a model where the core of the amyloid fibres assumes a 
continuous -sheet rather than a discontinuous model with breaks in the core -structure, which is 
currently understood to be the most prevalent structure (Petkova et al., 2005, Wasmer et al., 2008). 
 
3.3.4 Sequence Dependent Amyloid Prediction   
A comparison of the ‘amyloid hotspot’ prediction programs was performed on cystatin 
B to elucidate the expected core regions of the fibre and the results are shown in figure 
3.3.12.  The programs performed well with typically conservative results similar to the 
H/D exchange data.  In several cases the prediction programmes favourably matched the 
results from limited proteolysis in that they did not include β-strand 5 and the N-
terminal region.  This poor matching could indicate that β-strand 5 is a relatively weak 
amyloid β-sheet forming section of the protein and thus is more susceptible to 
proteolysis and a higher dynamic association/dissociation with the other fibre interfaces. 
Fibre 
Class 
MPL 
(KDa/nm) 
Amplitude 
(% total) 
Cystatin B number per 
4 -strand rise 
Cystatin number B per 
5 -strand rise 
I 26.2 ± 5 37 % 4.4 ± 0.85 5.5 ± 1 
II 38.7 ± 3.3 32 % 6.5 ± 0.55 8.2 ± 0.7 
III 49.8 ± 16 26 % 8.5 ± 2.7 10.5 ± 6.3 
IV 97.5 ± 22 4 % 16.5 ± 11 20.5  ± 4.6 
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Description            10                20       30     40                 50 
H/D Ex NMR MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG 
Sec. Structure              ββββββββββ α α α α α α αα α α α α α αα α α α        βββββββββββββββββββ 
Chem Nature  MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG
  
 
AGG  MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG 
WALTZ  MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG 
TANGO  MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG 
AmylPred MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG 
Packing  MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG 
Switches MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG 
Pattern  MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG 
Con Energy MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG 
Zagg (pH7.0) MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG 
Zagg (pH4.7) MMSGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAG 
 
        60        70     80   90         98 
H/D Ex NMR TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
Sec. Structure βββββββββββββ     ββββββββββββ         βββββββββββββ 
Chem Nature TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
 
AGG  TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
WALTZ  TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
TANGO  TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
AmylPred TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
Packing  TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
Switches TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
Pattern  TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
Con Energy TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
Zagg (pH7.0)  TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
Zagg (pH4.7)  TNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF 
 
Figure 3.3.12  WT E31 Cystatin B Amyloidosis Sequence Prediction  
H/D Ex. NMR = Hydrogen/ deuterium exchange protected regions (red) in the amyloid fibre (Morgan et 
al., 2008).  Sec. Structure = secondary structure in the dimer, α = α-helix, β = β-sheet.  Chem. nature = 
chemical nature of the amino acid:  Blue = basic, Pink = acidic, Polar = green, Non-polar = yellow.  AGG 
= AGGRESCAN (Conchillo-Sole et al., 2007), WALTZ (Maurer-Stroh et al., 2010), AmylPred 
(Hamodrakas et al., 2007), Packing = Average Packing density (Galzitskaya et al., 2006), Switches: = 
Conformational switches (Hamodrakas et al., 2007), Pattern (Lopez de la Paz and Serrano, 2004), Con 
Energy:  Conformational Energy (Zhang et al., 2007), Zagg = Zyggregator (Tartaglia et al., 2008). 
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3.4 Discussion 
 
3.4.1 Limited Proteolysis Data Implication on Cystatin B 
Amyloid Formation 
This study has generated additional evidence for the absence of a native-like α-helix in 
fibre associated protein, due to rapid hydrolysis throughout this region, and further 
supports the absence of H/D exchange protection previously observed in this region 
(Morgan et al., 2008).  This indicates that unfolding of the α-helix is essential in 
cystatin B fibre formation.  The α-helix role is essential to cystatin B stability, indicated 
by dictation of the folding rate in chimeras with α-helices from different cystatins, 
despite the helix representing only 25 % of the protein chain (Jelinska et al., 2011). 
 
In identifying an amyloid fibre core, it must be considered that proteases typically 
require ≥10 amino acid residues with high chain mobility for binding upstream of the 
cleavage site, thus limiting the exact definition of cystatin B amyloid fibre core regions 
(Hubbard, 1998).  Therefore, the protease resistant 27-80 amino acid fragment 
represents a maximal fibre core.  Removing a further 10 residues from each termini of 
this fragment results in an NT, one amino acid from the beginning of the native β-strand 
2 and a CT, one residue within β-strand 4.  Therefore it is proposed the cystatin B fibre 
core is minimally composed of native-like β-strands, 2, 3 and 4, residues 38-70, and 
maximally no more than residues 27-80.  Therefore, it is likely only one third of the 
cystatin B protein is incorporated into the fibre core.  A more conservative estimate 
would be 54% incorporation, assuming the 27-80 residues fragment is a perfect 
delineation of the fibre core.   
 
This result clearly indicates the currently posited simple structural model of native 
dimer-like stacked β-sheet (strand 2-3, 4 and 5) (Morgan et al., 2008) is unlikely due to 
hydrolysis within native β-sheet 5, whilst the amyloid fibre remains intact (figure 3.3.5).  
If the protease cleaved β-sheet 5 whilst incorporated into the fibre core, then the core 
structure is likely to collapse and either induce fibre break down or structural 
rearrangement.  It is improbable that digestion occurs within the fibre core structure 
with subsequent fibre structural remodelling, and there was no evidence of morphology 
changes or full-size soluble protein species which would be indicative of such events.  
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The implication is that strand 5 must form part of a separate sheet, which can be cleaved 
away independently of the main fibre structure. A number of models allow this 
including the widely proposed parallel in-register models of amyloid.   
 
3.4.2 Mass Mapping Restricts the Model Further 
The width of a single fibre ‘tape’ (8.6 ± 1. nm) is equivalent to the length of the dimer-
like extended, straightened β-strand made from the original strands 2 and 3 which is 
suggested to be preserved in the fibres from the H/D exchange data. The β-sheets are 
most likely to be arranged perpendicular to the fibre axis as suggested from the 
persistence of the 4.7 Å reflection in X-ray diffraction data of a partially aligned sample 
of cystatin B (Jenko et al., 2004).  The 3.4 ± 0.3 nm thickness of the fibre can thus only 
accommodate an absolute maximum of 3 β-sheets longitudinally, with each sheet 
contributing 1 nm (10 Å).  Given the dimensions and the requirement to encompass the 
presence of large amounts (perhaps 50% by volume, a third by polypeptide length) of 
unfolded protein, it seems likely that the originally proposed 2 -sheet thickness in 
Morgan et al. (2008) is consistent with the EM dimensions. This resulted in the 
presence of 4 cystatin B molecules per 4 -strand rise (Class I), a doublet thereof 
explaining the presence of fibres with 8 and 16 molecules of cystatin B per 4 -strand 
rise (Class III and IV). Class II fibres contain only 6 molecules per 4-strand rise, 
something which is more difficult to envisage within the reported dimensions but is 
reminiscent of proposed models for insulin, see figure 3.4.1 (Jimenez et al., 1999). 
 
 
Figure 3.4.1 Cross Sections of Various Insulin Fibre Morphologies  
Superposition of cross sections from different insulin fibre morphologies suggesting the presence of a 
common protofilament structure; shown in green, red and blue.  Figure from (Jimenez et al., 1999).  
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The MPL measurements suggest that the 5-β-sheet rise is unlikely. A model of cystatin 
B fibres with unpaired numbers of molecules (5, 8 and 10) is more difficult to 
accommodate. Further to this, with β-strands 2 and 3 forming a single β-sheet, β-strands 
4 and 5 are most likely required in the structure to form an opposing β-sheet.  In this 
case, the H/D exchange protected C-terminal is most likely to either be included in this 
balancing β-sheet or form a small independent structure extraneous to the main fibre 
core.   
 
Although the MPL measurements suggest that at least four fibre classes exist, this is not 
observed in the width measurements obtained, with the measurement distribution 
suggesting a single species.  This discrepancy could be due to several issues, such as the 
negatively stained EM images failing to determine fibre thickness which could multiply, 
assuming the fibre lays flat and has no periodic twist.  Equally the sampling method of 
the width measurements could be a reason for this, with sampling only of single fibres 
that could be unambiguously determined to be not laterally associating at the point of 
measurement.  STEM MPL images are intrinsically low resolution and as such it is 
difficult to determine and observe the smallest fibres and determine whether the fibres 
are laterally associated.  Therefore the minimum fibre structure could actually be 
composed of 2 cystatin B molecules per rise and were not measured due to the poor 
resolution which would explain the repeating unit of two cystatin B monomers per fibre 
class.  This is unlikely however as the technique resolution is typically sufficient to 
select the smaller fibres and there is a near absence of MPL measurements at the 
expected values if this were the case.  The most likely structural scenario is that the 
minimal fibre unit is composed of 2 protofibrils each with 2 cystatin B fibres per 4-β-
strand rise similar to that observed in Aβ1-40 (Petkova et al., 2002) and amyloid-like 
crystals (Serpell, 2000).  Cystatin B can then also produce fibre composed of 3, 4 and 8 
protofibrils and or/the class II fibres represent a different structural arrangement and 
class III and IV are laterally associated class I fibres.   
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Random errors from this experiment are due to noise from scattered electron signal 
from the fibre mass and the support carbon film.  Error from electron scattering can be 
reduced using higher electron exposure, although this also increases the error from 
electron-beam-induced mass loss.  However, with collagen fibre as an example 1-2 % 
accuracy can be achieved (Holmes et al., 2001).  Systematic error within the technique 
includes mass contamination, calibration errors and electron irradiation-induced mass 
loss.  Mass contamination of the sample and/or the reference fibre with small molecules 
such as salts can lead to error with TMV mass contamination showing a typical 2-5% 
error (Muller et al., 1992).  Electron irradiation mass loss is reduced by using STEM, 
minimising the number of scans in a particular area and measuring the mass loss 
occurring in the TMV calibration microscopy over time.  Thus the results produced are 
likely to be reliable with interpretation and data fitting being the most likely source of 
error.  
 
3.4.3 Non-Native Structure Model of Cystatin B Amyloid Fibre 
We propose a new simple working model (Figure 3.4.2) based on the limited proteolysis 
and H/D exchange data which posits that the native β-strand 2 and 3 is extended into a 
single strand stacking in parallel to form the fibre ‘backbone’ whilst β-strand 4 and 5 
forms the second arm of a β-arc (hairpin).  This model allows a number of things. 
Firstly, the conservation of the 20 amino acid continuous β-strand observed in the dimer 
(made from β-strands 2 and 3), secondly shielding of the hydrophobic regions of the 
protein is ensured, while still allowing the cleavage of β-strand 5, leaving a shortened 
second strand yet still maintaining a continuing β-sheet core of strand 2-3 and 4.  
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Figure 3.4.2  Modelling of Cystatin B Amyloid Fibre  
A.  The current model based on H/D exchange NMR maintains mostly native β-sheet structure with a 
disordered native α-helix (Morgan et al., 2008).  This model is not supported by the limited proteolysis 
data which requires β-strand 5 to be accessible to protease without fibre dissociation or large scale 
structural remodelling.  B.  Suggested working model, which allows access to β-strand 5 without major 
remodelling upon removal.  Both models fit the EM and AFM size restrictions and account for MPL 
measurements (classes I, II and IV). 
 
Figure 3.4.3 shows predicted patterns of hydrolysis for the two models proposed.  In 
both models proteolysis in the NT region is accommodated as observed.  However both 
models do not simply fit the limited proteolysis results when considering the cleavage 
within β-strand 5.  The H/D exchange based model cannot be used to explain the 
proteolysis data because β-strand 5 is completely inaccessible and if it were cleaved the 
fibre would fall apart.  However, the newly proposed β-strand arc model can 
accommodate this data if β-strand 5 is occasionally accessible by a melting and re-
annealing process.  
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H/D Exchange Model  
 
Β-Arc (Hairpin) Model  
 
Figure 3.4.3 Predicted Limited Proteolysis with Fibre Structure Models 
The predicted cleavage positions, shown by triangles, are based on the posited structural models and 
incorporates the observation that hydrolysis rarely occurs within 10 residues of structured regions. 
Proteinase K proteolysis is indicated by black triangles, elastase by green triangles and endoproteinase 
Lys-C digestion labelled with orange triangles.  The H/D exchange model fits only the cleavage from the 
N-terminus.  The βstrand arc (hairpin) model shown fits the proteolysis data robustly if the C-terminal 
region is occasionally accessible by a melting and re-annealing process.  The topology map is modified 
from (Morgan et al., 2008), where hydrogen bonding present in the dimer is shown using dashed arrows. 
The regions of the molecule involved in the formation of secondary structure in the fibre are shown as 
H/D exchange protected residues (red) whereas unstructured regions of the amyloid fibre which readily 
exchange hydrogen for deuterium are highlighted in blue. Residues for which no H/D exchange data is 
available are coloured white.  
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The accessibility of β-strand 5 could be mediated by dynamic fibre sub-unit melting and 
annealing leading to increased exposure and perhaps a lower frequency of secondary 
structure maintenance.  This process may explain the difference in the rate of 
proteolysis in the N and C terminal region.  In further support of this, it was noted that 
in the H/D exchange data at pH 9.0 the last 19 residues (including β-strand 5) are 10-
fold less protected than those in the native β-strand 2, 3 and 4. This was the only 
condition examined in which differential stability of fibrous cystatin B could be 
observed (due to a significant contribution from EX2 as well as EX1 exchange). At pH 
4.7 and 7.0 the protection amplitude is near identical for all protected residues (Morgan, 
2006) and at pH 8.0 (the conditions for proteolysis) it is assumed that the exchange rates 
would appear somewhere between the pH 7.0 and 9.0 data.  Alternatively the native 
loop (8 aa) between β-strand 4 and 5 may allow protease binding, leading to 
destabilisation of β-strand 5 and subsequent hydrolysis, perhaps in a processive manner.  
 
The cystatin B amyloid fibre core consists maximally of 54% of the total monomeric 
residues, which is consistent with results from many other amyloid forming proteins.  
For instance; HET-s fibres produce a 218-289 (25%) proteinase K resistant fragment 
(Balguerie et al., 2003a), α-synuclein has residues 31-109 (56%, 140 aa) protected from 
proteinase K proteolysis (Miake et al., 2002), human lysozyme residues 32-108 (58%) 
are protected from pepsin digestion (Frare et al., 2006), Ure2p filaments with addition 
of proteinase K were trimmed from 25 nm to 4 nm cores which composed of residues 1-
70 (20%) (Baxa et al., 2003).  In comparison; β2-microglobulin long straight fibres 
produced at low ionic strength were digested with pepsin to produce fragments of 9-99 
aa (90%) (Myers et al., 2006) and P13-SH3 fibres were completely resistant to 
proteinase-K proteolysis (de Laureto et al., 2003).  It is thus supportive that the data 
values obtained in this study is within the range observed in other systems. 
 
3.4.4  Sequence Specific Amyloid Prediction  
A comparison of the ‘amyloid hotspot’ prediction programs was performed on cystatin 
B to elucidate the expected core regions of the fibre.  All the programs tested predict 
several ‘hotspots’ of aggregation within the β-sheet regions of cystatin B.  Of particular 
note is the GTNYFIKV motif in β-strand 3 which nearly all the programs detect and is 
empirically thought to be the primary amyloidogenic region in the centre of the protein.  
It is difficult to decide which program is the best, although I personally prefer 
ZYGGREGATOR, closely followed by WALTZ and AGGRESCAN, the latter two 
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being the most user friendly. The programs overall performed well with typically 
conservative results similar to the H/D exchange data.  In several cases the prediction 
programmes favourably matched the results from limited proteolysis in that they did not 
include β-strand 5 and the N-terminal region.  This poor matching could indicate that β-
strand 5 is a relatively weak amyloid β-sheet forming section of the protein and thus is 
more susceptible to proteolysis and a higher dynamic association/dissociation with the 
other fibre interfaces. 
 
3.4.5 The Role of Domain Swapping in Cystatin B Amyloid Fibre 
The data presented herein develops the structural model of cystatin B fibre with 
implications on the understanding of amyloid formation in a multitude of natively 
folded proteins.  The primary relevance of simple 3D-domain swapping models to the 
mechanism of amyloid formation by cystatin B seems remote although the key element 
identified in the 3D domain-swapped dimer is preserved in the core of the fibres. The 
topology of the -strands proposed here is more reminiscent of the parallel-in-register 
structures proposed to account for large numbers of amyloids prepared in vitro 
(Margittai and Langen, 2008). Further fibre structural information collected from a 
range of cysteine mutants analysed by X-ray absorption near-edge spectroscopy and 
solid-state NMR projects which are ongoing will help refine the model and early 
indications suggest that the native-like model is unlikely. It is of particular intrigue that 
amyloid fibres can accommodate large segments of exposed unstructured regions 
extraneous to the fibre core and accessible to proteases.  Whilst many amyloid related 
diseases may have similar mechanisms of toxicity, yet to be conclusively determined, it 
is perhaps these unstructured regions which mediate variations in targeting and 
aetiology of disease.  The elucidation of amyloid structure and intermediates will assist 
in drug development and treatment for many degenerative diseases. 
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Chapter 4: Oligomer Production 
 
4.1 Introduction 
 
The Zerovnik group report the production of cystatin B oligomers composed of 5,6,7,8 
and up to 32 monomers (personal communication), (Ceru and Zerovnik, 2008).  These 
high molecular weight oligomers (HOs), often referred to in this chapter as oligomers, 
are suggested to be toxic and therefore currently of interest in developing treatments for 
neurodegenerative diseases (Lashuel et al., 2002).  Oligomeric species are typically 
transient in nature, thus difficult to isolate with previous cystatin B attempts proving 
unsuccessful.  Replication of the Zerovnik group oligomer generation has been 
attempted by both repeating and modifying the original protocol, but failed to yield 
HOs.  Site-directed mutagenesis of WT cystatin B to produce the G4R EPM1 related 
mutant and a variation of the standard protocol described in section 2.5 produced HOs.  
The generated oligomer was then characterised by EM, solvent stability and limited 
proteolysis. 
 
The G4R mutation as described in section 1.9 is one of the single point mutations 
implicated in myoclonus progressive epilepsy of type 1 (EPM1).  This mutation from 
the compact polar and highly conserved glycine to the long basic side chain of arginine 
is likely to have major implications on the stability of the tentative β-strand 1, which 
nearly forms a type II loop (see figure 4.1.1) (Stubbs et al., 1990).  This mutated β-
strand may mediate association of other cystatin B β-sheets by becoming flexible and 
dissociate from the protein core, it might also act as a tether through which it may 
associate with other cystatins to form oligomer and/or destabilise the α-helix and 
increase the propensity to unfold and form larger structures.  G4R has previously been 
shown to remain in the prefibrillar aggregate state for four times longer than the WT  in 
fibrilisation conditions, hence must induce a significant alteration to protein stability 
(Rabzelj et al., 2005).  Single point mutations destabilising amyloidogenic proteins are 
not unusual with the arctic mutant Aβ (E22G) inducing faster and higher levels of 
amyloidogenesis (Nilsberth et al., 2001) and the Δ6-β2-microglobulin which remains in 
a prefibrillar state for extended periods of time (Eichner et al., 2011). 
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Monomer     Dimer 
 
Figure 4.1.1 G4R Mutation Position 
The glycine residue position is denoted by a magenta sticks in the monomer and dimer.  The near loop in 
β-strand 1 is also quite clear.  PDB: monomer 1STF, dimer 2OCT, graphically rendered in Pymol 
(DeLano Scientific, CA).   
 
 
4.2 Materials and Methods 
 
4.2.1 Oligomer Generation from Cystatin B Monomers 
The standard cystatin B purification protocol described in section 2.5 was primarily 
used for most initial protein purification with variations based on a protocol from the 
Zerovnik group.  The Zerovnik group protocol detailed the use of a papain column in 
the first purification step followed by several rounds of diafiltration then SEC with a 
preparative sephadex 75 column.  The final step was four cycles of freeze-thawing 
followed by SEC analysis of the oligomeric state.  Immediately noted was that only 
monomeric cystatin B can bind a papain column (Abrahamson, 1993).  The monomeric 
population typically constitutes only ~10% of the total protein content, whilst ~90% is 
dimer and a few percent tetramer, thus the use of a papain column would dramatically 
reduce protein yield.   
 
In the first trial a monomer/ dimer/ tetramer mixture of WT E31 cystatin B, purified 
according to the standard method described in chapter 2.5, was used to replicate the 
conditions of papain column elution.  To replicate the conditions, 9 ml of cystatin B at 1 
mg/ml was buffer exchanged into an equal volume with an Amicon ultrafiltration 
stirred-cell with a Millipore regenerated cellulose 10 000 kDa MWCO filter into 20 mM 
ethanolamine/100 mM NaCl, pH 10.7.  The cystatin B solution was then added drop-
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wise into 1 ml 0.02 M NaPO4/1 M NaCl, pH 6.0. The protein solution was then buffer 
exchanged into 10 mM NaPO4/100 mM NaCl, pH 6.0 buffer.  1 ml aliquots of protein 
solution were then freeze-thawed for 4 cycles of 1 hour thawing in air at room 
temperature and a minimum 1 hour at -80°C.  Further purification attempts are 
described below in the results section. 
 
4.2.2 Oligomer Characterisation - SEC HPLC 
Samples were taken at each step and the oligomeric state analysed with SEC-HPLC 
(Shodex KW803 column) for separation of oligomers <700 kDa and SEC with a 100 ml 
sephacryl-400 column for very high molecular weight oligomers.  To remove the 
possibility that HO was interacting and/or binding to the Shodex KW803 column matrix 
or stainless steel hardware, a pre-packed analytical superdex 200 column with plastic 
and glass hardware (Biopharmacia) was also used to analyse the oligomer generation 
products.  Both columns yielded similar chromatograms in all cases.   
 
4.2.3 Oligomer Morphology - TEM   
To measure the HO diameters, Digital Micrograph 3 software was used to generate 
electron intensity histogram profiling to accurately determine and measure the oligomer 
width.  Three diameter measurements were performed for each oligomer, with the 
average of the three readings being subsequently used for averaging.  The three 
measurements and averaging were performed to account for variance in the approximate 
disk shape and error caused by edge irregularity and poor contrast of the oligomers.  
Five different electron microscopy grids produced from the 3 successful preparations 
were each analysed independently and contributed a maximum 10 values for each 
oligomer class to ensure no single preparation skewed the results if they proved 
significantly different.  The images used were selected to cover the 3 different 
preparations, have a high resolution and contrast and extensive oligomer coverage.  
Images were collected on a Phillips CM100 electron microscope with a 1024 x 1024 
pixel Gatan CCD camera using 21 000 x magnification negatively stained electron 
micrographs, thus each pixel was equal to 1 nm and defines the maximum level of 
accuracy  as ± 1 nm.   
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4.3 Results 
 
4.3.1 Oligomer Formation 
 
Published Protocols 
The replication of the Zerovnik group oligomer production protocol, described above, 
was attempted with the WT cystatin B (C3S) E31 variant with no success.  Freeze-
thawing was suggested to be the major step in high molecular weight oligomer (HO) 
production and proved to increase tetramer formation 5-fold in WT cystatin B (figure 
4.3.1) and 3-fold in the V59Q mutation when frozen and defrosted four times, with each 
cycle carried out with a 1 ml sample over a 1 hour period at room temperature and then 
at -80°C.  Intriguingly, increasing the WT cystatin B protein concentration and freeze-
thawing in an identical manner increases the tetramer concentration relative to the dimer 
population.  However, concentration dependence controls without freeze-thawing were 
not performed.  The Q46C-N52C mutant also produces large molecular weight species, 
but was not followed up, due to potential cysteine cross-linking, resulting in potential 
amorphous aggregation (see figure 4.3.2) .   
 
Papain Affinity Chromatography 
Following the first oligomer production trial, a 100 ml papain column was used to 
isolate cystatin B monomer from purified solution, in conditions described in the 
Zerovnik group protocol.  The first attempt was unsuccessful with no detectable levels 
of protein binding the column and subsequently eluting.  A further two attempts were 
made with a higher starting mass of protein and stirring of the papain beads overnight at 
4°C in a beaker with suitably buffer exchanged cystatin B and equilibrated  papain 
beads.  This stirring method allows monomer to bind to the papain beads, reducing the 
monomer population in solution which is then replenished dynamically from the 
dimeric and possibly tetrameric state.  Manipulation of the equilibrium in this manner 
theoretically allows large quantities of monomer to bind to the column and thus result in 
a high yield.  However in this case, the attempts proved unsuccessful and cystatin B did 
not bind the papain column sufficiently in the conditions described.   
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Figure 4.3.1 Freeze-Thawing Increases Tetramer Population in WT Cystatin B 
HPLC chromatograms of freeze-thawing have been scaled to the value of the highest dimer peak for 
comparison.  (A) Initial freeze-thawing of WT cystatin B ~1 mg/ml showing significant increase of 
tetramer (Shodex KW803 column) (B) Protein concentration dependence of freeze-thawing, with an 
incremental increase in the ratio of tetramer to dimer as protein concentration increases (superdex 200 
column).    
 
Bacterial Expression Strain Trials 
Very small peaks observed occasionally in SEC of the standard WT cystatin B 
preparation were observed and analysed by HPLC-SEC and electron microscopy, 
although no successful determination of the oligomer state was achieved most likely as 
a result of low concentration.  Following this E. coli BL21 (DE3) Gold pLysS cells, the 
same expression cells utilised by the Zerovnik group, were employed to express WT 
E31 cystatin B with an induction time of 5 hours in the hope that the different cellular 
conditions may yield HOs.  However, these cells also failed to produce oligomeric 
species.   
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Figure 4.3.2 Q46C-N52C Cystatin B Oligomer 
Q46C-N52C cystatin B (red) potentially produces oligomeric or aggregate species which elute on a 
superdex 200 column near the exclusion volume (11 minutes). 
 
Cystatin B G4R Variant 
It was subsequently suggested that the G4R mutant identified in the disease myoclonus 
epilepsy of type I (EPM1), produces significant amounts of HOs and in fibrilisation 
conditions remains in the prefibrillar aggregate state for a much greater time span 
(Rabzelj et al., 2005).  The G4R mutant was therefore produced by site-directed 
mutagenesis into the E31 (C3S) WT background.  During initial purification, an error in 
the anion exchange column purification step, whereby the column was equilibrated with 
500 mM NaCl, pH 6.0, 10 mM sodium phosphate gradient elution buffer which 
prohibited binding of the protein.  To rectify, the entire protein eluent was diluted 10-
fold in sodium chloride free buffer and loaded onto a correctly equilibrated sodium 
chloride free column overnight at RT.  This treatment produced a low overall protein 
yield, but allowed clear observation of a small peak of HO species upon elution on a 
G75 superdex SEC column (see figure 4.3.3).  The HO fractions, when examined by 
EM (see figure 4.3.4), showed an extensive coating of the grid surface with a 
heterogeneous mixture of oligomeric species.   
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Figure 4.3.3 G4R Oligomer Purification SEC 
The oligomeric peak typically eluted into fractions 17-21 (6 ml each), in a 400 ml bed volume superdex 
G75 column.  Some variability occurred in different preparations, such as a shouldering peak between the 
established oligomer peak and tetramer.  In this additional peak, oligomeric species were not observed in 
EM.   
 
Reproducing the oligomer preparation results was initially not straightforward, with the 
first two preparations carried out with the standard cystatin B purification methodology 
(chapter 2.5) failing to yield well defined structures and instead produced amorphous 
aggregate and/or the oligomer dissociated.  A mixture of monomer, dimer and tetramer 
as well as amorphous aggregate was observed in the same SEC fractions that previously 
bore distinct oligomer (see figure 4.3.5).  The key step proved to be ultrafiltration of the 
anion exchange protein solution fractions to half the standard concentration (10, not 20 
mg/ml) before SEC elution.  See figure 4.3.6 for a schematic of the purification, which 
is nearly identical to the standard method described in section 2.5.  Generally, each 
oligomer preparation has produced low yields (< 1.5 mg/l of LB growth media) and was 
much lower in M9 minimal media (0.1 mg/l).  A range of novel therapeutics such as 
epigallocatechin-gallate (EGCG) (Ehrnhoefer et al., 2008) and rifamycin SV (Woods et 
al., 2011) were considered in efforts to enhance oligomer production, but time 
limitations have forbade continuation of this study.   
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Figure 4.3.4 Initial Successful Preparation of G4R Cystatin B High Molecular 
Weight Oligomers 
Negative Stain Electron Micrographs of purified oligomeric species from the initial purification.  The 
structures were observably coating the entire grid, with a small selection of images shown.  (A) 5 200 x 
magnification (B) 11 500 x (C) 28 500 x (D) 39 000 x.  There are several different morphologies present, 
including the ‘cluster’ species, see figure 4.3.8 for further analysis of the morphologies. 
 
 
128 
 
 
Figure 4.3.5 Cystatin B Oligomer Preparation: High Concentration Aggregation 
G4R cystatin B purified by the standard protocol in an attempt to produce a high yield of oligomeric 
species.  The SEC fractions previously containing distinct oligomeric species exhibited an extensive 
population of oligomer-like aggregate which had a poorly defined structure and could not be adequately 
focussed upon at higher magnifications in an analogous manner to amorphous aggregate species.  (A) 21 
000 x magnification electron micrograph of oligomer-like aggregate.  The oligomer-like dark regions are 
negatively stained in a similar manner to amorphous aggregate.  (B)  Precipitate formed by G4R upon 
ultrafiltration prior to SEC.  The background is typical of high concentration soluble protein with some 
heavily stained oligomer-like structures.  Some of the precipitate may have resuspended or the soluble 
protein could be from protein solution remaining with the pellet.   
 
 
Figure 4.3.6 G4R Oligomer Purification Strategy 
The schematic strategy is nearly identical the standard purification method described in section 2.5 with 
the exception that the protein from the SP sepharose column is divided in two, concentrated to ~ 10 ml 
(<10 mg/ml) and then passed through the SEC column. 
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Attempted Production of G4R Higher Molecular Weight Oligomer Species from 
Purified Monomer, Dimer and Tetramer 
Exchanging G4R cystatin B monomer and dimer mixtures (1 mg/ml) into 6 M 
guanidine hydrochloride and refolding on SEC HPLC in the typical pH 6.0 sodium 
phosphate buffer (150 mM NaCl, 1 mM NaN3) did not produce any further oligomeric 
species.  Four cycles of freeze-thawing a 500 µl monomer and dimer mixture at -80°C 
for 15 minutes and thawing in air at 21°C for 30 minutes also failed to produce 
oligomeric species.  An EM image of the post cell lysis soluble material was obscured 
by a large amount of amorphously aggregated protein, thus no oligomer species was 
observed, whether present or absent. High molecular weight oligomer could only be 
produced directly from E. coli protein extractions, with manipulation of the monomer 
and dimer failing to yield oligomeric species.  The reason for this remains unclear, 
although specific in vivo conditions are dissimilar to those in vitro. 
 
G4R-Like Oligomers are Observed in WT Preparations Although are Rare 
The oligomers generated are similar to observations of rare single oligomers in WT 
cystatin B fibre preparations.  Originally these structures were thought to be artefacts 
due to the infrequency of observation.  HO structures have been observed in a WT 
cystatin B monomer/ dimer/ tetramer preparation in pH 4.7 sodium acetate buffer (150 
mM NaCl, 1 mM NaN3) which was stored at 4°C for two years and was then studied by 
EM due to the solution appearing cloudy in a manner analogous to fibre solutions (see 
figure 4.3.7).  The oligomers produced are also similar in appearance to those produced 
by Aβ1-42 peptide in pH 2.0 aqueous HCl after 4 days at 37°C.  This similarity may 
indicate a comparable overall morphology and therefore it would be worthwhile to test 
for toxicity.  The G4R cystatin B oligomers produced are also similar to those formed 
by purified monomeric human cystatin C shown in figure 4.3.8.  These cystatin C 
oligomers are observed in equilibrium with fibre in conditions such as pH 2.0.  
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Figure 4.3.7 WT Cystatin B and Aβ Oligomeric Structure Comparison  
(A) A cystatin B protein preparation was stored for 2 years in pH 4.7 fibrilisation buffer (minus 10% 
TFE) at 4°C, after which a significant volume became cloudy in an analogous manner to fibre 
preparations.  Sampling of this solution and EM (21 000 x magnification) indicates these conditions have 
induced a small proportion of oligomer formation with the electron micrograph representative of the few 
structures seen.   (B)  21 000 x magnification of Aβ1-42 peptide solution in fibre forming conditions of pH 
2.0 aqueous HCl (4 days at 37°C), following ultracentrifugation for 30 minutes at 190 000 x g (RCFMax).  
The oligomers observed in this image are similar in apparent morphology to the smaller structures formed 
by cystatin B.     
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Figure 4.3.8 G4R Cystatin B and WT Cystatin C Oligomer Comparison 
 (A and B) Negatively stained electron micrographs of oligomer at 11 500 x (A) and 21 000 x 
magnification (B).  G4R cystatin B oligomer observed after purification from E. coli.  (C and D) Cystatin 
C oligomer prepared from purified monomeric protein in fibre forming conditions, 11 500 x 
magnification (C) and 21 000 x magnification (D).  During fibre formation these oligomers are observed 
in equilibrium with fibre and associate with the fibre to a high degree.  Cystatin C images kindly supplied 
by Abigail Williams.   
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4.3.2 Oligomer Characterisation 
 
Classification of Oligomer Morphology 
The G4R cystatin B HO preparations display at least five distinct morphology classes as 
shown in figure 4.3.9 with the average diameters and statistics.  The five classes are; 
small annular, ‘square’ pore like, medium biconcave, cluster and large amorphous 
oligomers.  The small annular oligomers are the smallest EM measureable structures 
and define the limitations of the technique and equipment used.  Smaller potentially 
oligomeric structures were possibly observed in electron micrographs, however the 
contrast was not high enough to accurately assess the structure, delineate the edges or 
confidently distinguish them from the background.  The ‘square’ pore-like oligomers 
are perhaps composed of four small oligomer structures associating together to form a 
clear central cavity.  The medium annular oligomers along with large oligomers exhibit 
large diameter variation and primarily display an apparent biconcave appearance, 
although a hollow sphere is also feasible.  The cluster oligomers appear to be a 
conglomeration of very small annular oligomers associating together generally in an 
apparent disc.  The cluster morphology could be a proto-medium annular oligomer, 
which then matures and reduces in size through compaction.  From EM observation and 
measurement, the oligomers were displayed as flat round disks which appear to bind the 
grid in a uniform orientation.   
 
The frequency of oligomers and distribution of classes varied from preparation and grid 
area.  For instance the first preparation was devoid of square pore-like oligomers, but 
contained the clusters, whereas in the third successful preparation this situation was 
reversed.  Overall, in the electron micrographs a qualitative frequency was, small > 
medium > large > cluster > square pore-like oligomers.  A more detailed determination 
of frequency would likely be a falsehood, due to variations in EM grid binding, 
sampling of the grid and contrast difficulties which would likely skew the values in 
favour of the larger structures. 
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Figure 4.3.9 G4R Cystatin B Oligomer Structural Classes and Diameter Values 
Selected images of each structural class.  The 21 000 x negatively stained electron micrographs have been 
proportionally increased in size by a third for printed clarity.  Standard deviation was used to calculate the 
variance in the average diameter measurements.   
 
 
Oligomer 
Description 
Average 
Diameter 
(nm) 
Number of 
Particles 
Measured 
Maximum 
Diameter 
Observed 
(nm) 
Minimum 
Diameter 
Observed 
(nm) 
Small annular 10.6 ±1.4 26 13.1 8.2 
Square 
Pore-like 
15.0 ±0.4 6 15.5 14.3 
Medium 
annular 
33.5 ±4.7 30 43.7 23.5 
Cluster 
 
40.82 ±3.3 8 45.7 36.2 
Large 
Amorphous 
67.7 ±13.1 6 88.3 48.3 
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Oligomer Species Mass Determination 
G4R oligomer mass determination was attempted with SDS-PAGE, SEC HPLC and 
MS.  The high molecular weight oligomer fractions did not migrate readily through 
4/20% discontinuous SDS-PAGE gels thus suggesting 1% SDS resistance.  The 
stacking gel interface in oligomer containing lanes did however positively stain for 
protein with coomassie stain to a small extent, therefore also suggesting proteinaceous 
content.  Elution on a Shodex KW803 SEC HPLC column produced a single peak 
containing species >700 kDa (>63-mer), which matches the 2 M Da Blue Dextran 
which elutes at the column exclusion limit (700 kDa) (figure 4.3.10).   
 
Oligomer preparations were analysed by MALDI-TOF and ESI-TOF mass spectroscopy 
analysis, although were negative for masses corresponding to the G4R protein and also 
did not contain any other significant mass values which would correspond to 
phospholipid.  The sample mass was possibly too low for detection (<<µM), did not 
vaporise effectively in the spectrometer or did not fragment sufficiently into smaller 
species suitable for analysis.  Future experimentation to determine the mass, could 
include the use of a SEC column with a larger mass range, sucrose-gradient analytical 
ultracentrifugation and electrospray ionisation ion mobility mass spectrometry (ESI-
IMS-MS).   
 
 
Figure 4.3.10 G4R Oligomer Size Determination by SEC HPLC 
The brown peak is fraction 21 from the SEC of G4R purification step which matches the dark blue, blue 
dextran 200 MDa peak, and indicates the exclusion volume of the column (700 kDa).  The green peak is 
from a typical preparation mixture of dimeric and monomer WT cystatin B.   
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Immunoassay 
To determine the concentration and confirm G4R oligomer identity a dot blot 
immunoassay was performed (see section 2.6 for the method).  The primary antibody 
used was a polyclonal antibody raised against a full length E. coli derived WT cystatin 
B (R&D systems, AF1408), thus should reliably bind most forms of cystatin B through 
a variety of available paratopes.  This antibody binds WT cystatin B readily up to a 3 
µM concentration, however binds soluble G4R 10-fold lower than the WT as shown in 
figure 4.3.11.  Therefore the epitopes present in the antibody are most likely detecting 
the N-terminal region, which may be less structured in the G4R mutation.  The absence 
of G4R oligomer detection may however be a function of the antibody sensitivity to the 
low concentration oligomer.  This was clearly shown by low sensitivity binding to the 
G4R monomer/dimer/tetramer and thus does not necessarily reflect the actual oligomer 
identity.  Furthermore, the oligomer may not display a native-like epitope, thus 
oligomer specific antibodies such as 6E11 raised against Aβ oligomers may be more 
useful in such an assay. 
 
 
Figure 4.3.11  Dot Blot Immunoassay of G4R and WT Cystatin B 
The maximum G4R oligomer concentration was likely to be 10 µM or less and not the stated 30 µM.  The 
other sample concentrations are reliably determined by UV spectroscopy.  A 30 second (shown), 5 minute 
and 19 hour exposure was obtained to ensure sensitive detection.  
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1D Proton NMR  
In an attempt to determine structural information and confirm protein identity, solution 
state 1D proton NMR was performed and is shown in figure 4.3.12.  The spectrum of 
the oligomeric preparation however yielded no protein specific peaks.  This could be 
due to either insufficient protein concentration (<50 µM) which produces spectra with a 
high signal to noise ratio and thus is not interpretable.  It is also highly likely that the 
large oligomers will exhibit a low intrinsic tumbling rate in solution which leads to 
extensive line broadening and therefore no tangible protein signals.  In addition, signals 
from long chain hydrocarbons were not detected which would be indicative of 
phospholipid presence.  Therefore it is very unlikely that the structures observed are 
lipid based, because even the presence of small amounts would produce a very sharp 
strong signal.   
 
 
Figure 4.3.12 1D Proton NMR Spectrum of G4R Cystatin B Species 
(Green) monomer, (red) Dimer and (blue) oligomer.  The oligomer spectrum shown had a 20 times 
greater number of scans than the comparative spectra, yet did not present detectable amide signals (10-7.5 
ppm) nor signals from long chain hydrocarbons, which would be indicative of phospholipid.  Spectra 
were acquired on a Bruker 600 MHz spectrometer equipped with a TXI cryoprobe at 25°C.   
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Solvent Dissolution 
Following this experiment, the oligomer was lyophilised and dissolved in 95% d6-
DMSO (5% H2O, dichloroacetic acid, pH 5.0) to determine the feasibility of quenched 
H/D exchange NMR for structural analysis.  Subsequent 1D proton NMR produced no 
observable proteinaceous NMR signals, which is most likely a function of low 
concentration.  EM of this solution yielded images with small regions of non-uniform 
aggregated protein and non-distinct oligomer-like structures which suggests either 
freezing or DMSO dissolution has destroyed the oligomeric conformers (see figure 
4.3.13).  Addition of either chloroform or hexane in a 1:1 ratio with buffered oligomer 
preparations also induced amorphous aggregation and furthermore indicates the 
proteinaceous content of the oligomer preparation.  
 
Dissolution of G4R oligomer was also attempted by solvent exchange to 5.5 M 
guanidine hydrochloride (unbuffered at pH 5.3) by ultrafiltration.  Only the large 
oligomers remain, suggesting the smaller oligomers are less stable conformers (figure 
4.3.13).  The highest G4R oligomer concentration determined was 5.8 µM (UV 
absorbance spectroscopy) and displayed a characteristic protein profile.  Further 
dissolution attempts for limited proteolysis and H/D exchange were performed by SEC 
of oligomers in 100% acetonitrile (0.1% TFA) which did not work, followed by success 
with 70% acetonitrile/30% water (0.1% TFA).  Elution peaks from at least 4 distinct 
molecule populations were observed, with the initial peak (lowest amplitude peak) 
correlating with the elution of WT soluble protein, thus suggesting dissolution in 70% 
acetonitrile (see figure 4.3.14).  The subsequent peaks most likely represent species 
which are retarded on the column matrix as protein degradation was not observed in 
other experiments and perhaps relates to the various observed structural classes.  A 
similar occurrence of protein species SEC retardation has been observed with cystatin B 
fibre dissolution in 6.0 M GuHCl (Sharma, 2009).    
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Figure 4.3.13 G4R Cystatin B Oligomer Solvent Dissolution 
Electron micrographs of G4R oligomer dissolution attempts.  The white ring observed in the first two 
electron micrographs are camera artefacts caused by uneven cooling, a result of equipment issues at the 
time.  (A) 21 000 x magnification electron micrograph of G4R cystatin B oligomer exchanged into a final 
concentration of 5.5 M guanidine hydrochloride by ultrafiltration.  Only the large oligomers remain, 
suggesting the smaller oligomers are less stable conformers.  (B) 11 500 x magnification micrograph of 
G4R HO in 95% d6-DMSO (5% H2O, DCA, pH 5.0) showing small regions of aggregated protein and 
non-distinct oligomer-like structures which suggests either freezing or DMSO dissolution destroys 
oligomeric conformers.  (C and D) Addition of either chloroform or hexane in a 1:1 ratio with buffered 
oligomer preparations induced amorphous aggregation.  Electron micrographs are produced from protein 
in the organic solvent solutions following phase separation.  (C) 21 000 x magnification of chloroform 
treated G4R oligomer.  (D) 5 200 x magnification of hexane treated G4R oligomer.   
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Figure 4.3.14 G4R Cystatin B Oligomer SEC HPLC in 70 % Acetonitrile 
SEC of cystatin B G4R oligomers and WT tetramer/dimer/monomer in 70% acetonitrile/30% water (0.1% 
TFA) (Shodex KW803 column).  The chromatogram shows elution peaks from at least 4 distinct 
molecule populations, with the initial peak correlating with the elution of WT soluble protein and 
indicating oligomer dissolution.  The subsequent peaks most likely represent species which are retarded 
on the column matrix. 
 
Proteinase K and Lipase Digestion 
Limited proteolysis with 1:1000 (monomeric equivalent mass ratio) of proteinase K: 
G4R oligomer was performed at 25°C over a period of 24 hours using identical methods 
described in section 3.2.  The oligomeric structures however displayed complete 
proteinase K resistance by both MS and EM (see figure 4.3.15).  This resistance 
suggests that these structures are compact, strongly folded and have a low frequency of 
local unfolding events in a similar manner to amyloid fibre.  A digestion with 
approximately equimolar lipase, from Aspergillus oryzae (Sigma-Aldrich, 62285), at 
37°C for 24 hours was also performed to preclude the possibility that these oligomeric 
structures are lipid based.  The EM results after 24 hours identified that these structures 
were not disturbed by the robust digestion conditions and are thus unlikely to be 
phospholipids from the E. coli expression cells (see figure 4.3.16). 
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Figure 4.3.15 G4R Oligomer Limited Proteolysis Electron Microscopy 
Representative electron micrographs of G4R cystatin B oligomer before and after proteinase K digestion.   
(A and B) 21 000 x magnification of oligomer preparation after concentration and centrifugation and 
prior to proteolysis.  Panel A shows heterogeneous oligomers and a few mature fibres.  Panel B is an 
image from a different section of the same EM grid and shows small protofibrils as well as the same 
heterogeneous oligomeric species.  (C and D) 21 000 and 52 000 x respective magnification of oligomer 
digested for 24 hours with proteinase K.  All recorded images showed little change in apparent quantity or 
morphology of the oligomers following protease digestion.  There is however, a distinct absence of 
protofibrils.  
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Figure 4.3.16 G4R Cystatin B Oligomer Lipase Digestion 
Negatively stained electron micrographs of oligomer at 5 200 x (left) and 11 500 x magnification (right).  
(A and B) Oligomer preparation prior to lipase digestion.  (C and D) Oligomer preparation following 
lipase digestion for 24 hours at 37°C. 
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Circular Dichroism and Thioflavin T Fluorescence 
To determine the secondary structure composition of the G4R oligomer, circular 
dichroism (CD) was performed and compared to WT cystatin B 
monomer/dimer/tetramer mixtures and amyloid fibres, as shown in figure 4.3.17.  The 
G4R oligomers produced a weak CD signal, perhaps due to low protein concentration, 
but still yields residue elipticity [Θ]MRW values above the level of signal to noise at 
208, 218 and 224 nm (peak value at 224 nm of -159.18x10-3 deg∙cm2/dmol-1), thus 
suggesting the existence of some structural elements.  The oligomers may have induced 
caused some light scattering as indicated by some extra absorbance at >250 nm and red-
shift observed around 224 nm.  The cystatin B controls were serially diluted 10-fold 
from 30 µM and both spectra became less reliable and noisy at 3 µM and very poor at 
0.03 µM, thus indicating the limitations of this experiment at protein concentrations 
similar to that expected of the oligomer.  This experiment therefore provides tentative 
evidence of protein secondary structure content.  G4R cystatin B oligomer was observed 
not to induce thioflavin T fluorescence, suggesting the absence of extensive repeating β-
sheet structure (see figure 4.3.18).   
 
 
Figure 4.3.17 G4R Cystatin B Oligomer Circular Dichroism 
(Red) G4R cystatin B oligomer (~10 µM), (Black) WT cystatin B monomer/dimer/tetramer mixture (30 
µM), (Blue) WT cystatin B fibre (30 µM).  Values obtained were subtracted from a buffer baseline. 
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Figure 4.3.18 G4R Cystatin B Thioflavin T Binding  
Fluorescence emission spectrum showing absence of G4R oligomer inducing thioflavin T fluorescence.  
The WT cystatin B fibre preparation was prepared at the same 10 µM concentration as the oligomer 
preparation and was used as a control.  (B) 21 000 x magnification electron micrograph of G4R oligomer 
used in the thioflavin T binding study.  
 
 
4.4 Discussion  
 
4.4.1 Rationalisation of Oligomerisation  
In WT cystatin B, generation of HO structures, even in fibrilisation conditions is a rare 
occurrence, suggested by the absence in EM time-course experiments (Paramore, 2010).  
The N-terminal region of cystatin B is therefore suspect in mediating interactions 
between monomer/ dimer and tetramers with a position 4 arginine improving binding 
and subsequent HO generation.  Furthermore, the G4R mutant in typical pH 4.7 10% 
TFE fibre forming conditions is suggested to have a much longer lag phase than the WT 
and accumulates more prefibrillar aggregates (Rabzelj et al., 2005).   
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4.4.2 Oligomer Formation 
Oligomer was produced only in small amounts in soluble protein extractions from E. 
coli, thus suggesting the formation of these structures requires highly specific 
conditions within the cell, which would perhaps be difficult to reproduce in vitro.  
Yields were typically less than 1.5 mg/l of LB growth media and concentration by 
ultrafiltration has proved unsuccessful, perhaps due to adhesion to the cell membranes.  
Perhaps flowing nitrogen over the solution surface could prove successful as a means of 
protein concentration in future experiments.  Interestingly these oligomers remain stable 
for months at 4 °C which is ideal for experimental manipulation with the caveat that 
high concentrations of protein >10 mg/ml causes aggregation and/or dissociation.  In 
addition these G4R oligomers failed to produce fibres in the standard fibrilisation 
conditons, thus suggesting these particular oligomers are stable structures off-pathway 
to amyloid fibre formation.   
 
4.4.3 Confirmation of Protein Identity 
I believe these oligomers are definitively proteinaceous from the range of experiments 
performed, despite their similarity to vesicles in EM (See table 4.4.1 for an overview of 
the current oligomer characterisation).  The reasons are as follows:  characteristic 
protein UV absorption spectrum, characteristic folded protein spectrum, coomassie blue 
dye binding in SDS-PAGE, dissolution in polar aprotic solvents, as well as robust lipase 
resistance.  In addition, the similarity to structures formed over time from purified Aβ 
and cystatin B indicates these structures are similar.  Finally, the variance between WT 
cystatin B rarely forming these structures and G4R reproducibly producing measurable 
populations also clarifies that these structures are only formed significantly when the 
cystatin B protein is destabilised in a specific way. 
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Observation Experiment Comment 
Low 280 nm absorbance 
UV spectrometer, 
1 cm pathlength 
Reliably detected with liquid 
chromatography flow cells, thus 
likely to be at a low concentration     
(<10 µM for WT cystatin B).  
Produces typical absorbance 
spectrum when successful. Large 
structures may cause light scattering. 
Ultrafiltration failed to 
increase oligomer 
concentration (5x 
concentration attempted) 
Ultrafiltration (10 
kDa MWCO 
vivaspin 500 
centrifugation cell) 
Oligomer probably binds the 
polyethersulfone membranes, and 
also aggregates/dissociates at high 
concentrations. 
Does not migrate 
effectively in SDS-PAGE 
SDS-PAGE 
SDS resistant and low concentration 
(<5 µg/ml).  Oligomer binds 
coomassie blue stain in the 
stacking/resolving gel interface. 
5.5 M Guanidine 
Hydrochloride resistant 
EM, NMR Resistant to strong denaturant 
Dissolves in 100% DMSO EM, NMR Dissolves in polar aprotic solvent 
Dissolves in 70% 
acetonitrile, H2O, 0.1% 
TFA mix 
SEC HPLC Dissolves in polar aprotic solvent 
Amorphous aggregate 
identified when mixed in 
sodium phosphate buffer 
with chloroform or hexane 
EM 
Non-polar solvents cause protein 
aggregation at the solvent interface 
Proteinase K Resistant EM 
Resistant to efficient sequence 
independent protease 
Lipase Resistant EM 24 hour 37°C digest. 
Not observable in 1D 1H 
NMR 
NMR 
Large size dictates that the tumbling 
rate is likely to be slow, thus 
extensive line broadening occurs. 
Not observable in MS 
ESI-TOF/MALDI-
TOF MS 
Large oligomers did not sufficiently 
vapourise or fragment.  The presence 
of lipids was not observed. 
No antibody binding 
Dot blot 
immunoassay 
The primary antibody binding to the 
control G4R monomer/dimer/ 
tetramer was ineffective. 
Table 4.4.1 Cystatin B High Molecular Weight Oligomer Characterisation 
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4.4.4 Oligomer Morphology 
G4R Cystatin B produces measurable quantities of higher molecular weight oligomer < 
700 kDa in at least five different conformations, which are larger in diameter than WT 
cystatin B amyloid fibre.  The diameter measurements (max and min) range in size from 
8-88 nm.  The small annular oligomer is close however, at an average 10.6 nm diameter 
compared to the fibre diameter of 8.6 nm and this is not taking into account the 
possibility of smaller structures at the limits of detection which may be similar in size.   
 
4.4.5 Oligomer Structure 
The absence of thioflavin T binding indicates there is no large extended β-sheet similar 
to that of amyloid fibre.  The circular dichroism data tentatively suggests there is 
presence of some secondary structure but identification is currently tenuous without 
producing more oligomer and concentrating it for use in CD and FTIR.  The oligomers 
are highly resistant to strong denaturant such as 5.5 M guanidine hydrochloride, 1% 
SDS and impervious to hydrolysis by the potent proteinase K enzyme, thus indicating a 
very compact densely structured moiety.  However they can be dissolved by polar 
aprotic solvents such as 100% DMSO and 70% acetonitrile, thus may be accessible for 
H/D exchange studies once the yield is improved.  At this juncture little is known about 
the structure of these cystatin B oligomers or those formed by other proteins.  There is 
also no clear consensus in the literature of any particular structural preference, which 
may indicate an absence of a definitive structural entity present in these oligomers 
(Fandrich, 2012).  Hopefully with future work these rather intriguing structures will be 
elucidated.   
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4.4.6 Future Work 
Higher yields of HO induced by novel therapeutics in preparations from E. coli or from 
purified monomer/ dimer / tetramer mixes would dramatically improve the study of 
these interesting structures.  Another important step in the study of these structures 
would be separation of the different conformers, perhaps by specific antibodies, 
differential centrifugation of filtration.  A limitation however, might gaining a suitable 
concentration of the oligomers for structural methods.  EM tomography, FTIR, AFM 
and gradient analytical ultracentrifugation may provide more detailed structural 
information.  However, for all these experiments a low protein concentration would 
limit structural methods.  An example of this is H/D exchange which typically requires 
100 µM preparations as a minimum.  Any information produced would be highly 
valuable with the sensible next step being identification of toxicity or analysis of effects 
on long term potentiation in neuronal cells (Amijee et al., 2012) alongside structural 
studies and oligomer specific antibody binding.  These oligomers are of specific interest 
as they appear stable over a period greater than three months, as determined by EM, 
which therefore increases suitability for structural studies.  
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Chapter 5: Final Conclusions and Future 
Perspectives 
 
5.1  Final Conclusions 
The initial aim of this project was to develop faster, more generally applicable methods 
for defining the structure of cystatin amyloids and higher molecular weight oligomeric 
structures.  The methods employed were developed with the aim of using them to probe 
fibre polymorphism and determine if fibre structure is conserved between cystatin B 
and C, the former being better characterised.  Further to this, the methods were to be 
used in structural studies of cystatin oligomers.  
 
The use of limited proteolysis, TEM and STEM MPL (mass mapping) on cystatin B 
fibre, described in this thesis, has generated new information which challenges the 
currently posited model generated from H/D exchange data (Morgan et al., 2008).  
Limited proteolysis of cystatin B amyloid fibre has shown that the core structure 
consists at the maximum, residues 27-80 out of a total 98.  The first 27 residues 
(natively a β-sheet and α-helix) are readily cleaved whilst C-terminal residues 80-98 
(natively β-sheet) are digested at a slower rate than the N-terminal region.  We therefore 
propose a new simple working model (see figure 3.4.2) based on the data presented in 
chapter 3 and H/D exchange data (Morgan et al., 2008).  This model posits that the 
native β-strand 2 and 3 is extended into a single strand stacking in parallel to form the 
fibre ‘backbone’ whilst β-strand 4 and 5 forms the second arm of a β-strand arc 
(hairpin).  Furthermore, limited proteolysis on fibres formed at pH 3.3 and 4.0 suggest 
that the amyloid fibre is not clearly polymorphic when compared to the structures 
formed at pH 4.7.  Furthermore, the experimentally derived fibre core is consistent with 
predictions from a range of sequence specific amyloidogenic region programs (see 
section 3.3.4).   
 
Electron microscopy techniques, including mass per unit length measurements, have 
shown that the fibre is 8.6 nm in width and forms at least four classes of fibre indicating 
the architecture of the protofibril/fibre association.  The class I fibres are most likely 
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composed of 4 cystatin B molecules per 4 -strand rise, with subsequent doublets of 
class I explaining the presence of fibres with 8 and 16 molecules of cystatin B per 4 -
strand rise (Class III and IV). Class II fibres contain 6 molecules per 4-strand rise, 
which is more difficult to envisage within the reported fibre dimensions, although is 
reminiscent of proposed models for insulin (Jimenez et al., 1999).   
 
The reliable generation of stable G4R mutant cystatin B oligomer and initial EM and 
biochemical characterisation has been performed with the aim of initiating future 
structural analysis of this elusive species.  G4R cystatin B oligomers are heterogeneous 
with at least five distinct morphology classes, with diameters ranging from 8-88 nm.  
The five classes are; small annular, ‘square’ pore-like, medium biconcave, cluster and 
large amorphous oligomers, each having a different morphology and size distribution.  
These oligomers are very robust and have been shown by EM to be resistant to 24 hour 
proteinase K digestion (only some classes) and the structures persist in the strong 
denaturant guanidine hydrochloride (5.5 M).  However, these oligomers can potentially 
be dissolved or aggregated in organic solvents such as DMSO and 70:30% v/v 
acetonitrile and water, thus enabling the use of quenched H/D exchange.  Furthermore, 
these oligomers remain stable for months when observed by EM, thus are suitable for 
structural studies.  Limitations on the study of these structures include: homogeneity, 
low yields and difficult manipulation.  Hopefully these challenges are not 
insurmountable. 
 
The investigation of small molecules which induce oligomerisation, such as 
epigallocatechin gallate (EPCG) were initially of interest in the generation of high yield 
cystatin oligomer.  This initial interest led to the collaborative study of a potential 
amyloid therapeutic present in Salvia sclareoides plant extracts.  Examining the efficacy 
and effects of these extracts was performed by thioflavin T dye binding kinetic assays, 
EM and additional NMR data.  The data collected suggests these extracts can potently 
destabilise mature fibres, leading to the rapid formation of amorphous aggregates and 
thus has provided the basis for identification and mechanism elucidation. 
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5.2 Future Work 
The structural work on cystatin B presented in this thesis will aid an on-going SSNMR 
cystatin B fibre structural study, which will lead to the determination of an atomic 
resolution model.  In addition to this, it may be interesting to explore the removal of the 
native α-helix region with the α-3C-β mutant or a stable elastase digestion fragment 
with the primary aim of determining interactions between the unfolded moieties and 
whether these mediate lateral association.  Further to this, an array of truncated mutants 
described in the appendix could act as a verification of the structural models.  The work 
to date includes the design and production of new plasmid constructs as well as 
preliminary peptide purification procedures, therefore would require little extra 
preliminary investigation.   
 
Comparison of the cystatin B and cystatin C amyloid fibre structure could prove very 
interesting in terms of structural polymorphism between two homologous natively 
folded proteins, the latter directly associated with cerebral amyloid angiopathy.  For the 
comparison study, limited proteolysis, TEM and STEM MPL measurements, which are 
relatively quick, may be sufficient for structural assessment.  The determination of 
structural information from oligomeric structures is of keen interest to the amyloid field 
at present and if successful, would bridge a gap in current understanding and aid future 
therapeutic development.  Furthermore, the discovery of the active compound in Salvia 
sclareoides, if proven novel, could be a very exciting discovery, as suggested by the 
very rapid destabilisation of cystatin B amyloid fibre. 
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Appendix 1: X-ray Fibre Diffraction 
 
A1.1 Introduction 
Partially aligned cystatin B fibre has previously been observed to diffract at 4.7Å on the 
meridional plane and at 10 Å on the equatorial plane, (Jenko et al., 2004) which is 
indicative of cross-β structure (Geddes et al., 1968) and is diagnostic of amyloid fibres 
(Blake and Serpell, 1996).  The meridional reflections are produced by the repeated 
interstrand hydrogen bond spacing whilst the orthogonal equatorial reflections are 
generated by intersheet interactions.  A completely aligned cystatin B fibre preparation 
would allow determination of further cystatin B structural information, such as helical 
pitch/helical repeating unit (115.5 Å/ 24 β-strands in transthyretin (Blake and Serpell, 
1996)).  Fibre diffraction can only image molecular details in exceptionally favourable 
cases (Chandrasekaran and Stubbs, 2006, Stubbs, 1999) but can often provide accurate 
overall shapes and dimensions (McDonald et al., 2012). 
 
A1.2 Methodology, Results and Discussion 
To generate additional fibre structural constraints, several attempts to align cystatin B 
fibres have been made in collaboration with Louise Serpell.  However, each attempt 
failed to result in suitably aligned fibres, perhaps due to the substantial lateral 
association found in cystatin B fibre preparations.  Initially the fibres were prepared in 
the standard pH 4.7 (15 mM NaAc, 10% TFE, 150 mM NaCl) conditions (described in 
2.6.1), before centrifugation of the insoluble fibres and 2 wash steps in d.H2O, ready for 
fibre alignment and diffraction.  The first fibre preparation produced short fibres, caused 
by mechanical shearing in the washing steps which subsequently failed to align.  A 
second attempt, with gentler handling yielded less shearing but equally did not align.   
 
The previous partial fibre alignment was achieved by fibre formation for 4 months in a 
2.3 tesla magnetic field, thus fibrilisation within a 20 tesla field was attempted by 
incubating a fibre preparation at 21°C centrally underneath an unshielded 800 MHz 
NMR spectrometer to maximise the effective magnetic flux.  After 9 months, fibre 
formation had not occurred, therefore, a 20% (v/v) fibre ‘seed’ preparation generated 
from 10 minute sonication of mature fibres was added to initiate fibre elongation, which 
requires future follow-up study.  Fibre formation with increased sodium chloride (0.5-
1.0 M) may in the future yield fibres with lower lateral association due to the 
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interruption of ionic interactions between the fibres.  Low salt conditions (10 mM 
sodium phosphate buffer) were tested but did not reduce lateral association.  In addition, 
cystatin B fibre formed from a truncated protein with all regions extraneous to the fibre 
core removed may identify if association is mediated by the fibre core or unfolded 
residues.  Further attempts to align fibres should be followed up to produce a better 
model of cystatin B fibre. 
 
 
Appendix 2     Cystatin B Truncate Mutant Study 
 
A2.1 Introduction 
The sequence based amyloid prediction programs inspired the study of a range of 
truncate mutant proteins and peptides based on human cystatin B.  These truncate 
mutants were to be used in determining whether the short amino acid sequences drive 
amyloid fibre formation in a full length folded protein and ascertain whether the formed 
amyloid fibres retain the same structure.  Three mutant proteins and two peptides were 
designed from the amyloid hotspot prediction software results and disease implicated 
mutants.   
 
An alpha-helix truncate E31 cystatin B mutant with a 3C protease site insert after 
residue 35 (α-3C-β) (see figure A2.6.1) was designed to provide insight into helix 
functionality in amyloidosis, due to the specific cleavable nature of the inserted 3C-
protease site thereby allowing accurate removal of the α-helix.  The D61X truncate 
mutant has β-strands 4 and 5 removed to elucidate the function of these strands in 
amyloid formation, study the amyloid formation of strands 2 and 3 and analyse fibre 
polymorphism.  R68X is similar to D61X and has β-strands 5 and half of β-strand 4 
removed to elucidate the function of these strands in a similar manner to D61X.  R68X 
has the additional interest as this mutant, and others have been found in sufferers of 
myoclonus epilepsy of type 1 (EPM1), a rare progressive and degenerate epilepsy 
(Rabzelj et al., 2005).  Two peptides with the sequences, 
KAVSFKSQVVAGTNYFIKV and GTNYFIKV, which are cystatin B residues 39-59 
and 50-57 were designed to provide insight into the main amyloidogenic and domain 
swapping β-strand 2 and 3 and the highly amyloidogenic β-strand 3. 
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Figure A.2.6.1 Cystatin B Truncate Mutant Topology  
The truncated region of these mutants is masked to indicate the remaining structures and the extant of the 
truncation.  The topology diagram colouring is from H/D exchange data of cystatin B amyloid fibre  
(Morgan et al., 2008) with red indicating protection, blue no protection and white undetermined. 
 
A2.2 Materials and Methods 
The alpha-helix truncate E31 cystatin B with a 3C protease site insert after residue 35 
(α-3C-β) was produced by nucleic acid de novo synthesis and sub-cloning of the gene 
into a pET-11a vector by GeneArt.  D61X and R68X truncate E31 cystatin B mutants 
were produced by stop codon insertion via site-directed mutagenesis of the WT in pET-
11a. Summer project student, Steve Harbourne, produced the D61X and R61X mutants 
by site-directed mutagenesis addition of two stop codons into the (C3S), E31 WT 
cystatin B sequence.  The two peptides with the sequences, 
KAVSFKSQVVAGTNYFIKV and GTNYFIKV were de novo synthesised by Biotec 
(USA) and Arthur Moir (University of Sheffield). 
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Purification 
Several attempts to produce the three truncate proteins in the soluble cell lysate failed, 
including low temperature (25°C) expression, use of E.coli BL21 (DE3) Gold PLys-S 
cells and shorter induction times to reduce the cellular protein concentration and avoid 
aggregation. The most successful purification strategy used a purification method 
similar to that described in section 2.5, modified by dissolving the high yield inclusion 
bodies in 4-5 M urea in which the anion exchange was performed followed by refolding 
and urea removal.  See table A2.6.2 for buffer conditions used and the physic-chemical 
characteristics table in section 2.5.   
 
The range of buffers required for dissolving and purifying the truncate mutants was 
based on the predicted protein pI value and a urea concentration dissolution assay 
probed by centrifugation and SDS-PAGE.  Each specific buffer was used throughout the 
purification steps with appropriate addition of sodium chloride when required.  Any 
urea containing buffer was freshly made on or closely before the day of use to reduce 
the decomposition of urea into uric acid, which amidates protein C-terminal carboxylate 
groups.  During truncate purification, the protein was exchanged into new solution at 
least every two days.   
 
Cystatin B 
Protein 
pH Buffer (10mM) 
Hydrogen 
Donor 
Hydrogen 
Acceptor 
Additives 
WT E31 6.0 Sodium Phosphate NaH2PO4 Na2HPO4 N/A 
α -3C-β 6.0 Sodium Phosphate NaH2PO4 Na2HPO4 
4M urea, 
1mM EDTA 
D61X 7.0 Sodium Phosphate NaH2PO4 Na2HPO4 
5M urea, 
1mM EDTA 
R68X 5.0 Sodium Acetate AcOH CH3COONa 
5M urea, 
1mM EDTA 
Table A2.6.2.  Buffer Table for WT and Truncate Mutant Purification  
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The modified protocol starts by resuspending the insoluble cell lysis pellet in 4-5 M 
buffered urea solution and sonication repeated in identical manner to cell lysis.  The 
resuspension was then dialysed overnight against 1 litre of appropriate urea containing 
buffer at 4°C in suitable 6-8 000 or 3 000 Da MWCO Spectra/Por dialysis tubing 
(Spectrum Laboratories) to remove excess DNA fragments which interfere with ion-
exchange chromatography.  Following dialysis, the resuspension was centrifuged at    
24 500 rpm at 4°C for 15 minutes to remove cell debris and insoluble protein.  
Subsequent anion-exchange and refolding of the protein in a urea-free equilibrated size-
exclusion chromatography proved to be the most successful procedure.  Rapid dilution 
refolding was attempted but failed to produce sufficient concentrations of folded protein 
and proved to be rather slow when concentrating the protein from several hundred 
millilitres of protein.   
 
α-3C-β additionally, once purified and soluble in biological buffer requires proteolysis 
with the highly specific 3C-protease to remove the α-helix, this however has not been 
attempted due to poor yields in the first purification step. 
 
A3.3 Results 
The truncate mutants proved difficult to work with due to intrinsic instability and were 
readily degraded, with a usable lifetime of less than 2 weeks.  The mutants have been 
purified to a low yield (~1 mg per litre of growth medium).  A fibrilisation trial was 
unsuccessful.  The most likely reason for this failure was the use of an old stock bottle 
of accelerant trifluoroethanol (TFE), which potentially had high a moisture content.  
The structure of D61X and R68X was probed by 1D H-NMR (see figure A2.6.2) and 
identified that the side chain methyl groups were not structurally constrained, which can 
be indicative of unfolded protein or molten-globule state.  Circular dichroism 
spectroscopy (CD) was then performed on R68X and the α-3C-β mutant to obtain 
structural information of the protein backbone.  CD identified that both proteins had 
significant backbone secondary structure, thus suggesting that both mutants were in the 
molten-globule state.  The D61X mutant was also tested but appeared to be degraded 
and produced a noisy CD spectrum. 
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1D 1H-NMR 
  
Circular Dichroism 
 
Figure A.2.6.2 1D H-NMR and CD of WT, D61X and R68X Cystatin B 
Top: 1D H-NMR; WT cystatin B is a typically folded protein with <0.5 ppm NMR resonances 
produced from side-chain methyl aromatic residue interactions which is indicative of protein folding.  
D61X and R68X are devoid of these resonances suggesting a potentially unfolded state.  Bottom:  
Circular dichroism spectra showing that both the WT (black), R68X (blue) and α-3C-β (red) amide 
backbone is folded.  The signal from α-3C-β could be weak due to either a very low concentration 
and/or weak signal generated by β-sheet in the instance of α-helical destabilisation.    
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A2.3  Discussion  
This study was followed up no further due to difficulties encountered in purification and 
time constraints.  Limited proteolysis of WT cystatin B was pursued instead with the 
aim of then using the technique to elucidate structural information about the truncate 
mutant amyloid fibres formed and ascertain whether the formed amyloid fibres retain a 
similar structure.  Thioflavin T fibrilisation assays to measure the rate of fibre formation 
compared to the mutants and the WT could also be performed with the aim of 
determining whether short amino acid sequences drive fibre formation in a full length 
folded protein with the two de novo synthesised peptides of particular interest.   
 
 
Appendix 3: Study of Novel Amyloid Therapeutics  
 
A3.1  Introduction 
The development of novel therapeutics to treat amyloid disease is of paramount 
importance.  Salvia plant species are reputed for their medicinal properties and have 
been regularly used in European and Chinese folk medicine as an antiseptic, and as 
treatment for memory loss and insomnia (Rauter et al., 2012). Salvia species are thus an 
excellent plant family for natural product searches to treat amyloid-related diseases.  
Salvia sclareoides is a native Portuguese aromatic herb related to common sage and has 
been studied in this work and that of others.  The preliminary studies on Salvia 
sclareoides n-butanol extract shows it contains components shown to interact with 
human prion protein (91-231 amino acid construct, huPrP91-231) (Rauter et al., 2012).  In 
that HSQC-NMR experiment, attenuation of amino acid resonances of 93-112, 130-187 
and 205-225, which represent regions in the unstructured N-terminal region, two strands 
of the β-sheet and the three α-helices, indicates potential extensive binding and 
associated conformational changes.  This attenuation of resonances is typically 
associated with ligand exchange dynamics, and is commonly observed under non-
saturating conditions for ligands with dissociation constants in the µM range (Rauter et 
al., 2012).   
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Further to this study, persistently infected scrapie mouse SMB cell lines were tested for 
reduced levels of scrapie form prion protein (PrP
SC
) with only the Salvia water extract 
attenuating the PrP
SC
 concentration significantly (EC50 = 5 µg/ml) (Jennifer Louth, 
personal communication).  All Salvia sclareoides extracts were tested along with the 
subsequently listed pure compounds from 1-50 µM: rosmarinic acid, ferulic acid, 
vanillic acid, syringic acid, p-coumaric acid, catechin, rutin, gentisic acid and ursolic 
acid.  The majority of extracts studied have proven to be non-toxic in cell culture, thus 
viable for further therapeutics research.    
 
In addition to the prion studies, Salvia extracts have been shown to destabilise cystatin 
B dimer, which exchanges to a species not detectable by NMR, most likely amorphous 
aggregate (work by Nadia Makaya and Matthew Cliff).  To extend these preliminary 
results, a range of Salvia sclareoides extracts and pure compounds identified in the 
extracts have been screened for binding to soluble cystatin B species by HSQC NMR, 
and the effects upon fibrilisation and preformed fibre stability were probed.  Nadia 
Makaya and Catarina Dias (Masters level students) performed these experiments wholly 
or partly whilst I designed, assisted or completed the experiments and analysed the 
results.  The study objectives were to investigate the interaction of Salvia sclareoides 
extracts, determine the active compound and identify the underlying modal activity.   
 
A3.2 Materials and Methods 
 
Salvia sclareoides Extracts; Component Compounds and Extraction Procedures 
The Salvia sclareoides extracts used herein were produced by Prof. Amelia Rauter at 
the University of Lisbon, with identification of some of the compounds present.  These 
extracts contain phenolic compounds and flavenoids such as (+)-catechin, (see table 
A3.2.1) (Rauter et al., 2012) which are currently of great interest in AD drug discovery 
(Hard and Lendel, 2012).  Figure A3.2.1 illustrates the extraction processes and 
highlights that all the extracts have had the extraction solvent removed by evaporation.  
10% DMSO buffered aqueous solvent was used to resuspend the majority of the 
extracts and act as a general organic solvent to solvate organic active compounds 
(infusion and water extract were suspended in buffer).  DMSO was used due to its high 
solvating qualities and suitability for NMR and fluorescence spectroscopy experiments.  
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 Extracts 
Phenolic Compound Methanol Ethanol Butanol Acetone 
Gallic Acid 0.8 0.8 1.2 1.7 
(+)-Catechin - - 0.5 - 
Gentisic Acid - 1.0 - 3.6 
Chlorogenic Acid 1.1 - 1.3 - 
Caffeic Acid - 0.8 1.4 2.4 
Vanillic Acid 2.5 1.3 2.8 6.9 
Syringic Acid - - - 2.1 
Coumaric Acid 1.3 0.1 0.6 0.8 
Ferulic Acid 0.8 - 0.5 0.1 
Rutin Hydrate - - - 1.6 
Kaempferol glucoside - - 0.7 - 
Quercetin dehydrate - - 1.4 - 
Table A3.2.1 Phenolic Compounds in Salvia sclareoides Extracts 
Relative percentages of phenolics determined by HPLC.  Data from (Rauter et al., 2012). 
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Figure A3.2.1 Salvia sclareoides Natural Product Extraction Procedures 
The natural product extraction procedure is performed on the plant aerial parts which are above ground.  
The abbreviation O/N and RT are short for overnight and room temperature.  Vacuum dessication 
produces a powdered extract which was then typically resuspended in a 10% DMSO/water solution. 
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Cystatin B Defibrilisation Thioflavin T Assays with Addition of Salvia Extracts 
The continuous defibrilisation assays were performed at 37°C in a similar manner to the 
fibrilisation assay standard method described in section 2.6.  Mature amyloid fibres 
produced by the method described in section 2.6 were centrifuged at 14 000 g for 15 
minutes, washed with pH 6.0, 11 mM sodium phosphate buffer (165 mM NaCl, 1 mM 
NaN3) centrifuged again and the procedure repeated to wash the fibres and ensure the 
correct and reproducible pH value was obtained.  Shortly before assay initiation 10% 
DMSO was added to the resuspended fibre in aqueous buffer.  10 µl/ml of Salvia extract 
or pure compound was added to the protein solutions in all the experiments described 
herein and the relative concentrations of the primarily investigated extracts and 
compounds are shown in table A3.3.2  The discontinuous assay method was similar to 
the continuous assay, except that several millilitres of the fibre and extract solution were 
incubated without Thiflavin T (ThT), then at specific time intervals 1 ml of the solution 
was aliquotted and ThT (10 µM final concentration) was added before quickly 
measuring fluorescence.   
 
The defibrilisation assays were performed at pH 6.0 with the rationale for this being that 
the soluble protein is maximally stable at this pH (predicted pI 7.0 and molten globule 
state at pH 4.7), thus reducing the amyloid fibres dynamic ‘on’ rate, and therefore 
allowing clear observation of the extract effects.  The expected effects of the extract 
upon amyloid fibre were uncertain thus the experiment was designed to maximise 
potential observable changes.  In addition, pH 6.0 is closer to physiological conditions 
than the pH 4.7 amyloid forming milieu, thus altering the protonation state of protein 
and extract molecule closer to that encountered as a therapeutic agent in vivo. Cystatin 
B amyloid fibres, by EM and H/D exchange, had been previously reported as stable up 
to pH 9.0 for a period of months (Morgan et al., 2008), therefore the fibres were 
expected to be suitably stable.  It was thought that performing the experiment at pH 4.7, 
with or without 10% Trifluoroethanol (TFE) would not work due to competition with 
fibre formation, thus a presumed stable pH was chosen. 
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Table A3.2.2 Primary Tested Extract Concentrations  
 
Cystatin B Fibrilisation Thioflavin T Assays with Addition of Salvia Extracts 
The Salvia extract fibrilisation assay used the standard fibrilisation conditions described 
in section 2.6.  The samples were incubated at 37°C, with the addition of 10% DMSO 
and 10 µl of extracts performed rapidly before commencement of data collection 
resulting in an experimental dead-time of 9 minutes with up to four samples at a time.   
 
A3.3  Results 
 
Cystatin B Defibrilisation Thioflavin T Assays with Addition of Salvia Extracts 
The initial cystatin B continuous defibrilisation thioflavin T (ThT) fluorescence assay 
with acetone and butanol S. sclareoides extracts and a 10% DMSO fibre control (figure 
A3.3.1) showed a rapid decrease in ThT fluorescence in all the samples tested.  This 
included the fibre control, which indicates reduction of amyloid fibre.  Attenuation of 
the amyloid fibre control threw the results into question and indicated fibre 
destabilisation, which could have been caused by the presence of 10% DMSO, pH 6.0 
solvent and/or ThT.  However, the rate of fluorescence emission reduction to a matter of 
minutes with the addition of the butanol extract and within hours in the presence of 
acetone extract suggested this experiment should be repeated with more controls due to 
significantly faster attenuation rates in the extract samples.  To ensure fluorescence 
quenching was not occurring, absorption spectra of the extracts in identical buffer 
conditions and concentration as the assay were performed from 220-600 nm.  These 
spectra proved the extracts did not absorb above signal-to-noise levels at or near 482 nm 
(data not shown).  Furthermore, EM confirmed conversion of mature fibres to 
amorphous aggregate. 
 
 
Salvia Extract 
Preparation 
Concentration 
(mg/ml) 
Final 
Concentration 
(µg/ml) 
DMSO 
Percentage 
 
Acetone (SB) 12.5 62.5 10 
 
Butanol (SD) 25 125 10 
 
Water Extract (SE) 12.5 62.5 0 
 
Infusion 25 125 0 
 
Gentisic Acid 3.1 (20 mM) 30.8 (200 µM) 0 
 
Rosmarinic Acid 3.6 (10 mM) 36.0 (100 µM) 10 
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Figure A3.3.1 First Cystatin B Defibrilisation with Salvia Extracts 
Defibrilisation experiment with the addition of acetone extract (red), butanol (blue) and a 10% DMSO 
(black) fibre control.  Data fitted with a single exponential. All samples were incubated at 37°C and 
contain 1 ml of 30 µM mature cystatin B fibre in pH 6.0 sodium phosphate buffer, 10% DMSO, 10 µM 
thioflavin T and a 10 µl addition of extract.   The control fibre (10% DMSO) and S. sclareoides extract 
preparations all exhibit rapid defibrilisation suggesting the assay conditions as well as the extracts are 
responsible for fibre reduction.   
 
A subsequent defibrilisation experiment repeated the previous conditions with replicate 
samples, and a mature fibre control with and without 10% DMSO or 10% TFE, all at 
pH 6.0 (see figure A3.3.2).  All the samples tested, including the controls, once again 
indicated a decrease in ThT fluorescence.  The reduction of the controls indicated that at 
pH 6.0, the addition of ThT significantly destabilises the mature amyloid fibre and the 
additional DMSO solvent was not responsible for the previous control fibre 
destabilisation.  Against expectations, 10% TFE in these conditions did not promote 
fibre stability, thus suggesting that neither soluble protein nor amorphous aggregate is 
suitably destabilised in these conditions to maintain the fibre population.  Once again 
acetone and butanol S. sclareoides extracts caused rapid defibrilisation, and are thus 
pharmacologically interesting.  
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Figure A3.3.2 Second Cystatin B Defibrilisation Assay with Salvia Extracts 
Defibrilisation experiment with acetone (red) and butanol (blue) S. sclareoides extracts and fibre controls 
with and without 10% DMSO and 10% TFE (black, green and orange respectively).  The raw 
fluorescence response of the samples has been baselined with ThT-extract controls, which were minimal 
except for the acetone extract which exhibited some intrinsic fluorescence at 482 nm.  The curves are 
fitted with a double exponential which was required for fitting, because a single exponential fitted the 
data poorly.  All samples were incubated at 37°C and contain 1 ml of 30 µM mature cystatin B fibre in 
pH 6.0 sodium phosphate buffer, 10% DMSO, 10 µM thioflavin T and a 10 µl addition of extract.  The 
controls such as the fibre blank, fibre with 10% TFE and fibre with 10% DMSO all show a similar 
reduction in fluorescence.  However, the preparations with salvia extracts show a marked and rapid 
decrease in fibre compared to the slower decrease shown in the controls.   
 
Two subsequent discontinuous defibrilisation assays were performed (see figure 
A3.3.3), whereby incubated preformed fibre controls or samples with Salvia extract 
were aliquotted at specific intervals from an incubated solution, ThT added and the 
fluorescence measured within a minute.  The first (top) assay identifies a reduction in 
cystatin B amyloid fibre within minutes of acetone and butanol extract addition.  The 
second (bottom) assay shows cystatin B amyloid fibre dissociation within a matter of 
hours with additions of infusion, water extract and rosmarinic acid.  Both fibre and 10% 
DMSO fibre controls produce a high, flat fluorescence signal indicating that the fibres 
are stable in the conditions used, particularly in the absence of ThT until shortly before 
the measurements were taken.  This verifies that ThT is destabilising under these 
experimental conditions.  The discontinuous assays show that all the Salvia extracts 
tested and rosmarinic acid induce fibre dissociation in the conditions tested.  The fibre 
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controls remained stable and fibrous throughout the experiments due to the absence of 
ThT.  In all the defibrilisation assays perfomed, EM of the final solutions with extracts 
or pure compounds proved mostly negative for amyloid fibre and displayed amorphous 
aggregate structures as shown in figure A3.3.4. 
 
 
Figure A3.3.3 Discontinuous Cystatin B Defibrilisation Assays with Salvia Extracts 
 (A and B) The first assay conducted with acetone extract (red triangles) and butanol extract (blue 
squares) both show significant decreases in fibre content.  The fibre control (green diamonds) and a 10% 
DMSO fibre control (black circles) show relatively flat profiles thus indicating that in the discontinuous 
assay conditions the fibre remains stable.  (C and D)  Second assay with water soluble extractions which 
include; rosmarinic acid (purple triangles), infusion (green squares) and water extract [SE] (orange 
crosses).  The fibre control remains relatively stable, however a value of 1000 is the detection limit of the 
instrument, so the actual value may have been higher.  All samples were incubated at 37°C and contain 1 
ml of 30 µM mature cystatin B fibre in pH 6.0 sodium phosphate buffer, 10% DMSO, 10 µM thioflavin T 
and a 10 µl addition of extract.   
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Figure A3.3.4 Selected Defibrilisation Electron Micrographs 
Electron micrographs of fibre solutions following defibrilisation assays which shows conversion of 
amyloid fibre into amorphous aggregate and potential oligomer species.  All images are magnified 11 500 
x except for C and E which is at 21 000 x magnification.  WT cystatin B fibre destabilised with the 
addition of; (A) acetone extract (SB), (B) butanol extract (SD), (C) water extract (SE), (D) rosmarinic 
acid which shows potential oligomer formation and little amorphous aggregation.   Example control 
images include; (E)   fibre control with 10% TFE at pH 6.0 and (F) Extract B which identifies small 
globular and protein aggregate structures.  These are however much smaller, often have a different 
morphology and are less extensive than the aggregate products found in extract and fibre preparations.    
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In an attempt to capture the early defibrilisation event, which was mainly missed with 
the discontinuous assays, a short continuous 25 minute assay was performed with 
sampling every 0.5 minutes, a dead-time of 24 seconds and gentle mixing of the sample 
every 2 minutes by hand.  This rapid defibrilisation assay was performed with butanol 
extract (figure A3.3.5) and proved successful, although the initial exponential phase was 
most likely missed as the typical fluorescence response of this fibre preparation was 
about 800 units.  Improvement of this experiment by diluting the extract and reducing 
the temperature (conducted by Amy Irvine) indicates that the defibrilisation rate 
remains very fast and cannot be measured without resorting to stopped flow methods. 
 
   
Figure A3.3.5 Rapid Cystatin B Defibrilisation Assay with Salvia Butanol Extract 
This rapid continuous assay with ThT present allowed clearer observation of the defibrilisation event 
caused by addition of Salvia sclareoides butanol extract to mature cystatin B fibre.  Data fitted to a double 
exponential curve. 
 
WT Cystatin B Thioflavin T Fibrilisation Assay with Addition of Salvia Extracts  
The aim of this experiment was to observe an expected reduction in fibrilisation rate 
caused by S. sclareoides extracts.  The fibrilisation experiments were performed in 
standard fibrilisation conditions at pH 4.7 and the thioflavin T fluorescence time courses 
are shown in figure A3.3.6.  Compared to the control, the fibrilisation rate is either 
equal or enhanced with the addition of the extracts.  EM of these samples at the end of 
the experiment identified that all the samples had significant quantities of amyloid fibre 
present.   
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Figure A3.3.6 Cystatin B Fibrilisation with S. sclareoides Extracts   
 (A and B) The first assay conducted with acetone extract (red triangles), butanol extract (blue squares) 
and 10% DMSO/TFE Control.  The acetone extract does not impede fibrillogenesis with a marginally 
increased rate.  The butanol extract either forms fibre very rapidly or inhibits fibre formation with the 
former most likely as EM shows mature fibre formation in all samples at the end of each incubation 
period.  (C and D)  The second assay used water soluble extractions which include; gentisic acid (brown 
diamonds), infusion (green squares), water extract [SE] (orange crosses) and a 10% TFE fibre control 
(black circles).  The reaction containing gentisic acid is clearly faster than the control and rapidly forms 
fibres.  The absolute fluorescence values of reactions with infusion and water extract however are lower 
than the control but when observed comparatively in (E and F) the rates of formation are quicker than the 
control reaction.  (E and F)  Comparison of a selection of fibrilisation reactions with S. sclareoides 
extracts.  The data when normalised suggests that all the extracts form fibre faster than the control.  The 
overall fluorescence intensities with extract present are typically much lower than the controls as shown 
in panels A-D.  All samples were incubated at 37°C and contain 1 ml of 30 µM mature cystatin B fibre in 
pH 6.0 sodium phosphate buffer, 10% DMSO, 10 µM thioflavin T and a 10 µl addition of extract.   
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A3.4 Discussion 
It has been determined that 10 µM ThT in combination with the pH 6.0 conditions 
destabilises mature cystatin B amyloid fibre over a period of hours.    In comparison, 10 
µM ThT at pH 4.7 has been shown not to alter the fibrilisation rate (Giannini, 2004).  
Thioflavin T binding at pH 6.0 clearly destabilises the amyloid fibre most likely through 
its binding interactions to the continuous β-sheet.  Thioflavin T binding is stronger at 
pH 6.0 than at lower pH values such as pH 4.7 (Naiki et al., 1989, LeVine, 1997).  
Equally, the binding of ThT and the environment (pH 6.0) could combine to sufficiently 
stabilise the soluble cystatin B species and disturb the equilibrium and/or the fibre in 
these conditions becomes less robust, which leads to fibre dissociation.  If significant, 
this stability could perhaps be studied by CD or FTIR with thermal or chemical 
denaturation.  The discontinuous assays and EM showed that in the absence of ThT, the 
fibre controls remained stable and fibrous throughout the experiments.   
 
From the two discontinuous assays it is clear that all the Salvia extracts and pure 
compounds tested induce fibre dissociation as detected by ThT fluorescence and EM.  
An example of tested pure compound is rosmarinic acid which has been shown to 
produce a very similar effect to that of the Salvia extracts, has been identified in the 
extracts as a major component (Catarina Dias, personal communication) and is observed 
to destabilise and inhibit Aβ fibre in ThT assays and EM (Ono et al., 2004).  Cystatin B 
and Aβ fibres in stable conditions would ideally be studied further in similar 
discontinuous ThT assays or through the use of other techniques such as CD, FTIR or 
quantitative dot blot assays (Wanker et al., 1999) using fibre specific antibodies (Kayed 
et al., 2003).  The presence of ThT in the assays has been shown to produce false 
positives and negatives due to competition for binding, (Lendel et al., 2009, Buell et al., 
2010, Hudson et al., 2009) and although useful must also be followed up with other 
experimental methods.   
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The rapid defibrilisation assay with butanol extract proved successful with measurement 
of the end stages of the defibrilisation reaction, which had not been observed previously 
with this highly effective extract.  Over the 25 minute period, the effect of 10 µM ThT 
and pH 6.0 on fibre destabilisation was not measurable.  Therefore ThT presence was 
deemed not to affect these results unduly and was necessary for the regular 
measurements required.  Extracts exhibiting slower kinetics over a period of hours may 
have problems with the ThT effect, thus adequate controls would have to be trialled 
before screening the remaining extracts and pure compounds in this manner.  Without 
using a stopped flow system this is likely to be the best ThT based assay method 
possible, without the manipulation of the conditions such as reducing the temperature 
and extract concentration. 
 
The fibrilisation results indicate that compared to the control, the fibrilisation rate is 
either equal or slightly enhanced with the addition of the extracts.  This could be due to 
increased amorphous aggregate formation, upon extract addition, which from cystatin B 
fibre forming EM time-course experiments appears to be on-pathway to fibre formation 
(Paramore, 2010).  Escalating the amorphous aggregate population may increase the 
rate of nucleation or elongation of the amyloid fibres at pH 4.7 by presenting randomly 
folded and orientated cystatin B.  Equally, given that the results are within experimental 
error, it is possible that the true effect is missed under the conditions used.  The work 
should be repeated at 30°C, to slow the kinetics of the reaction for clearer observation 
of the lag and elongation phases. 
 
Potential binding of soluble Salvia extracts or pure compound to Cystatin B was tested 
by HSQC NMR with only butanol and ‘water’ extracts indicating marked changes in 
spectra, whereby the dimer species resonances disappeared without increase in 
monomer or tetramer peaks.  The pure compound which causes dimer conversion to 
what is most likely amorphous aggregate is yet to be identified.  This result along with 
the prion protein studies indicate that the most interesting extracts to study are the 
butanol and water extracts (SD and SE).  In addition, the aqueous solubility of the water 
extract would make the active compound an ideal therapeutic agent in terms of meeting 
ADMET conditions.   
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A3.5 Conclusions 
10 µM Thioflavin T at pH 6.0 causes mature cystatin B fibre formed at pH 4.7 to 
dissociate over a period of hours, thus suggesting the soluble protein and or/fibre 
stability is altered.  All the extracts tested for defibrilisation show strong activities at 
comparable concentrations.  The pure compound which causes the dimer conversion to 
what is most likely amorphous aggregate is yet to be tested or identified, thus requires 
further study.  The most interesting extracts to study are the butanol and water extracts 
(SD and SE).  The rapid defibrilisation assay proves to be the most successful method 
employed, thus with alteration of the conditions it could prove to be an excellent 
screening method.  To conclude, the effects of Salvia sclareoides extracts is worth 
pursuing further due to the positive preliminary results presented herein. 
 
 
 
 
